



ex rel. Dr. Ana Maria Abreu Velez and Dr. Michael S Howard on behalf of the alive and deceased relevant patients, and the US taxpayers et al.

vs.

GILEAD SCIENCES, INC., et al.



Gilead Sciences Inc

UNCLAIMED

4100 Avenida De La Plata Oceanside, CA 92056

(760) 724-1728

GILEAD

About

We are a privately held company in Oceanside, CA.

Executive Office Of The United States Government

0 customer reviews - add your review

1600 Pennsylvania Avenue Nw
Washington, DC 20500
Phone: (202) 456-1414
Web: www.whitehouse.gov

Executive Office Of The United States Government is a privately held company in Washington, DC and is a Headquarters business. Categorized under Presidents' Office. Our records show it was established in 1787 and incorporated in District of Columbia. Current estimates show this company has an annual revenue of unknown and employs a staff of approximately 1917456.

PRECEDENTS: SPECIAL DAMAGE:

- Loss of trillions of USDs for US tax payers.
- Illegally maintaining monopolies for HIV and hepatitis medications
- Murder of patients in mismanaged clinical trials.
- False patents were accepted and taxpayers lost the right to generic and more affordable medications.
- Severe retaliations against plaintiffs.
- Special damage is claimed, based on description of precedent. An attached proposal settlement was also sent via Attorney Walter Brown, Civil Division DOJ, and others and attached here again. For our precarious economic situation **we request immediately that the building** we used to rent at 1534 North Decatur Road NE Atlanta, GA, 30307 that was bought through a ghost buyer to destroy our practice (and we believe is held by either the FBI Atlanta and the DOJ (**Exhibits 11 and 12**) be given immediately to Dr. Abreu and or be sold for 1 dollar, and that the defendants give Dr. Abreu immediately \$

Department of Homeland Security

UNCLAIMED

1120 Vermont Avenue NW Washington, DC 20005

(202) 331-1927

Homeland Security

About

We are a privately held company in Washington, DC.



US Department of Health and Human Services

4 Seagate Toledo, OH 43604 (800) 325-0778



About

We are a privately held company in Toledo, OH.

Central Intelligence Agency ? UNCLAIMED

617 North 2nd Street Altoona, PA 16601 (412) 513-1467



About

We are a privately held company in Altoona, PA.



BAKER, DONELSON, BEARMAN, CALDWELL & BERKOWITZ, PC

/s/ Joe. D. Whitley

Joe D. Whitley, GA Bar No. 756150
Brett A. Switzer, GA Bar No. 554141
Sarah M. Carrier, GA Bar No. 377848
3414 Peachtree Rd. NE, Ste 1500
Atlanta, Georgia 30326
Phone: 404-577-6000
Facsimile: 404-221-6501
Email: jwhitley@bakerdonelson.com
Email: bswitzer@bakerdonelson.com
Email: scarrier@bakerdonelson.com

Attorneys for Defendant Gilead Sciences, Inc.



UNITED STATES SENATE
COMMITTEE ON THE JUDICIARY
QUESTIONNAIRE FOR JUDICIAL NOMINEES

<https://www.judiciary.senate.gov/imo/media/doc/Steven%20Grimberg%20SJQ%20-%20PUBLIC.pdf>

JUL 22 2019

1

July 22, 2019

JAMES N. HATTEN, Clerk
By:  Deputy ClerkUNITED STATES DISTRICT COURT, NORTHERN DISTRICT OF GEORGIA, ATLANTA
DIVISION**1:19-CV-3299**

ex rel. Dr. Ana Maria Abreu Velez and
Dr. Michael S Howard on behalf of the
alive and deceased relevant patients, and the US taxpayers et al.,

Plaintiffs,

vs. GILEAD SCIENCES, INC., et al.,

Defendants

RE: writ of *qui tam pro domino rege quam pro se ipso in hac parte sequitur*, (*qui tam*)
meaning (**filing pro se**). **Cause:** 31:3729 False Claims Act

Nature of Suit: 376 Qui Tam (31 U.S.C. 3729(a))

Defendants: Who did the illegal actions: Gilead Sciences Inc., (Gilead) (Foster City, California), Emory University in Atlanta, Georgia (GA), (Emory), University of Georgia Foundation as part of the Board of Regents of the University System of Georgia (BOR), Dennis Liotta, PhD, Raymond F. Schinazi, PhD, DSc (Hon) [(both professor at Emory and Board of Regents of the University System of Georgia (BOR)], (Triangle Pharmaceutical Inc., and Pharmasset Inc., both companies formed at Emory and incorporated by Gilead), John C Martin PhD, (ex- CEO of Gilead), Ex research and Development (R&D) director at Gilead Norbert Bischofberger PhD, Mr. John Milligan ex-Chief Executive Officer at Gilead, Mr. Gregg H. Alton, JD Chief Patient Officer at Gilead, Mr. Steven D. Sencer (current Chief Counsel for Emory for covering these criminal actions). Gilead Sciences Ireland UC, Akros Pharma Inc., Gilead Holdings, LLC, Japan Tobacco International U.S.A. Inc., Janssen R&D Ireland, Johnson & Johnson Inc., E. R. Squibb & Sons, LLC, Bristol-Myers Squibb Company, Gilead Sciences,

LLC, Japan Tobacco Inc., Emory University and the Board of Regents of the University System of Georgia.

Plaintiffs and original sources:

Ana Maria Abreu Velez, M.D., Ph.D., D.Sc. 2250 North Druid Hills Road NE; Suite 124, Atlanta, GA 30329, E-mail: abreuvelez@yahoo.com, cell:404-660-5558.

Michael S. Howard, M.D., Georgia Dermatopathology Associates, 2250 North Druid Hills Road, NE; Suite 124, Atlanta, Georgia 30329, E-mail: mhoward@gadermpath.com
Work Phone: 404-371-0077, Cell: 404-431-9249.

RE: writ of *qui tam pro domino rege quam pro se ipso in hac parte sequitur*, (*qui tam*) meaning (**filing pro se**). **Cause:** 31:3729 False Claims Act (FCA). *Cochise Consultancy, Inc. v. United States ex rel. Hunt*, unanimously affirming the Eleventh Circuit's holding (887 F.3d 1081) that the 31 U.S.C. § 3731(b)(2) tolling provision applies to False Claims Act (FCA) *qui tam* actions regardless of whether the Government intervenes. § 3731(b)(2) allows for tolling of the statute of limitations: suit may be filed within three years after "the official of the United States charged with responsibility to act" either "kn[ew] or reasonably should have [] known" of the alleged fraud, but it must be brought "no . . . more than 10 years after" commission of the alleged fraud. We refer to § 3731(b)(2) because for the past years we had exposed and requested the investigation and prosecution of the **BIGGEST PHARMACEUTICAL SCAM IN US AND WORLD HISTORY unsuccessfully** to the following agencies: Department of Justice (DOJ), to the Department of Health and Human Services (HHS), to the Federal Trade Commission (FTC), to the Federal and Drug Administration, the United States Patent and Trademark Office (USPTO), the Department of Defense (DOD), Veterans Affairs (VA), the Security and Exchange Commission (SEC), and USCIS, with many other federal and state governmental agencies. The lack of prosecution is due likely based on bribes for at least two decades, given to top officials at DOJ and FTC; they allowed the illegal merger of Gilead Sciences Inc. with dozens of companies to maintain an illegal monopoly on the medications for HIV and hepatitis in the US and worldwide; the resultant abuse of drug prices made these medications inaccessible for millions of patients. This suit also includes the murder of many innocent patients in the clinical trials by these defendants, and retaliation against the plaintiff whistleblowers. The plaintiffs had revealed to the above agencies these contracts and other frauds for years.

Nature of Suit: 376 Qui Tam (31 U.S.C. 3729(a), § 3731(b)(2)). The False Claims Act permits a private person, known as a relator, to bring a qui tam civil action "in the name of the [Federal] Government," 31 U. S. C. §3730(b), against "any person" who "knowingly presents . . . a false or fraudulent claim for payment" to the Government or to certain third parties acting on the Government's behalf, §§3729(a), (b)(2). The Government may choose to intervene in the action. See §§3730(b)(2), (4). Two limitations periods apply to a "civil action under section 3730." §3731(b). An action must be brought within either 6 years after the statutory violation occurred, §3731(b)(1), or 3 years after the "the official of the United States charged with responsibility to act in the circumstances" knew or should have known the relevant facts, but not more than 10

years after the violation, §3731(b)(2). The period providing the later date serves as the limitation period.

EXTREMELY WORRISOME AND SUSPICIOUS INDICATIONS THAT SOME TOP CURRENT AND PAST OFFICIALS AT THE DOJ HAS BEEN PROTECTING GILEAD AND THE DEFENDANTS LIKELY FOR EXCHANGE OF MATERIAL THINGS ABUSING THEIR POSITIONS OF PUBLIC TRUST.

- I. DOJ denied participating Petition Stage Amicus Brief (Invitation) in Civil Div. I: General (e.g., DOT, FEC, FOIA, FTC (except antitrust), Brief of United States as Amicus Curiae at 8-14, Gilead Sciences, Inc. v. United States ex rel. Campie, et al., No. 17-936. 2019.
- II. DOJ denied the FCA whistleblower suit against Gilead accused of funneling kickbacks to providers to boost sales. Feb 2019. In an unsealed FCA case in California federal court, a whistle-blower claimed Gilead's Frontlines of Communities in the United States program, which partners with healthcare organizations, government agencies, universities and community groups to facilitate hepatitis and HIV screenings, resulted in billions of dollars in excess government spending. U.S. sales of Gilead's Sovaldi and Harvoni through both public and private payers totaled \$20.6 billion after rebates from December 2013 to August 2015, according to the company's financial reports. The drugs can cost between \$80,000 and \$100,000 for a full treatment cycle and Medicare spent nearly \$8.2 billion before rebates for the 18-month period after Sovaldi was introduced in December 2013. This includes The FOCUS program allegedly identified and paid part of the salaries of certain "champion" doctors who are charged with advocating change across the entire institution in support of Gilead products. Case 3:17-cv-02612 JSC Document 17 Filed 02/06/19 https://www.scribd.com/document/399665567/Gilead-FCA-lawsuit?campaign=VigLink&ad_group=xxclxx&source=hp_affiliate&medium=affiliate.
- III. DOJ Declines To Intervene In Ranexa Lawsuit Against Gilead. <https://www.rttnews.com/.../doj-declines-to-intervene-in-ranexa-lawsuit-against-gilead>. Dec 16, 2010 - Gilead Sciences, Inc. (GILD) said Thursday that the DOJ has notified the United States District Court for the Northern District of California of its decision not to intervene in a False Claims Act lawsuit filed by a former employee of CV Therapeutics, Inc. regarding the promotion of Ranexa. Gilead acquired CV Therapeutics in April 2009.
- IV. We are aware of the "Granston memo" the "Rosenstein memo" the "Yates memo" and the "Benczkowski memo", and their "timing" in regards to decreasing punishment and economic as well as institutional penalties for white collar criminals and commercial institutions such as Gilead and other defendants. We believe these

memos were written probably as results of bribes at top levels given to Federal employees, whom acted dishonestly given our whistleblower activities protecting the US taxpayers and protecting the patients illegally murdered in their clinical trials. We have proof of sending thousands of documents including USBs, certified USPS, UPS, FedEx and in person via ex-White House chief of staff John Kelly, his predecessor, ex-chief of attorneys at the same place, to VP Pence, to POTUS, to SCOTUS, to FLOTUS, to Ms. Pence, to Ms. Conway, to Ms. Ivanka and Mr. Jared Kushner, and many others we have proof of delivery. Some of the multiple agencies we contacted included **the FBI, DOJ, HHS, FDA, FTC, SEC, DOD and many federal agencies. WE ALSO ARE AWARE THAT "OUT OF THE BLUE" UNDER MR ROSENSTEIN'S TENURE AT DOJ** the ex-five top Gilead leaders(who were the brainpower behind **THE BIGGEST PHARMACEUTICAL SCAM IN US AND WORLD HISTORY**), were covered via the Rosenstein memo decreasing penalties on white collar criminals.

- V. We tried by many ways via AG Sally Q Yates, AG Loretta Lynch, John A Horn (former US North Georgia Attorney) and top officers in the North Georgia US Attorney's Office (including Mr. Steven Grimberg) as well as in the Southern Georgia US Attorney's office, including Mr. Edward Tarver. We contacted the Office of the Inspector General (OIG) of the DOJ many times, and most US Federal regulatory agencies and so far, after contacting for all these past years, nothing has changed and we have been awarded nothing. Also many top leaders at DOJ had received illegal payments from Gilead and we are requesting how much they have received as subpoenaed below.
- VI. We had sent a previous Qui tam to Ex DOJ AG Jeff Sessions (**Exhibits 1, and 2**) and to Mr. Michael Granston at the Civil Division DOJ, using mail and e-mails and we never received any answers.
- VII. We also filled a Tort Claim under the Federal Tort Claims Act (FTCA) using the proper in a "sum certain" amount (that is, a specific amount) claimed for personal injury, death, or injury to or loss of property including the sum certain specified in Standard Form 95 block 12d and the DOJ also illegally rejected our claims please see (**Exhibits 3, 4 and 5**). The United States has waived sovereign immunity to a limited extent, mainly through the Federal Tort Claims Act, which waives the immunity if a tortious act of a Federal employee causes damage, and **the Tucker Act**, which waives the immunity over claims arising out of contracts to which the federal government is a party. The DOJ illegally violated our rights. We have sent hundreds of communications to investigate and prosecute the issues we exposed using a Grand Jury and a special prosecutor to the DOJ in Georgia and in Washington, DC (we have plenty of proofs of delivery); please see one of the multiple temerity illegal answers from DOJ saying that this case didn't contain a Federal violation (**Exhibit 6**). For the severe retaliations against us, we also had asked

the DOJ hundreds of times to encourage Gilead, Emory and BOR (and/or directly the DOJ) to give us immediately our proposed settlement, and such also never happened. The civil, criminal, antitrust, immigration and other parts of the DOJ have failed over many years to protect our rights and the US taxpayers' rights (with plenty proofs of delivery and copies to other people/entities).

PRECEDENTS: SPECIAL DAMAGE:

- ⇒ -Loss of trillions of USDs for US tax payers.
- ⇒ -Illegally maintaining monopolies for HIV and hepatitis medications
- ⇒ -Murder of patients in mismanaged clinical trials.
- ⇒ -False patents were accepted and taxpayers lost the right to generic and more affordable medications.
- ⇒ -Severe retaliations against plaintiffs.
- ⇒ Special damage is claimed, based on description of precedent. An attached proposal settlement was also sent via Attorney Walter Brown, Civil Division DOJ, and others and attached here again. For our precarious economic situation **we request immediately that the building** we used to rent at 1534 North Decatur Road NE Atlanta, GA, 30307 that was bought through a ghost buyer to destroy our practice (and we believe is held by either the FBI Atlanta and the DOJ (**Exhibits 11 and 12**) be given immediately to Dr. Abreu and or be sold for 1 dollar, and that the defendants give Dr. Abreu immediately **\$ 500,000 USD and Emory will pay the taxes on this** to gut it and move our practice there. We also need immediately about **\$100,000** to fix the roof of our house, the drainage, put in a retention wall and other repairs that we have not being able to afford. Dr. Howard also owes Dr. Abreu about **\$ 60,000 USDs**.
- ⇒ Plaintiff's rights have been severely violated. On the other hand, we have helped the patients affected by endemic pemphigus foliaceus in the jungles of El Bagre, Colombia South America for over 29 years with free medical care, scientific research, dental care, medications, food and clothing with our own savings and salaries but these last years we cannot continue doing so economically. This includes more than 10,000 poor and sick people Dr. Abreu helped in these jungle areas for free using her own resources. This disease is deadly and nobody else helps the patients whom are extremely ill, and poor. Keep that in your conscience. See <https://www.facebook.com/Endemic.Pemphigus.Foliaceus.in.ElBagre/>

For 14 years and eight months, we our family, our practice, our reputation, our professional activities, our economy, mental and physical health have suffered the most severe persecution, attacks and retaliations (**Exhibit 7**) via the above institutions for exposing the murder of multiple

patients in clinical trials in the US and overseas (**Exhibit 13**) by the defendants and severe violations of multiple federal laws. In addition, we exposed severe antitrust violations by Gilead (**for more than 20 years**), never prosecuted by the Department of Justice (DOJ) (as far as we can determine), besides sending them the information hundreds of times using Federal express, US mail, phone calls and e-mail (of which we have proof). We also exposed severe violations of non-profit status by EU, BOR and their Trustees and top administrators and the IRS non-profit unit, as well as the DOJ (which I copied), who combined did nothing to recover trillions of US Dollars. We lost our assets; we have been a victim with our family of more than 50 attacks. The defendants destroyed us, our family and practice via all means (from attacking my minor daughter who was hospitalized for one month after the attack) by physical, emotional, immigration acts and other dirty practices. They wrecked our reputation and practice. Dr. Abreu lost her job in June 2016; and has applied to more than 250 positions, and has been unable to obtain a new position due to persecution and defamation against her, Dr. Howard and our practice: Georgia Dermatopathology Associates (GDA). In (**Exhibits 8 and 9**) are our proposed settlements that are minimal comparing to the trillions of US and world-wide potential recovery. In one of our FOIA we asked how much money the Veterans affairs tax payers had paid to Gilead in these years of monopoly in HIV and hepatitis medications and the answer was almost 1.7 trillion of USD (**Exhibit 10**). **This will be the biggest potential recovery in the history of the DOJ, ie trillions of USDs.**

Here we present a summary of our journey of harassment, discrimination and lack of justice for protecting patients, taxpayers and those affected by 1) HIV, and 2) Hepatitis B and C worldwide the Federal Government and the taxpayers. We document abuse of patients in clinical trials using taxpayer money, **abusing the Bayh-Dole Act and the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (Public Law 94-435, known commonly as the HSR Act, violation of The Federal Trade Commission Act of 1914** by Big Pharma, some universities and professors using technology transfer creating a Big Pharma monopoly, all with the approval of the many top leaders of Federal Government.

How: They all conspired for the biggest pharmaceutical scam in US History abusing the Federal government, the taxpayer and the Bayh-Dole Act.

We exposed the biggest pharmaceutical scam in US history, where Dr. Raymond Schinazi and Dr. Dennis Liotta at EU, along with Gilead(GSI), and BOR have claimed false original patents (and thus false “genuine Bayh-Dole status”) to sell products at huge profits like Emtriva® (that is likely Lamivudine). **When: since at least 1992 UNTIL NOW (THIS MEANS NO STATUTE OF LIMITATIONS HAS EXPIRED)**, the US taxpayers cost via Medicare, Medicaid and Tricare among other federal and state programs had paid to the defendants for their medications trillions of USDs from 2005 to today because the lack of competition. SCOTUS denied the certioraries in two failed civil lawsuits filed by Dr. Abreu, both *pro se*. However we keep updating SCOTUS until today of the lack of actions by the DOJ. Dr. Abreu filed my first civil case, *Pro se* 2005-2009 (ABREU-VELEZ VS. BOARD OF REGENTS OF THE UNIV.

SYSTEM OF GA. NO CV105-186, 2009 WL 362926 AT *11(S.D. GA FEB 12, 2009) in The District Court of Augusta, GA and in The Eleventh Court of Appeals in Atlanta, GA. Plaintiffs had been attacked constantly for over 14 years and seven months (including present days) as retaliation for being the whistleblower who exposed these **trillion dollar scams**. Today, the attacks on us, our family, our practice, our properties, immigration, reputation and lives have continued. I filed a second pertinent lawsuit in late 2013, ABREU-VELEZ V. BOARD OF REGENTS OF THE UNIVERSITY SYSTEM OF GEORGIA/BOR, ET AL., in The US District Court, Northern District of Georgia, Atlanta Division, No. 1:13-CV-04187-TWT Then, I also lost the appeal in April, 2016, at the US 11TH Court OF Appeals, specifically Civil Action NO. 15-11843-CC and the SCOTUS denied me a certiorari for second time in May, 2016.

How: Gilead, EU, BOR and several people had paid off top administrators likely at the Department of Justice (DOJ), and top administrators have been involved at the Federal Bureau of Investigation (FBI), US Food and Drug Administration (FDA), SEC, FTC, USPTO, United States Citizenship and Immigration Services (USCIS) to cover their illegal practices. Other criminal practices included the “early termination of the waiting period for the global partnership agreements” for each medication. The root causes are the conflicts of interest generated by allowing Big Pharma firms to maintain a monopoly in this case, specifically in HIV as well as Hepatitis B and C medications, abusing the Bayh-Dole Act, using tax dollars from grants for research and development of these medications and they maintain all the profits because universities and colleagues are tax exempt. **How:** They also have violated antitrust, criminal (including the Asset Forfeiture and Money Laundering Section), civil and immigration laws and had disregarded human lives in mismanaged clinical trials. (**When:** since 1991 until now). Our evidence sent over years would allow the putative recovery of hundreds of billions of US tax dollars. It clearly shows the monopolies of Gilead and the defendants maintaining the monopoly in the medications for 1) Hepatitis and 2) HIV worldwide. They used criminal practices by incorporations, acquiring other drug companies’ medications/patents, licenses, stealing and/or by misidentifying medications to obtain higher profits.

For as long as the defendants (especially Gilead) have been making HIV (AIDS) and Hepatitis medications they have been the target of AIDS groups over the pricing and availability of drugs.

We also had asked repeatedly to the DOJ, FBI, HHS and other federal agencies for the prosecution of the people who **manslaughtered**/murdered the 2004 patients at the former MCG, (currently Augusta University) and have not seen a response. O.C.G.A. 16-5-3 (2010), 16-5-3. Involuntary manslaughter (see **Exhibit 2** with the list of the patients).

Precedents: 99.9% of the legal cases in all the US courts against Gilead, Emory and BOR are won by these institutions, which speaks to corruption and the millions if not billions of dollars in bribes and lobbying. Some of the reasons may be because top leaders current and or past of U.S. SEC are part of the “Emory Trustees and or Board of the Visitors at Emory” and or from the

State of Georgia such Elizabeth Branch 94L, Judge, Georgia Court of Appeals, Paul Thomas Kim, Senior Counsel, US SEC, Shinji Morokuma, Program Director, Office of Court Professionals, Administrative Office of the Courts, G. Christopher Nunn 96C, Deputy Commissioner Department of Community Affairs State of Georgia, Elena Parent, State Senator, District 42, Georgia General Assembly, Robert S. Reeves 66C 69L, Judge Superior Court of Middle Georgia, Walter Jospin, Regional Director of SEC Atlanta (Emory alumni). **One of the DOJ's top officers in the North Georgia US Attorney's Office (Mr. Steven Grimberg) IS AN ADJUNCT PROFESSOR AT EMORY (a blatant conflict of interest); AND MR. GRIMBERG NEVER INVESTIGATED any of our claims.**

Emory and the BOR's top administrators and Trustees have also violated multiple rules of tax exempt organizations since at least 2007 to the present as proven by IRS Forms 990 from 2007 to 2014. Ex-CEO of Emory investment Mary Cahill and other top administrators at Emory including many VPs and trustees, also took unfair advantage of Emory staff personnel via their retirement funds management using the companies of the Trustees such the Rollins family companies. The same happens with the former MCG foundation that was forced to be closed by the Federal government for the same reasons. **Gilead top holders are linked to institutional investors, in turn linked to Emory and its trustee's companies currently holding the great majority of stocks. Look at its top three institutional owners: Blackrock Inc. Vanguard Group Inc., and the third largest holder is State Street Corp.**

We had ASKED REPEATEDLY TO MULTIPLE PEOPLE AT THE DOJ FOR A FEDERAL GRAND JURY INVESTIGATION, WHICH HAS NEVER OCCURRED.

SOME OF THE MULTIPLE FEDERAL VIOLATIONS REQUIRE REQUEST OF SUBPOENA DOCUMENTS AND UNSEALING OF LAWSUITS, TO ADD AS PROOF AND THE FOLLOWING WITNESSES TO BE CALLED TO SHOW THE CRIMINAL ACTIONS AND FALSE PATENTS AND HOW THE GOVERNMENT HAD DONE SOME 'NEGOTIATION UNDER THE TABLE WITH THE DEFENDANTS':

-Dr. David Chu in the College of Pharmacy, Department of Pharmaceutical and Biomedical Sciences. At The University of Georgia Medical Chemistry. He is called to verify that Emtriva was not discover by himself, Drs. Liotta and Schinazi or by Emory/ and that they misrepresented this and other patents.

-Dr. Michael C Sofia (real inventor of Sovaldi when he was at Pharmasset). <https://www.acsmedchem.org/?nd=Sofia>. Division of Medicinal chemistry. He is called to verify that the Emtriva was not discover by himself, Drs. Liotta and Schinazi or by Emory/ and that they misrepresented this and other patents.

-Dr. Jean-Pierre Somadossi <http://www.bioexecinstitute.com/sommadossi/>. He is called to verify that the Emtriva was not discovered by himself, Drs. Liotta and Schinazi or by Emory/ and that they misrepresented this and other patents.

- Dr. Katyna Borroto-Esoda. Managing partner, KBE Consulting. Raleigh-Durham, North Carolina. <https://www.linkedin.com/in/katyna-borroto-esoda-8a878322/>. She is called to verify that the Emtriva was not discovered by her, Drs. Liotta and Schinazi or by Emory/ and that they misrepresented this and other patents. And also that 3TC and FTC are basically the same. Evidence has been provide to DOJ many times with proof of deliver.

- Dr. Woo-Baeg Choi. <http://fobsynthesis.com/overview.htm>, FOB Synthesis, Inc., 3400 Cobb International Blvd. Kennesaw, GA 30152, (Main) 404-601-1410 / (Fax) 404-601-1411, (E-mail) admin@fobsynthesis.com. He is called to verify that the Emtriva was not discover by himself, Drs. Liotta and Schinazi or by Emory/ and that they misrepresented this and other patents.

-Attorney Walter Brown, Civil Div., Commercial Litigation Branch. DOJ, 1100 L Street, NW, Room 11128, Washington, DC. 20530, US, 202-307-0341, U.S. Patent Office Registration ID: #47457. He is called as witness to testify we had willingly reported these crimes to the US government in good faith, and that is thanks to the relators that the US got free Truvada for years saving the government millions of dollars.

-Dr. Francis S Collins, MD, PhD, NIH Director. NIH, 9000 Rockville Pike, Bethesda, Maryland 20892, HHS. He is called to testify we had willingly reported these crimes to the US government in good faith, and that is thanks to the relators that the US got free Truvada for years saving the government millions of dollars.

-Dr. Jonathan Mermin, MD, MPH (RADM, USPHS) National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention at CDC Atlanta. Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30329 USA 800-CDC-INFO | (800-232-4636). He is called to testify we had willingly reported these crimes to the US government in good faith, and that is thanks to the relators that the US got free Truvada for years saving the government millions of dollars.

-Special agent William Share of the FBI Atlanta, GA. 3000 Flowers Rd S, Chamblee, GA 30341, Phone: (770) 216-3000. He is called as witness to testify we had willingly reported these crimes to the US government in good faith. We also request him to reveal why the Medical College of Georgia Foundation was forced to close and create a new one, why Dr. Thomas Lawley “left Emory for one year”, why more than 50 employees at the former MCG were force to leave, why more new IRBs were created at MCG, why top people at Emory such as Mary Cahill, and others were force to leave, why the former Chief Judge at the Eleventh Circuit Court of Appeals in Atlanta left his position early, why former Atlanta FBI Chief Johnson “retired”, and why former USCIS Atlanta personnel “left”. These same questions we request to get from Ms. Sally Q Yates.

-Drs. Liotta and Schinazi, professors at Emory, are called to provide their original investigation data on FTC, to provide the identifiers of each of the medications used in the clinical trials where the African patients died, documentation of all severe adverse events in these trials, the name of

each patient who died in the studies done in Africa, and all pertinent written responses from Triangle Pharmaceuticals to the US FDA and the African health authorities.

REQUEST TO RESPECTFULLY SUBPOENA THE FOLLOWING:

-We request **to subpoena** The Federal Bureau of Prison for not answering in 20 days our requested a FOIA #2018-04400, filed 4/21/2018. This will be considering as evidence to this FCA.

-We also request **to subpoena** the Federal and Drug Administration (FDA FOIAs requested: 2015-3368,) filed on 04/27/2015, FOIA requested: 2018-2281, filed on March 22, 2018, FOIA FDA1842614 filed on 4/3/2018, FOIA -FDA1842614, 2018-2918, FOIA- FDA1842080, and 3/14/2018, and FOIA FDA1842077. Illegally not answered. This will be considering as evidence to this FCA.

-We also request **to subpoena** of the HHS for not answering in 20 days our requested FOIA #050820187043 filed several months ago. Illegally not answer. This will be considering as evidence to this FCA.

-We also request **via subpoena** of why Emory is still paying Mr. Michael Mandel and Dr. Thomas Lawley such high salaries years after they retired or left Emory? This will be considered as evidence to this FCA.

-We also request **to subpoena asking** to be answered in writing to the following DOJ personnel how much money, stocks or other assets they and/or their family members have received from Gilead and/or the defendants in the past 10 years: Antitrust, Civil, Criminal and Counsel Directors. Mr. Corey Amundson, Director and Chief Counsel Office of Professional Responsibility, Mr. Steven A. Engel, Assistant Attorney General, Office of Legal Counsel, Mr. Stephen E. Boyd is the Assistant Attorney General for the Office of Legislative Affairs. Mr. Joseph H. (Jody) Hunt Assistant Attorney General, for the Civil Division and Mr. Rod Rosenstein ex-DOJ Deputy Attorney for accepting illegal lobbying form Gilead Sciences Inc., as well as for not prosecuting Gilead, Emory etc. **Multiple top current and past leaders at the Department of Justice (DOJ) have been involved in the lack of prosecution of this by likely receiving "rewards" from lobbying firms representing Gilead via top DOJ employees:** Mr. Steven A. Engel, Assistant Attorney General, Office of Legal Counsel, Mr. Stephen E. Boyd is the Assistant Attorney General for the Office of Legislative Affairs, Mr. Joseph H. Hunt Assistant Attorney General, for the Civil Division. Some lobbied issues included the H.J.Res. 31- Consolidated Appropriations Act, 2019, pharmaceutical access and affordability, Ryan White, PEPFAR, 340B, HCV Screening, drug pricing and access and six protected classes, Medicare Part D, HIV, Medicaid H.R. 259 - Medicaid Extenders Act of 2019. They were "lobbied" from January 1, 2019 to present by **Pamela Smith, 3rd LLC**. She was used to work at DOJ: Title: Counselor to the Assistant Attorney General, Civil Division, Title Special Counsel, Office of

Legislative Affairs. Therefore we request to subpoena the above DOJ top leaders to put in writing how much money, stocks and other have they and or their relatives and family have received in the past 10 years including this one by the defendants. This will be considering as evidence to this FCA.

-We also request to subpoena Mr. Granston, Mr. Benczkowski, Mr. Stephen E. Boyd Mr. Steven A. Engel, and Mr. Joseph H. Hunt employees at DOJ, and the two ex-employees of same institution, ie Mr. Rosenstein, and Ms. Yates to ask for an affidavit if they have received any money, favors, stocks, prices, recognitions or other assets (and/or their relatives) by the defendants in the last 10 years and explain and state the amounts and/or recognitions etc. in written affidavits. We also request that they put in writing the legal reasons why they have not prosecuted the defendants. This will be considering as evidence to this FCA.

**WE ALSO RESPECTFULLY REQUEST TO UNSEAL AND SUBPOENA THE
FOLLOWING:**

-We also request to unseal and **subpoena** of the former Glaxo Wellcome (GW) of the document that former Triangle shall prepare and deliver to Triangle, one complete photocopy of GW's Canadian IND for FTC (HPB file number [***]). Thereafter, GW shall promptly take such actions as are necessary to inactivate (or to effectuate the Canadian regulatory equivalent of inactivate) the Canadian IND, while still allowing Triangle the opportunity to incorporate by reference any of the information contained in the Canadian IND with respect to the Licensed Compound. GW shall not thereafter make any request to reactivate the Canadian IND filing. The Feds can request to see the number in yellow, request a copy from the Canada government: Canadian department of National Health and Protection branch (HPB). This information is also in a sealed lawsuit and settled the case between GlaxoSmithKline and Shire Pharmaceuticals Group and Emory. This will be considering as evidence to this FCA.

-We request **the subpoena** of all the agreements of IOCB/REGA to Gilead in regards of any medications for HIV and hepatitis including the Seventh Amendment Agreement to the License Agreement, between IOCB/REGA and Registrant dated July 1, 2013 amending the October 1992 License Agreement and the December 1992 License Agreement. (In the form SEC 10K A December 31, 2018, Amendment No. 1 Gilead please review exhibits numbers from 10.35 to 10.45 including. This will be considering as evidence to this FCA.

-We also found **the subpoena of all the documents**, which were sealed under court order in the 3 companies Triangle, Pharmasset and Gilead to SEC. This will be considering as evidence to this FCA.

-We request **the subpoena of the, BioChem Pharma** filed in the United States and foreign countries several patent applications on manufacturing methods relating to a class of nucleosides

that includes FTC. If the Company uses a manufacturing method that is covered by patents issuing on any of these applications. This will be considering as evidence to this FCA.

-We also request **to unseal the lawsuit between GlaxoSmithKline and Shire Pharmaceuticals Group and Emory University** including all the documents and the amount paid by Emory to them. This includes Emtricitabine: 524W91, BW524W91, Coviracil®, FTC, lamivudine among others patents and licenses settled in court and sealed. This will be considering as evidence to this FCA.

- We request Emory and BOR to be subpoenaed and produce all the complete past two years to make public and produce their **990 IRS non-profit forms**. Please do not provide the KMPG audit results. This will be considering as evidence to this FCA.

Knowing, this case constitutes a **THE MAJOR FRAUD ACT** for the trillions of USDs and its complexity.

Knowingly, Gilead had violated most rules of The Office of Federal Contract Compliance Programs from the Department of Labor (OFCCP). <https://www.dol.gov/ofccp/>

Knowingly, Gilead and the defendants had the monopoly for the US and entire world for the medications for HIV (AIDS) and hepatitis for more than 20 years, violating anti-monopoly laws and Acts. They also knowing and illegally(likely due to bribes) maintained this monopoly using illegal practices of patent extensions approved by USPTO. With this practice they put the high prices on these medications, preventing millions of people affected by these diseases to get their treatments.

Knowingly, The defendants maintained for **over 2 decades a world monopoly**, likely bribing top governmental officials in the US and worldwide, and had bought the rights over each one of **THE ACTIVE PHARMACEUTICAL INGREDIENT (API PRODUCTS)** to make anti HIV and Hepatitis medication world-wide, to destroy generic medications world-wide and **TO STOP ANY COMPETITION WORLD-WIDE by intimidation, lawsuit and/or by other practices**. They also obstructed the production, approval, and patents of generic medications

world-wide, including the chemicals to produce them. Some of those “merged” companies are also illegal such Teva Pharmaceutical Industries Ltd. (Teva), **the world’s largest manufacturer of generic pharmaceutical products**, and its wholly-owned Russian subsidiary, Teva LLC (Teva **Russia**), agreed to resolve criminal charges and to pay a criminal penalty of more than **\$283 million in connection with schemes involving the bribery of government officials in Russia, Ukraine and Mexico** in violation of the Foreign Corrupt Practices Act (FCPA). Teva was bought by Gilead Sciences Inc.

Knowingly using (or causing to be used) a false record or statement to get a claim paid by the federal government: Emtriva[®] maybe Lamibudine. Similar *Modus Operandi* maybe associated with multiple patented medications examples is included:

Knowingly, Gilead and defendants violated the following: Intellectual Property Section, United States Code, Title 28, section 1498: 28 U.S.C. § 1498, United States Code, Title 35, section 271(a): 35 U.S.C. § 271(a), The Foreign Assistance Act: 22 U.S.C. § 2356, The Tariff Act: 19 U.S.C. § 1337, The Atomic Energy Act: 42 U.S.C. § 2223, The Patent Secrecy Act: 35 U.S.C. § 183, The Trademark Amendments Act of 1999.

Knowingly the DOJ has the obligation to prosecute Health care fraud:
<https://www.justice.gov/civil/corporate-financial-litigation-section> such: Medicare overpayments from health-care providers, protects the government's financial interest in fraud recoveries and litigates matters involving the United States' interests in federally-supported health-care facilities, such as hospitals and skilled nursing facilities. The Section also handles both affirmative and defensive claims for money related to federal health-care programs and protects the United States' interests in the payment and recovery of funds under programs created by the Affordable Care Act.

Knowingly, the DOJ has the obligation to prosecute international crimes such this based on: [https://www.justice.gov/civil/office-international-judicial-assistance-0\](https://www.justice.gov/civil/office-international-judicial-assistance-0)

The Office of International Judicial Assistance (OIJA) serves as the Central Authority for the United States under the Hague Convention on the Taking of Evidence Abroad in Civil or Commercial Matters, T.I.A.S. No. 7444, 23 U.S.T. 2555 ("Hague Evidence Convention"), as well as for evidence requests concerning civil or commercial matters from non-Convention States received through diplomatic channels. Requests relating to criminal matters should be forwarded to the Office of International Affairs of the United States Department of Justice, Criminal Division (see "Criminal Requests" for more information). OIJA serves as the Central Authority under the Hague Convention on the Service Abroad of Judicial and Extrajudicial Documents in Civil or Commercial Matters, T.I.A.S. No. 6638, 20 U.S.T. 361 ("Hague Service Convention"), the Inter-American Convention on Letters Rogatory, S. Treaty Doc. No. 27, 98th Cong., 2d Sess. (1984), and the Additional Protocol to the Inter-American Convention on Letters Rogatory, S. Treaty Doc. No. 98-27, 58 Fed. Reg. 31,132 (1988) ("Inter-American Convention") for purposes of service. OIJA also executes service requests received through diplomatic channels from non-Convention States. Guidance regarding requesting service of judicial and extrajudicial documents is found under "Service Requests." Service requests are executed through a private contractor, ABC Legal. Accordingly, service requests and service-related inquiries should be sent directly to ABC Legal at 633 Yesler Way, Seattle, WA 98104 USA.

Knowingly, The US Federal government and taxpayer rights on the following patents from the defendants because they used The Bayh-Dole Act: The patented medications included: Lamivudine (3TC), Emtricitabine [(-)-FTC or FTC], Sovaldi, Telbivudine (LdT).

US 6,642,245 B1. The U.S. Government has rights in this invention arising out of the partial funding of work leading to this invention through the National Institutes of Health Grant Nos. AI-26055, AI-28731, NIH 5-21935, as well as a Veteran's Administration Merit Review Award. Antiretroviral Activity in Various Cell Lines. Uptake of (+)-FTC Into Human PBX Cells. CSF/Serum Ratio of FTC and its Metabolites in Rhesus Monkey.

US 6,703,396 B1. The U.S. Government has rights in this invention arising out of the partial funding of work leading to this invention through the National Institutes of Health Grant Nos. NIH 5-21935 and NIH AI-26055, as well as a Veteran's Administration Merit Review Award

US 7,468,436 B2. The U.S. Government has rights in this invention arising out of the partial funding of work leading to this invention through the National Institutes of Health Grant Nos. NIH 5-21935 and NIH AI-26055, as well as a Veteran's Administration Merit Review Award.

US 7,160,999 B2. The U.S. Government has rights in this invention arising out of the partial funding of work leading to this invention through the National Institutes of Health Grant Nos. NIH 5-21935 and NIH AI-26055, as well as a Veteran's Administration Merit Review Award.

US 5,914,331. The U.S. Government has rights in this invention arising out of the partial funding of work leading to this invention through the National Institutes of Health Grant Nos. AI-26055, AI-28731, NIH 5-21935, as well as a Veteran's Administration Merit Review Award.

US 7,115,584 B2. This invention is partially funded by a grant from the United States National Institutes of Health under Grant No. 1R01-AI-41980-01. The U.S. government has certain rights to this invention.

US 6346627. The U.S. Government has rights in this invention arising out of the partial funding of work leading to this invention through the National Institutes of Health Grant Nos. NIH 5-21935 and NIH AI-26055, as well as a Veteran's Administration Merit Review Award.

US 6,232,300 B1. None know.

US 6,348,587 B1 (SOVALDI). The invention described herein was made with Government support under number AI32351 awarded by the National Institutes of Health. The United States Government has certain right to this invention.

US 7,307,065 B2. (SOVALDI). The University of Georgia Research foundation part of the **BOR, and Emory.** The invention described herein was made with Government Support under grant number AI32351 awarded by the National Institutes of Health. The United States Government has certain rights to this invention.

US 6,911,424 B2. (SOVALDI)...The previous patents were obtained with US government money ...This application is a continuation application of U.S. patent application Ser. No. 09/257,130 filed on Feb. 25, 1999, now U.S. Pat. No. 6,348,587, which claims priority to U.S. provisional application No. 60/075,893, filed on Feb. 25, 1998, now abandoned, and U.S. provisional application No. 60/080,569, filed on Apr. 3, 1998, now abandoned.

US 6,911,424 B2. (SOVALDI). The previous patents were obtained with US government money ...This application is a continuation application of U.S. patent application Ser. No. 09/257,130 filed on Feb. 25, 1999, now U.S. Pat. No. 6,348,587, which claims priority to U.S. provisional application No. 60/075,893, filed on Feb. 25, 1998, now abandoned, and U.S. provisional application No. 60/080,569, filed on Apr. 3, 1998, now abandoned.

The law provides that the Government may override patent protection when the action is important for the welfare of the nation.

Knowingly, and with malice intended, the defendants, especially Gilead and Emory had maintained the HIV and Hepatitis medication monopoly over the past 20 years. They also used (or causing to be used) a false record or statement to conceal, avoid, or decrease an obligation to pay money or transmit property to the federal government by abusing the following acts and/or laws: The Sherman Antitrust Act of 1890, the Massachusetts Antitrust Act., The Clayton Antitrust Act of 1914, The Robinson-Patman Act of 1936, 18 U.S.C.). The Securities Act of 1933, The Securities and Exchange Act of 1934, The Tax Evasion (Section 7201 of the Internal Revenue Code, 26 U.S.C. §§ 7201-7217, The “Responsible Corporate Officer” (RCO) doctrine, The Bank Secrecy Act of 1970, the Money Laundering Control Act of 1986, The Patriot Act, see 18 U.S.C. 1956. This information had been send to the DOJ, FBI, HHS etc. showing the multiples lawsuits filled by mainly Gilead and Emory against any competitors for the medications and generics for HIV and hepatitis in the last 20 years. Consulting justia.com. Also showed proof evidence of the records consulted via SEC at EDGAR with Gilead, Triangle, and Pharmasset especially the forms 10K where they show all the incorporation, merger, licenses etc. THE FEDERAL REGISTRY proves all these claims and how most of these leaders in the antitrust division, FTC and multiple other agencies didn’t report and/or misled them.

Knowingly and conspiring and with malice intended, with others, the defendants have made false or fraudulent claims paid by the federal government for programs such **Medicaid, Medicare, Tricare, VA, Federal Bureau of Prisons**, among many other Federal programs selling medications that should cost only some **millions** of dollars, pretending to be “newly discovered” medications; and instead the government has expended **trillions** of dollars”.

Knowingly and with malice intended, The defendants had participated in: Obstruction of Justice 18 U.S.C. §§ 1501-1521, Racketeering Influence and Corrupt Organizations Act (RICO) (18 U.S.C. §§ 1961-1968), have abused and retaliated against me and my daughter immigration

violating The Naturalization Act of 1790 and their amendments in 1795, 1850 and 1882 the 1921, The Emergency Immigration Act, 1924, the Immigration Act of 1924, The Modern Immigration and Nationality Act of 1952 (INA), also known as the McCarran-Walter Act, 1975, The Immigration Act of 1990, The Illegal Immigration Reform and Immigrant Responsibility Act (IIRIRA) of 1996, the 8 U.S. Code Subchapter II – IMMIGRATION PART II - Nationality Through Naturalization (§§ 1421 to 1459).

Knowingly, and with malice intended, patients died in the clinical trials for the HIV medications in South Africa and other African countries done by Triangle (a biotechnology company created by Emory University professors Drs. Raymond Schinazi and Dennis Liotta and others from Emory abusing the Bayh-Dole Act). Other patients also died in the clinical trials at MCG in Augusta GA, currently known as Augusta University (AU).

Knowingly, and with malice intended, the plaintiffs have experienced severe retaliation for protecting the patients in clinical trials, and the US taxpayers. Plaintiffs' family, finances, business, reputation, professional activities had been attacked by the defendants to silence them for over 14 and a half years; all these attacks were reported to the local police, the FBI Atlanta the DOJ and multiple federal agencies.

Knowingly, and with malice intended, "Gilead" and also Emory violated the federal Anti-Kickback Statute by offering illegal paybacks to induce doctors to prescribe Gilead's drugs. These kickback violations caused submission of false claims to the government, as prohibited by the federal False Claims Act and state analogues. We have provided many times the names of the doctors and institutions to which Gilead and others made the payoffs. The Anti-Kickback Statute is a federal criminal statute that prohibits "knowingly and willfully" offering "remuneration . . . to induce" someone "to refer an individual . . . for . . . any item or service" reimbursable under a federal health care program. 42 U.S.C. § 1320a7b (b)(2)(A). Such conduct is a felony punishable by years in prison and significant fines.

Knowingly and with malice intended, the relevant medications against HIV (AIDS), and Hepatitis B and C were falsely patented in the USA, as original research patents, and approved by using something called "fast-track approval", "priority approval," "voucher approval" or "humanitarian approval" for the FDA using false pretenses.

Knowingly, and with malice intended, the Defendants have evaded paying US taxes using several fraudulent practices and violating nonprofit privileges, abusing US taxpayers.

Knowingly, and with malice intended, the defendants have paid millions of dollars in kickbacks, using revolving doors, paying off politicians, abusing with conflicts of interest, paying off doctors, scientists, university professors, hospitals, medical providers, pharmacists etc. for years.

Knowingly, and with malice intended, the Security and Exchange Commission (SEC) rules have been violated due to illegal insider trading with corrupt intent. The defendants also used methods such as pump and dumps, penny stocks, and other criminal practices in their created biotechnology companies, especially those using the Bah-Dole Act by Emory and some component of the BOR.

Knowingly, and with malice intended, The United States Patent and Trademark Offices (USPTO) have been likely bribed, allowing the illegal extension of patents by Gilead to maintain the monopolies in HIV (AIDS) and hepatitis world-wide for over 20 years.

Knowingly, and with malice intended, they reported impurities in manufacturing medications by Gilead Science described by ex rel. Mr. Jeffrey Campie and Sherilyn Campie (petition for certiorari at SCOTUS), respondents can be easily seen in the 601 FOIA from EPA and other agencies in this following website. <https://foiaonline.regulations.gov/foia/action/public/home> (multiple agencies). The DOJ for dark reasons declined to intervene. In the Bayh-Dole Act the taxpayer through the federal government maintains the license, the technology on the respective granted product, **AND THE MANUFACTURING MUST BE IN THE USA**. They violated all three of these requirements.

Knowingly, and with malice intended, Gilead top executives violated SEC rules on insider trading since 2003, initially when they were troubles with unlawful off label marketing and no or inadequate response to multiple FDA warning letters about Viread®, and later when someone at the DOJ had alerted Gilead about possible investigation and/or prosecution. Such is still happening. This information has sent to the DOJ, FBI and other federal agencies.

How did it start? Precedents: Dr. Abreu informed authorities that Dr. Thomas Lawley, ex-dean of the School of Medicine at Emory University, and Gilead ex-CEO John C. Martin had "worked together since 2000," advising the National Institute of Allergy and Infectious Diseases (NIAID), that belongs to the National Institute of Health (NIH), to give grants to Emory University where all these medicines supposedly were discovered. Dr. Abreu also discovered and averred in her 2013 lawsuit that, about the same time or one year earlier, Drs. Schinazi and Liotta and Dr. Woo-Baeg Choi, also with Emory University, held patents derived from NIH-funded research. Dr. Abreu suggests that these may become a liability to Emory University if ongoing investigations prove that Racemic BCH-189 [the minus enantiomer known as Lamivudine (3TC), invented by **Dr. Bernard Belleau** while working at McGill University and the Montreal-based IAF Biochem International Inc. in 1988] is **INDEED Lamivudine (generic) AND is very similar to Emtricitabine (Emtriva®/FTC)**. Dr. Abreu finds it quite abnormal that several publications comparing these two drugs (including multiple publications by the World Health Organization (WHO) in June 2012, found that both medications are the same (lamivudine and Emtriva®). High performance Liquid Chromatography, NMR and LC-HRMS technology evidence provided also pointed to this and the DOJ, FBO, HHS, NIH, FDA, USPTO, DEC,

DOD, CDC has been informed. Also we sent information showing the complete applications sent to the FDA for these medications, randomized clinical trials comparing these medications, the pooled results of these trials found no difference in terms of virological suppression (relative risk), 95% confidence interval, virological failure and CI, cohorts, nucleoside reverse transcriptase inhibitor mutations, viruses without resistance mutations, M184V/I mutation resulting in high-level resistance, medicinal effective concentrations, based on biological (99th percentile of the distribution of WT virus population) and clinical cutoffs etc.

The antiretroviral drug is included in current WHO Model Lists of Essential Medicines and is in various international guidelines for the treatment of HIV infection. Specifically, The WHO evaluated 3TC and FTC, and considered them very similar and indeed the legal records indicate this medication WAS NOT INVENTED AT EMORY, IT WAS STOLEN FROM BELLEAU AND OTHERS.

Indeed, the relators have revealed that these three professors from Emory University stole the patent from Dr. Belleau (Emory's patent for 3TC/Epivir® Lamivudine® was invalidated by the U.S. Patent Office); and, then, Emory University bought the rights of 3TC/FTC from GlaxoSmithKline and Shire Pharmaceuticals Group., which merged with these small companies, and a large settlement was paid by Emory to cover all this. Then Drs. Dennis Liotta and Raymond Schinazzi "pretended to discover Emtriva" but indeed this is lamivudine, the same medication discovered by Dr. Belleau in Canada. The relators believes it is likely these doctors have stolen many other patents on drugs to treat HIV and Hepatitis C worldwide to maintain, along with Gilead, the monopoly and to manipulate the patent system. They manipulate the patent system by not allowing the patents to expire and not allowing generics to enter the market, which would help to lower the prices, and by preventing competition and abusing the provisions of the Hatch-Waxman Act, The Drug Price Competition and Patent Term Restoration Act, Pub.L. 98-417, that encourage generic competition. The relators note that multiple antitrust lawsuits have been filed against Gilead and Emory by many companies, and patient advocates, among others, and that these dirty practices block affordable access to lifesaving HIV and Hepatitis B and C drugs. In fact, the relators note that in late 2015, Emory lost a wrongful death case arising out of a sleep study which proves that money is more important to Emory than the safety of its patients.

Academy of Sciences of the **Czech Republic** (1992 – 2002). **Antonín Holý** (He specialized in the field of chemistry and cooperated on the development of important antiretroviral drugs used in the treatment of HIV and hepatitis B. He was involved in the creation of the most effective drug (as of early 2009) in the treatment of AIDS. Dr. Antonín Holý is the author of more than 400 scientific discoveries and holds 60 patents. With more than 400 discoveries to his credit, his work has affected millions of people with viral diseases such as HIV/AIDS and Hepatitis B, C and other viral disease.

In 2006 the US biopharmaceutical company Gilead Sciences and the Institute of Organic Chemistry and Biochemistry (IOCB) of the Academy of Sciences of the Czech Republic jointly established a new research center, oriented to the development of new preparations. Gilead promised the IOCB a \$1.1 million donation, to fund its operations and research for 5 years. **Viread generic (Tenofovir)** (from 86 USD\$ max to 292) was approved in the USA in 2001 for the treatment of AIDS, and **Hepsera®** was approved in 2003 for the treatment of Hepatitis B. **Truvada® (at least four times more expensive than the generic)**, a combination of **Viread and Emtricitabine**, was approved in 2006 for use in the USA this for the cost of at least \$84,000 USD (for a medication that cost maximum \$200 USD).

Dr. Abreu notes that Pharmasset Inc. was founded in 1998 by Emory University professors Drs. Schinazi and Liotta. The company was initially incorporated in Barbados (as Pharmasset Ltd.) and separately in Georgia; however, the company was redomiciled as a Delaware corporation on June 8, 2004. Drs. Schinazi and Liotta have received millions of dollars in grants at Emory University from the NIH and other federal agencies including, this year, the Defense Threat Reduction Agency. Later, the same group was involved in many lawsuits based on "merging and buying companies" to maintain the monopoly on HIV, Hepatitis B, Hepatitis C, and other antiviral treatments and medications worldwide, violating antitrust laws, and related to the drug Emtricitabine.

The Bayh Dole Act: The Bayh Dole Act (BDA) via Patent and Trademark Law Amendments Act (Pub. Law 96-517, Dec 12, 1980) permits universities, small businesses, or non-profit institutions to elect to pursue ownership of an invention in preference to the government. In addition to tax-exemption and BDA profits, universities and colleges receive millions of dollars in grants, ranging from 40 to 100 billion given for research and development (**R&D**) in each fiscal year. In addition, they receive about \$46 billion in free scholarship money, awarded each year by the Department of Education. In addition these universities/institutions also received, **43% of overhead administrative costs for each federal grant**. The people at stake abused of tax exemptions and Bayh Dole, where unscrupulous physicians, scientists and administrators found a way to quickly perform basic science studies, then in animal models and also on humans (using clinical trials). These trials were then approved, falsifying results and jeopardizing lives. We realized that the approval of the clinical trials, and the basic science and animal model studies **RELIED ON THE DEAN OF EACH MEDICAL SCHOOL**. Thus, these institutions had motive for the repeated attacks on my career and personal life. I discovered their *modus operandi*. I exposed these issues to the US government: The *modus operandi* is simple. The universities are tax exempt and receive billions in Federal grants, etc. The Bayh Dole Act is abused via technology transfer of poorly regulated products, and the universities gain huge profits. Using the Bayh-Dole Act the universities do studies "*in vitro*" (in cells), then in animals, then in humans (clinical trials). The pharmaceutical companies and/or the universities' own

biotechnology companies likely pay under the table for fast approval of the clinical trials in humans and to "avoid reporting severe adverse events" (SAEs). It is the function of the Dean of Medicine at each university medical school to approve the results these clinical trials. The Deans also are supposed to monitor what is called "external activities": specifically, what the investigators can do in advertising and/or speaking for the pharmaceutical companies. If these Deans are unethical or corrupted (as in the case of **Emory's former Dean Lawley**), conflicts of interest proliferate and false medical data is then sent to the FDA, the NIH and other governmental funding agencies for quick approval of the drugs and/or devices. The Offices of Technology Transfer are in the center of the process at the universities, and their attorneys specialize in patents. The following web site show the grants that Dr. Liotta and Schinazi had received from the federal government, give the amounts, and the years of finance. After reviewing these you can ask Gilead, Pharmasset, Liotta, or Schinazi if they still have the nerve to say that "the federal government has not given them any dollars use for R&D in their medications for Hepatitis B and C and HIV". The Bayh-Dole Act entitles the federal government to maintain the licenses on patents, also the technology and most products should be manufactured in the US to benefit the taxpayer and Federal Government.

One possible mechanism for negotiating with Emory and BOR to negotiate our requested settlement is to remind them that they are tax exempt, and have abused such using their foundations, and investments. They also receive training grants, Bayh Dole Act and technology transfer patent/royalty income, nontaxable endowment income, property and other tax exemptions as well as VA, Dep of Defense and NIH grants that can be stopped.

A qui tam action must be confidentially filed under seal in Federal district court in accordance with the Federal Rules of Civil Procedure. A copy of the complaint, with a written disclosure statement of substantially all material evidence and information in the plaintiff's possession, must be confidentially served on the US Attorney General and the US Attorney for the district in which the complaint is brought. An action under the False Claims Act must be filed on camera and under seal.

Potential recovery for the US government, taxpayers and others:

We are talking about:

1. **About 23 Trillion USDs** overcharged from US taxpayers from falsely patented medications and 20 years of monopolies on these medications for HIV and hepatitis. The RECOVERY OF THIS MONEY **COULD PAY OFF THE ENTIRE US DEBT.** We had sent plenty of proof that the VA alone paid to Gilead almost 1.7 trillion USD.
2. **About 3 trillion USDs** against private health care companies such Kaiser Permanente, Blue Cross BlueShield, Aetna etc. This is an indirect damage for tax

payers also because this illegal practices increase the price and copayments for tax payers via health insurances.

3. **About 100 trillion USDs** worldwide outside the US due fraudulent patents and monopolies in HIV and hepatitis medications for over 20 years.
4. **Medicare's monthly spending on hepatitis C** treatment increased more than six-fold from \$116.4 million in January 2014 to \$793.2 million in June 2015, the Senate investigation revealed. Also Senators Wyden-Grassley Sovaldi investigation finds revenue-driven pricing on Sovaldi and Harvoni, Medicare pay at least 80 billion USD to gilead and defendants for those overpriced medications.

<https://www.finance.senate.gov/.../wyden-grassley-sovaldi-investigation-finds-revenue...>

The masterminds of the scam were: Dennis Liotta, PhD, Raymond F. Schinazi, PhD, DSc (Hon) (Triangle, Pharmasset, Emory and BOR), [(both at Emory and Board of Regents of the University System of Georgia (BOR)], John C Martin, (ex CEO of Gilead Sciences of Foster City, Calif.), Ex R &D of Gilead Dr. Norbert Bischofberger, Ex-Chief Executive Officer John Milligan, Gregg H. Alton, JD at Gilead, Steven D. Sencer (the current Chief Counsel for Emory for covering these criminal actions), who also helped to cover up the killing of hundreds of patients in sham clinical trials (in Romania, Mexico, two centers at South Africa and two centers in the USA) **with likely pay-offs at all levels.**

ACCORDING TO THE JUSTICE MANUAL, -4 111 - DOJ DISMISSAL OF A CIVIL *QUI TAM* ACTION IS BASED ON THE FOLLOWING:

When evaluating a recommendation to decline intervention in a *qui tam* action, attorneys should also consider whether the government's interests are served, in addition, by seeking dismissal pursuant to 31 U.S.C. § 3730(c)(2)(A). While it is important to be judicious in utilizing § 3730(c)(2)(A), such dismissals also provide an important tool to advance the government's interests, preserve limited resources, and avoid adverse precedent.

When determining whether to seek dismissal, the Department should evaluate the following non-exhaustive list of factors that can serve as a basis for dismissal:

1. Curbing meritless *qui tams* that facially lack merit (either because the relator's legal theory is inherently defective, or the relator's factual allegations are frivolous). **We have factual, not frivolous allegations sent many times to the FBI, DOJ, VA, HHS, DOD SEC, USPTO, USCIS among many federal agencies.**
2. Preventing parasitic or opportunistic *qui tam* actions that duplicate a pre-existing government investigation and add no useful information to the investigation. **We had led the federal agencies on this this investigation for years. We are not parasitic. FOR DARK REASONS THEY HAVE PROTECTED THE WHITE COLLAR CRIMINALS.**

3. Preventing interference with an agency's policies or the administration of its programs. **This does not apply because the DOJ and other federal agencies MUST PROTECT THE PUBLIC AND US TAXPAYERS, PATIENTS AND WHISTLEBLOWERS. INDEED THIS ROAD MAP HAS BEEN FULL OF RED FLAGS AND FOR DARK REASONS DOJ AND FTC ALLOWED THE ILLEGAL MERGERS OF GILEAD TO MAINTAIN THE MONOPOLIES IN HIV AND HEPATITIS MEDICATIONS.**
4. Controlling litigation brought on behalf of the United States, in order to protect the Department's litigation prerogatives. **We do not have access to the DOJ litigations on this matter, but consulted the antitrust and criminal DOJ websites for action against these defendants and have not found any information.**
5. Safeguarding classified information and national security interests. **This matter does not imply national security interest.**
6. Preserving government resources, particularly where the government's costs (including the opportunity costs of expending resources on other matters) are likely to exceed any expected gain. **This does not apply, we had shown that the VA alone paid almost 1.7 trillion USDs to Gilead using FOIA and several FOIAs to HHS, Federal Bureau of Prisons, FDA and to other agencies had been delayed for unknown reasons.**
7. Addressing egregious procedural errors that could frustrate the government's efforts to conduct a proper investigation. **The Atlanta FBI has led efforts investigating this case. There is no excuse for claiming these were our errors. The information below provides proof that our claims have been taken seriously by multiple federal agencies:**

AS RESULTS OF THE RELATOR ACTIONS PROTECTING TAXPAYERS, THE US GOVERNMENT AND THE PATIENTS THE FOLLOWING REMEDIES WERE PUT IN PLACE:

Some accomplishments from this terrifying experience were that the HHS and FDA:
<https://www.fda.gov/RegulatoryInformation/Guidances/ucm607652.htm>..

On May 14, 2018 new regulations were implemented to improve the Bayh-Dole Act and preventing abuse by institutions such Emory and others. The Secretary of Commerce has delegated to the National Institute of Standards and Technology the authority to promulgate implementing the new regulations to favor the tax payers who at the ended funded these projects-patents.

As results of us exposing this, other changes as a result occurred in the Securities and Exchange Commission Act of 1934, including new amendments in Self-Regulatory Organizations, in

Clearing Corporation Stress Testing and Clearing Fund methodology and reorganization and consolidation of clearing fund by-laws and rules.

The DOD General Services Administration, and the National Aeronautics and Space Administration updated rules including civilians and other companies' acquisitions updated its regulations in regard to the Federal Acquisition Regulations on June 15, 2018: Federal Acquisition Circular 2005-99.

At the National Institute of Health (NIH) including the AIDS Study Section and Related Research integrated review group, created six new study sections were created and will cover the areas of basic, translational, clinical, and population science: HIV Molecular Virology, Cell Biology, and Drug Development, HIV Immunopathogenesis and Vaccine Development, HIV Comorbidities and Clinical Studies, HIV Coinfections and Associated Cancers.

Other accomplishments beside the "retirement" of the top leaders at Gilead was that on September 24, 2018 Gilead announced a plan to introduce a generic version of their leading cures for Hepatitis C (HCV) in the United States. <http://www.gilead.com/news/gilead-subsiary-to-launch-authorized-generics-to-treat-hcv>.

On Septembers 4, 2018 FDA approved generic medications for HIV: <https://aidsinfo.nih.gov/understanding-hiv-aids/fact-sheets/21/58/fda-approved-hiv-medicines>. FDA-Approved HIV Medicines. (Including the false patented by Emory and Gilead BOR).

HIV generics in Europe were also approved on June 2018.

On November 6, 2018, The Office of Inspector General, HHS update notice on the Federal Registry replacing all language in Part Q (Office of the Secretary) of the Statement of Organization, Functions, and Delegations of Authority for HHS. They updated rules in how to conduct and supervise audits, investigations, evaluations, and inspections relating to HHS programs and operations. Also updated identifying systemic weaknesses giving rise to opportunities for fraud and abuse in HHS programs and operations and makes recommendations to prevent their recurrence Agency/Docket Number: OIG-1810-N.

On April 30, 2019, The DOJ, Criminal Division released a new guidance document intended to assist prosecutors in evaluating corporate compliance programs and guide corporations in creating them. Improving compliance program is in fact operating effectively, exploring a program's capacity for continuous improvement, periodic testing, and review, investigation of misconduct, and analysis and remediation of underlying misconduct <https://www.justice.gov/opa/pr/criminal-division-announces-publication-guidance-evaluating-corporate-compliance-programs>.

On July 11, 2018, The House Committee on Oversight and Reform held a hearing of possible undeclared conflicts of interest by ex- Office of Management and Budget Associate Director of

Health Programs Joseph Grogan's was forced to leave for conflict of interest for his former employer, Gilead Sciences, Inc., Director <https://oversight.house.gov/news/press-releases/new-documents-raise-concerns-about-potential-conflict-of-interest-of-former-drug>.

The House Committee on Oversight and Reform held a hearing on May 15, 2019 about high drug prices on Gilead <https://oversight.house.gov/news/press-releases/committee-to-hold-hearing-on-gilead-s-exorbitant-price-for-hiv-prevention-drug>.

DOJ updated their rules on handling antitrust issues: <https://www.justice.gov/opa/pr/departments-justice-hold-roundtable-antitrust-criminal-civil-penalty-enhancement-reform-act>.

On May, June and July 2019, the DOJ antitrust, criminal and civil update their rules noncompetition but also raised question as "PROTECT THE WHITE COLLAR CRIMINALS". <https://www.justice.gov/opa/pr/departments-justices-antitrust-division-joins-framework-competition-agency-procedures-founding>

The International Competition Network (ICN) held its 18th annual conference, hosted by Colombia's Superintendent of Industry and Commerce, on May 15-17, 2019, in Cartagena, Colombia. This with the goal of establishment a Framework on Competition Agency Procedures (CAP) that reflects the commitment by its participants to uphold fundamental procedural fairness principles and adopted Recommended Practices for Investigative Process that offer aspirational guidance and norm-setting principles on procedural fairness.

<https://www.justice.gov/opa/pr/international-competition-network-adopts-framework-competition-agency-procedures-and>.

On May 2019, The FTC also updated and changes several rules on this regard: <https://www.ftc.gov/about-ftc/bureaus-offices/bureau-competition>; <https://www.ftc.gov/enforcement/premerger-notification-program>.

On May 2019 NIH updated the rules on Bayh-Dole Act and retrained the grantee institutions in their rights and obligations <https://regionalseminars.od.nih.gov/baltimore2019/sessions/00e/>, <https://public.era.nih.gov/iedison/public/login.do?TARGET=https%3A%2F%2Fpublic.era.nih.gov%2Fiedison%2Finit.do>

On May 23, 2019 SEC updated rules promoting the Sunshine Act: <https://www.sec.gov/news/closedmeetings/2019/ssamtg052319.htm>. Some of the subject matters included: Institution and settlement of injunctive actions; Institution and settlement of administrative proceedings; Resolution of litigation claims; and other matters relating to enforcement proceedings.

On May 9, 2019, The Center for Disease Control (CDC) (Dr. Mermin call as witness below) and DOJ (Attorney Brown call as witness below), negotiated with Gilead to give free Truvada pills to

200,000 uninsured people for the next 11 years to help prevent new HIV infections. Such likely as result of negotiation for less criminal, patents and antitrust charges.
<https://www.nbcnews.com/feature/nbc-out/gilead-donate-hiv-prevention-drug-truvada-200k-uninsured-patients-n1004381>

On May 13, 2019, the U.S. Supreme Court (SCOTUS), Extends Statute Of Limitations for Privately Initiated False Claims Act Lawsuits to 10 years.
<https://www.drinkerbiddle.com/insights/publications/2019/05/us-supreme-court-extends-statute-of-limitations>.

On Jul. 17, 2019-- Gilead Sciences, Inc. (Nasdaq: GILD) announced more departures to the company's senior leadership team. Gregg Alton, Chief Patient Officer, and Katie Watson, Executive Vice President, Human Resources, will be departing Gilead.
<https://www.gilead.com/news-and-press/press-room/press-releases/2019/7/gilead-sciences-announces-changes-to-senior-leadership-team>

Sincerely,



Ana Maria Abreu Velez, M.D., Ph.D., D.Sc. (signed electronically)
1192 Cumberland Road, NE; Atlanta, Georgia 30306
E-Mail: abreuvelez@yahoo.com.
Home Phone: 404-876-4897.
Cell phone: 404-660-5558.



Michael S. Howard, M.D., (signed electronically)
Georgia Dermatopathology Associates
2250 North Druid Hills Road, NE; Suite 124, Atlanta, Georgia 30329,
E-mail: mhoward@gadermpath.com
Work Phone: 404-371-0077, Cell: 404-431-9249

1

June 13, 2019

Michael Granston, III

Director, Civil Fraud Section, Civil Division at US Department of Justice

(202) 305-0632

RE: Request for a Qui tam (filing *pro se*). Cause: 31:3729 False Claims Act
Nature of Suit: 376 Qui Tam (31 U.S.C. 3729(a))

Defendants: Who did the illegal actions: Gilead Sciences Inc., (Gilead) (Foster City, California), Emory University in Atlanta, Georgia (GA), (Emory)University of Georgia Foundation as part of the Board of Regents of the University System of Georgia (BOR), Dennis Liotta, PhD, Raymond F. Schinazi, PhD, DSc (Hon) (Triangle, Pharmasset, Emory and BOR), [(both at Emory and Board of Regents of the University System of Georgia (BOR) professors], John C Martin, (ex CEO of Gilead), Ex R&D of Gilead Dr. Norbert Bischofberger, Ex-Chief Executive Officer John Milligan, Gregg H. Alton, JD at Gilead, Steven D. Sencer (current Chief Counsel for Emory for covering these criminal actions). Gilead Sciences Ireland UC, Akros Pharma Inc., Gilead Holdings, LLC, Japan Tobacco International U.S.A. Inc., Janssen R&D Ireland, Johnson & Johnson Inc., E. R. Squibb & Sons, LLC, Bristol-Myers Squibb Company, Gilead Sciences, LLC, Japan Tobacco Inc.

Plaintiffs and original sources: Ana Maria Abreu Velez, M.D., Ph.D., D.Sc. 2250 North Druid Hills Road NE; Suite 124, Atlanta, GA 30329, Work Phone: 404-371-0077, E-mail: abreuvelez@yahoo.com.

Michael S. Howard, M.D., Georgia Dermatopathology Associates, 2250 North Druid Hills Road, NE; Suite 124, Atlanta, Georgia 30329, E-mail: mhoward@gadermpath.com
Work Phone: 404-371-0077, Cell: 404-431-9249

RE: A False Claims Act (FCA) and state corollaries 31 U.S.C. Sections 3729 through 3733. Qui tam, against Gilead Sciences Inc. (GSI), Emory University (EU), the Board of Regents of the University System of Georgia (BOR) and former Medical College of Georgia, (MCG) currently Augusta University (AU) and the defendants above mentioned for abuse/fraud against federal programs/the taxpayers, the plaintiffs to sue the wrongdoer on behalf of the United States Government. The FCA's qui tam provision is intended to encourage insiders with unique knowledge to bring fraud to light. The FCA targets those who intentionally deceive the government by "knowingly" presenting or causing to be presented "a false or fraudulent claim" for payment to the United States. 31 U.S.C. § 3729(a)(1)(A). Given its targeted focus and severe punishment—including treble damages and thousands per false claim in civil penalties.

We are aware of the Granston memo and its timing, with the Rosenstein memo decreasing penalties on white collar criminals; these both raise many questions.

We had sent a previous Qui tam to Ex DOJ AG Jeff Sessions (**Attachment 1**) and we never received any answers. We have sent hundreds of communications to investigate and prosecute the issues we exposed using a Grand Jury and a special prosecutor to the DOJ in Georgia and in Washington; it seems that only now these issues are being taken seriously (we have plenty of proofs of delivery). For the severe retaliation against us, we also had asked the DOJ hundreds of times to encourage Gilead, Emory and BOR (and/or directly the DOJ) to give us immediately the proposed settlement and such also never happened. The civil, criminal, antitrust, immigration and other parts of the DOJ (with plenty proofs of delivery and copies to other people/entities) have failed over many years to protect our rights and the US taxpayers' rights.

Precedents: Special damage: For 14 years and seven months, I, my family, my daughter, our practice, our reputation, our economy, our mental and physical health have suffered the most severe persecution, attacks and retaliations via the above institutions for exposing the death of multiple patients in clinical trials and severe violations to the code of federal regulations. In addition, I exposed severe antitrust violations by Gilead (**when: for 20 years**), never prosecuted by the Department of Justice (DOJ) (as far as we can determine), besides sending them the information hundreds of times using Federal express, US mail, phone calls and e-mail (of which we have proof). I also exposed severe violations of non-profit status by EU, BOR and their Trustees and top administrators and the IRS non-profit unit, as well as the DOJ (which I copied), who combined did nothing to recover trillions of US Dollars. We lost our assets; I have been a victim with my family of more than 62 attacks. The defendants destroyed us, our family and practice via all means (from attacking my minor daughter who was hospitalized for one month after the attack) by physical, emotional, immigration acts and other dirty practices. They wrecked our reputation and practice. Dr. Abreu lost her job in June 2016; and has applied to more than 250 positions, and has been unable to obtain a new position due to persecution and defamation against her, Dr. Howard and our practice: Georgia Dermatopathology Associates (GDA).

We tried by many ways via Ms. Sally Q Yates, Loretta Lynch, John A Horn (current US North Georgia Attorney) and top officers in the North Georgia US Attorney's Office (Mr. Steven Grimberg) as well as in the Southern Georgia US Attorney's office, including Mr. Edward Tarver. We contacted the Office of the Inspector General (OIG) of the DOJ many times, and most US Federal regulatory agencies and so far, after contacting for all these past years, nothing has changed and we have been awarded nothing.

Here we present a summary of our journey of harassment, discrimination and lack of justice for protecting patients, taxpayers and those affected by 1) HIV, and 2) Hepatitis B and C worldwide the Federal Government and the tax payers. We document abuse of patients in clinical trials

using taxpayer money, abusing the Bayh-Dole Act and the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (Public Law 94-435, known commonly as the HSR Act, violation of The Federal Trade Commission Act of 1914 by Big Pharma, some universities and professors using technology transfer creating a Big Pharma monopoly, all with the approval of the many top leaders of Federal Government.

How: They all conspired for the biggest pharmaceutical scam in US History abusing the Federal government, the taxpayer and the Bayh-Dole Act.

We exposed the biggest pharmaceutical scam in US history, where Dr. Raymond Schinazi and Dr. Dennis Liotta at EU, along with GSI, and BOR have claimed false original patents (and thus false “genuine Bayh-Dole status”) to sell products at huge profits like Emtriva® (that is likely Lamivudine). **When:** since at least 1992, the US taxpayers cost via Medicare, Medicaid and Tricare among other federal and state programs had paid to the defendants for their medications trillions of USDs from 2005 to today because the lack of competition. The US Supreme Court denied the certiorari in two failed civil lawsuits filed by Dr. Abreu, both *pro se*.

How: Gilead, EU, BOR and several people had paid off top administrators likely at the Department of Justice (DOJ), and top administrators have been involved at the Federal Bureau of Investigation (FBI), US Food and Drug Administration (FDA), the U.S. Securities and Exchange Commission (SEC), US Federal Trade Commission (FTC), United States Patent and Trademark Office (USPTO), United States Citizenship and Immigration Services (USCIS) to cover their illegal practices. Other criminal practices included the “early termination of the waiting period for the global partnership agreements” for each medication. The root causes are the conflicts of interest generated by allowing Big Pharma firms to maintain a monopoly in this case, specifically in HIV as well as Hepatitis C and B medications, abusing the Bayh-Dole Act, using tax dollars from grants for research and development of these medications and they maintain all the profits because universities and colleagues are tax exempt. **How:** They also have violated antitrust, criminal (including the Asset Forfeiture and Money Laundering Section), civil and immigration laws and had disregard the human lives in horribly done clinical trials. (**When:** since 1991).

Our evidence sent over years would allow the putative recovery of hundreds of billions of US tax dollars. It clearly shows the monopolies of Gilead and the defendants maintaining the monopoly in the medications for 1) Hepatitis and 2) HIV worldwide. They used criminal practices by incorporations, acquiring other drug companies’ medications/patents, licenses, stealing and/or by misidentifying medications to obtain higher profits.

For as long as the defendants (especially Gilead) have been making HIV (AIDS) and Hepatitis medications they have been the target of AIDS groups over its pricing and availability of drugs.

We also had asked repeatedly to the DOJ, FBI, HHS and other federal agencies for the prosecution of the people who **manslaughtered**/murdered the 2004 patients at the former MCG, (currently Augusta University) and have not seen a response. O.C.G.A. 16-5-3 (2010), 16-5-3. **Involuntary manslaughter THE LACK OF JUSTICE INDICATES SOME KIND OF CORRUPTION, ESPECIALLY IN GEORGIA BUT ALSO AT HIGHER LEVELS** that is disgusting.

Precedents: 99.9% of the legal cases in all the US courts against Gilead, Emory and BOR are won by these institutions, which speaks to corruption and the millions if not billions of dollars in bribes and lobbying. Some of the reasons may be because top leaders current and or past of U.S. Securities and Exchange Commission (SEC) are part of the “Emory Trustees and or Board of the Visitors at Emory” and or from the State of Georgia such Elizabeth (Lisa) Branch 94L, Judge, Georgia Court of Appeals, Paul Thomas Kim, Senior Counsel, US Securities and Exchange Commission, Shinji Morokuma, Program Director, Office of Court Professionals, Administrative Office of the Courts, G. Christopher Nunn 96C, Deputy Commissioner Department of Community Affairs State of Georgia, Elena Parent, State Senator, District 42, Georgia General Assembly, Robert S. (Bobby) Reeves 66C 69L, Judge Superior Court of Middle Georgia, Walter Jospin, Regional Director of SEC Atlanta (Emory alumni). One of the DOJ’s top officers in the North Georgia US Attorney’s Office (Mr. Steven Grimberg) IS AN ADJUNCT PROFESSOR AT EMORY (a blatant conflict of interest); AND MR. GRIMBERG NEVER INVESTIGATED any of my claims.

Emory and the BOR’s top administrators and Trustees have also violated multiple rules of tax exempt organizations since at least 2007 to the present as proven by IRS Forms 990 from 2007 to 2014. Ex-CEO of Emory investment Mary Cahill and other top administrators at Emory including many VPs and trustees, also took unfair advantage of Emory staff personnel via their retirement funds management using the companies of the Trustees such the Rollins family companies. The same happens with the former MCG foundation that was forced to be closed by the Federal government for the same reasons. **Gilead Sciences, Inc. (GILD) top holders are linked to** institutional investors, in turn linked to Emory and its trustee’s companies currently holding the great majority of stocks. Look at its top three institutional owners. **Blackrock Inc. Vanguard Group Inc.,** and the third largest holder is **State Street Corp.**

We had ASKED REPEATEDLY TTO MULTIPLE PEOPLE AT THE DOJ FOR A FEDERAL GRAND JURY INVESTIGATION, WHICH HAS NEVER OCCURRED.

Some of the multiple federal violations:

Knowingly, Gilead had violated most rule of The Office of Federal Contract Compliance Programs from the Department of Labor (OFCCP). <https://www.dol.gov/ofccp/>

Knowingly using (or causing to be used) a false record or statement to get a claim paid by the federal government: Emtriva[®] maybe Lamibudine. Similar Modus Operandi maybe associated with multiple patented medications examples are included:

Knowingly, The Federal government and tax payers rights on the following patents from the defendants because they used The Bayh-Dole Act: The patented medications included: Lamivudine (3TC), Emtricitabine [(-)-FTC or FTC], Sovaldi, Telbivudine (LdT).

US 6,642,245 B1. Primary Examiner Richard L. Raymond (74) Attorney, Agent, or Firm-King & Spalding, LLP, Sherry & Knowles, Esq. The U.S. Government has rights in this invention arising out of the partial funding of work leading to this invention through the National Institutes of Health Grant Nos. AI-26055, AI-28731, NIH 5-21935, as well as a Veteran's Administration Merit Review Award. Antiretroviral Activity in Various Cell Lines. Uptake of (+)-FTC Into Human PBX Cells. CSF/Serum Ratio of FTC and its Metabolites in Rhesus Monkey.

US 6,703,396 B1. Primary Examiner James O. Wilson (74) Attorney, Agent, or Firm-Sherry M. Klowles, Esq.; King & Spalding. U.S. Government has rights in this invention arising out of the partial funding of work leading to this invention through the National Institutes of Health Grant Nos. NIH 5-21935 and NIH AI-26055, as well as a Veteran's Administration Merit Review Award

US 7,468,436 B2. The U.S. Government has rights in this invention arising out of the partial funding of work leading to this invention through the National Institutes of Health Grant Nos. NIH 5-21935 and NIH AI-26055, as well as a Veteran's Administration Merit Review Award.

US 7,160,999 B2. The U.S. Government has rights in this invention arising out of the partial funding of work leading to this invention through the National Institutes of Health Grant Nos. NIH 5-21935 and NIH AI-26055, as well as a Veteran's Administration Merit Review Award.

US 5,914,331. The U.S. Government has rights in this invention arising out of the partial funding of work leading to this invention through the National Institutes of Health Grant Nos. AI-26055, AI-28731, NIH 5-21935, as well as a Veteran's Administration Merit Review Award.

US 7,115,584 B2. This invention is partially funded by a grant from the United States National Institutes of Health under Grant No. 1R01-AI-41980-01. The U.S. government has certain rights to this invention.

US 6,346,627. The U.S. Government has rights in this invention arising out of the partial funding of work leading to this invention through the National Institutes of Health Grant Nos. NIH 5-21935 and NIH AI-26055, as well as a Veteran's Administration Merit Review Award.

US 6,232,300 B1. None know.

US 6,348,587 B1 (SOVALDI). The invention described herein was made with Government support under number AI32351 awarded by the National Institutes of Health. The United States Government has certain right to this invention.

US 7,307,065 B2. (SOVALDI). The University of Georgia Research foundation (part of the Board of Regents of the University System of Georgia (**BOR**), and **Emory**. The invention described herein was made with Government Support under grant number AI32351 awarded by the National Institutes of Health. The United States Government has certain rights to this invention.

US 6,911,424 B2. (SOVALDI)....The previous patents were obtained with US government money ...This application is a continuation application of U.S. patent application Ser. No. 09/257,130 filed on Feb. 25, 1999, now U.S. Pat. No. 6,348,587, which claims priority to U.S. provisional application No. 60/075,893, filed on Feb. 25, 1998, now abandoned, and U.S. provisional application No. 60/080,569, filed on Apr. 3, 1998, now abandoned.

US 6,911,424 B2. (SOVALDI). The previous patents were obtained with US government money ...This application is a continuation application of U.S. patent application Ser. No. 09/257,130 filed on Feb. 25, 1999, now U.S. Pat. No. 6,348,587, which claims priority to U.S. provisional application No. 60/075,893, filed on Feb. 25, 1998, now abandoned, and U.S. provisional application No. 60/080,569, filed on Apr. 3, 1998, now abandoned.

...Emory has cut a deal cashing in all future royalties for a record-setting \$525 million dollars. They're selling 65% of the royalty stream to Gilead, the company that markets Emtriva (the original deal was done with Triangle Pharmaceutical, a firm of Burroughs Wellcome refugees later bought by Gilead), and 35% to VC firm Royalty Pharma. And the deal provides that the University itself gets 60% of that, with the rest to be split between Liotta, Raymond Shinazi (on the medical side), and former Emory researcher Woo-Baeg-Choi. That is 210 million dollars to be split between the three of them.

Knowingly, and with malice intended, the defendants, especially Gilead and Emory had maintained the HIV and Hepatitis medication monopoly over the past 20 years. They also used (or causing to be used) a false record or statement to conceal, avoid, or decrease an obligation to pay money or transmit property to the federal government by abusing the following acts and/or laws: The Sherman Antitrust Act of 1890, the Massachusetts Antitrust Act., The Clayton Antitrust Act of 1914, The Robinson-Patman Act of 1936, 18 U.S.C.). The Securities Act of 1933, The Securities and Exchange Act of 1934, The Tax Evasion (Section 7201 of the Internal Revenue Code, 26 U.S.C. §§ 7201-7217, The "Responsible Corporate Officer" (RCO) doctrine, The Bank Secrecy Act of 1970, the Money Laundering Control Act of 1986, The Patriot Act, see 18 U.S.C. 1956. This information had been send to the DOJ, FBI, HHS etc. showing the multiples lawsuits filled by mainly Gilead and Emory against any competitors for the medications and generics for HIV and hepatitis in the last 20 years. **Consulting justia.com.** Also showed proof evidence of the records consulted via **SEC at EDGAR** with Gilead, Triangle, Pharmasset especially the forms 10K where they show all the incorporation, merger, licenses etc. **THE FEDERAL REGISTRY** proves all these claims and how most of these leaders in the antitrust division, FTC and multiple other agencies didn't report and/or misled them.

Knowingly and conspiring and with malice intended, with others the defendants had made false or fraudulent claims paid by the federal government for programs such **Medicaid, Medicare, Tricare, VA, Federal Bureau of Prisons**, among many other Federal programs selling medications that should cost only some millions of dollars, pretending to be “newly discovered medications; and instead the government had expended trillions of dollars”.

Knowingly and with malice intended, The defendants had participated in: Obstruction of Justice 18 U.S.C. §§ 1501-1521, Racketeering Influence and Corrupt Organizations Act (RICO) (18 U.S.C. §§ 1961-1968), have abused and retaliated against me and my daughter immigration violating The Naturalization Act of 1790 and their amendments in 1795, 1850 and 1882 the 1921, The Emergency Immigration Act, 1924, the Immigration Act of 1924, The Modern Immigration and Nationality Act of 1952 (INA), also known as the McCarran-Walter Act, 1975, The Immigration Act of 1990, The Illegal Immigration Reform and Immigrant Responsibility Act (IIRIRA) of 1996, the 8 U.S. Code Subchapter II – IMMIGRATION PART II - Nationality Through Naturalization (§§ 1421 to 1459).

Knowingly, and with malice intended, patients that died in the clinical trials for the HIV medications in South Africa and other African countries done by Triangle (a biotechnology company created by Emory University professors Drs. Raymond Schinazzi and Dennis Liotta and others from Emory abusing of the Bayh-Dole Act). Other patients also died in the clinical trials at MCG in Augusta GA, currently known as Augusta University (AU).

Knowingly, and with malice intended, the plaintiffs have experienced severe retaliation for protecting the patients in clinical trials, and the US taxpayers. Plaintiffs family, finances, business, reputation, professional activities had been attacked for Defendants to silence them for over 14 and a half years, all these attacks informed to the local police, the FBI Atlanta the DOJ and multiple federal agencies.

Knowingly, and with malice intended, “Gilead” and also Emory, violated the federal Anti-Kickback Statute (“AKS”) by offering illegal paybacks to induce doctors to prescribe Gilead’s drugs. Theses kickback violations caused the submission of false claims to the government, as prohibited by the federal False Claims Act (“FCA”) and state analogues. We have provided many times the names of the doctors and institutions to whom Gilead and others made the payoffs. The Anti-Kickback Statute is a federal criminal statute that prohibits “knowingly and willfully” offering “remuneration . . . to induce” someone “to refer an individual . . . for . . . any item or service” reimbursable under a federal health care program. 42 U.S.C. § 1320a7b(b)(2)(A). Such conduct is a felony punishable by years in prison and significant fines.

Knowingly and with malice intended, the medications against HIV (AIDS), Hepatitis B and C were falsely patented in the USA, as original research patents, and approved by using something called “fast-track approval”, “priority approval,” “voucher approval” or “humanitarian approval” for the FDA using false pretenses.

Knowingly, and with malice intended, the Defendants had evaded paying US taxes using several fraudulent practices and violating nonprofit privileges, abusing US tax payers.

Knowingly, and with malice intended, the defendants had paid off millions of dollars in kickbacks, using revolving doors, paying off politicians, abusing of conflicts of interest, paying off doctors, scientist, university professors, hospitals, medical providers, pharmacists etc. for years.

Knowingly, and with malice intended, the Security and exchange Commission (SEC) rules have been violated due to illegal insider trading with corrupt intent. The defendants also used methods such as pump and dumps, penny stocks, and other criminal practices in their created biotechnology companies, especially those former using the Bayh-Dole Act by Emory and some component of the BOR.

Knowingly, and with malice intended, The United States Patent and Trademark Offices (USPTO) have been likely bribed ALLOWING THE ILLEGAL EXTENSION OF PATENTS BY GILEAD TO MAINTAIN THE MONOPOLY IN HIV AND HEPATITIS WORLD-WIDE for over 20 years.

Knowingly, and with malice intended, they reported impurities in manufacturing medications by Gilead Science described by ex rel. Mr. Jeffrey Campie and Sherilyn Campie (petition for certiorari at SCOTUS), respondents can be easily seen in the 601 FOIA from EPA and other agencies in this following website. <https://foiaonline.regulations.gov/foia/action/public/home> (multiple agencies). In the Bayh-Dole Act the taxpayer through the federal government maintains the license, the technology on the respective granted product, AND THE MANUFACTURING MUST BE IN USA. They violated the three of them.

Knowingly, and with malice intended, Gilead top executives had violated SEC rules on insider trading since 2003, initially when they were troubles with unlawful off label marketing and none or inadequate response to multiple FDA warning letters about Viread[®], and later when someone at the DOJ and other unknown had alerted about the possible investigation and or prosecution. This is still happening. This information has sent to the DOJ, FBI among other federal agencies.

How did it start? Precedents: Dr. Abreu informed authorities that Dr. Thomas Lawley, ex-dean of the School of Medicine at Emory University, and Gilead ex-CEO John C. Martin had "worked together since 2000," advising the National Institute of Allergy and Infectious Diseases (NIAID), that belongs to the National Institute of Health (NIH), to give grants to Emory University where all these medicines supposedly were discovered. Dr. Abreu also discovered and averred in her 2013 Lawsuit that, about the same time or one year earlier, Drs. Schinazi and Liotta and Dr. Woo-Baeg Choi, also with Emory University, held patents derived from NIH-funded research. Dr. Abreu suggests that these may become a liability to Emory University if

ongoing investigations prove that Racemic BCH-189 [the minus enantiomer known as Lamivudine (3TC), invented by **Dr. Bernard Belleau** while working at McGill University and the Montreal-based IAF Biochem International Inc. in 1988] is **INDEED Lamivudine (generic) is likely to be Emtricitabine (Emtriva®) (commercial with false patent) (FTC)**. Dr. Abreu finds it quite abnormal that several publications comparing these two drugs (including multiple publications by the World Health Organization (WHO) in June 2012, found that both medications are the same (lamivudine and Emtriva®). High performance Liquid Chromatography (HPLC), NMR and LC-HRMS technology evidence provided also pointed to this and the DOJ, FBO, HHS, NIH, CDC has been informed. Also we sent information showing the complete applications sent to the FDA for these medications, randomized clinical trials comparing these medications, the pooled results of these trials found no difference in terms of virological suppression (relative risk) [RR], 95% confidence interval [CI], virological failure and CI, cohorts, nucleoside reverse transcriptase inhibitor mutations (NRTI-R), viruses without resistance mutations (WT), M184V/I mutation resulting in high-level resistance, medicines effective concentrations, based on biological (99th percentile of the distribution of WT virus population) and clinical cutoffs etc.

This antiretroviral drug is included in current WHO Model Lists of Essential Medicines and is in various international guidelines for the treatment of HIV infection. Specifically, The WHO evaluated 3TC and FTC and considered them very similar, **if not the same**.

Indeed, Dr. Abreu's research has revealed that these three professors from Emory University stole the patent from Dr. Belleau (Emory's patent for 3TC/Epivir® **Lamivudine®** was invalidated by the U.S. Patent Office); and, then, Emory University bought the rights of 3TC from Glaxo Wellcome, Inc., which merged with these small companies, and a large settlement was paid by Emory University to cover all this. Then Drs. Dennis Liotta and Raymond Schinazzi "pretended to "discover Emtriva" but indeed this is lamivudine the same medication discovered by Dr. Belleau in Canada. Dr. Abreu believes it is likely these doctors have stolen many other patents on drugs to treat HIV and Hepatitis C worldwide to maintain, along with Gilead, the monopoly and to manipulate the patent system. They manipulate the patent system by not allowing the patents to expire and generics to enter the market, which would help to lower the prices, and by preventing competition and abusing the provisions of the Hatch-Waxman Act, The Drug Price Competition and Patent Term Restoration Act, Pub.L. 98-417, that encourage generic competition. Dr. Abreu notes that multiple antitrust lawsuits have been filed against Gilead and Emory University by many companies, and patient's advocates, among others, and that these dirty practices block affordable access to lifesaving HIV and Hepatitis B and C drugs. In fact, Dr. Abreu notes that in late 2015, Emory University lost a wrongful death case arising out of a sleep study which proves to her that money is more important to Emory University than the safety of its patients.

Academy of Sciences of the **Czech Republic** (1992 – 2002). **Antonín Holý** (He specialized in the field of chemistry and cooperated on the development of important antiretroviral drugs used in the treatment of HIV and hepatitis B. He was involved in the creation of the most effective drug (as of early 2009) in the treatment of AIDS. Dr. Antonín Holý is the author of more than 400 scientific discoveries and holds 60 patents. With more than 400 discoveries to his credit, his work has affected millions of people with viral diseases such as HIV/AIDS and hepatitis B, C and much other viral disease.

In 2006 the US biopharmaceutical company Gilead Sciences and the Institute of Organic Chemistry and Biochemistry (IOCB) of the Academy of Sciences of the Czech Republic jointly established a new research center, oriented to the development of new preparations. Gilead promised the IOCB a \$1.1 million donation, to fund its operations and research for 5 years. **Viread generic (Tenofovir)** (from 86 USD\$ max to 292) was approved in the USA in 2001 for the treatment of AIDS, and **Hepsera®** was approved in 2003 for the treatment of hepatitis B. **Truvada® (commercial false patent) (at least four times more expensive than the generic)**, a combination of **Viread and Emtricitabine**, was approved in 2006 for use in the USA this for the cost of at least \$84,000 USD (for a medication that cost maximum \$200 USD).

Dr. Abreu notes that Pharmasset Inc. was founded in 1998 by Emory University professors Drs. Schinazi and Liotta. The company was initially incorporated in Barbados (as Pharmasset, Ltd.) and separately in Georgia; however, the company was redomiciled as a Delaware corporation on June 8, 2004. Drs. Schinazi and Liotta have received millions of dollars in grants at Emory University from the NIH and other federal agencies including, this year, the Defense Threat Reduction Agency. Later, the same group was involved in many lawsuits based on “merging and buying companies” to maintain the monopoly on HIV, Hepatitis C, Hepatitis B, and other antiviral treatments and medications worldwide, violating antitrust laws, and related to the drug Emtricitabine.

The Bayh Dole Act: The Bayh Dole Act (BDA) via Patent and Trademark Law Amendments Act (Pub. Law 96-517, Dec 12, 1980) permits universities, small businesses, or non-profit institutions to elect to pursue ownership of an invention in preference to the government. In addition to tax-exemption and BDA profits, universities and colleges receive millions of dollars in grants, ranging from 40 to 100 billion given for **RESEARCH AND DEVELOPMENT (R&D)** in each fiscal year. In addition, they receive about \$46 billion in free scholarship money, awarded each year by the Department of Education. In addition these universities/institutions also received, **43% of overhead administrative costs for each federal grant. The people at stake** abused of tax exemptions and Bayh Dole, where unscrupulous physicians, scientists and administrators found a way to quickly perform basic science studies, then in animal models and also on humans (using clinical trials). These trials were then approved, falsifying results and jeopardizing lives. I realized that the approval of the clinical trials, and the basic science and

animal model studies **RELIED ON THE DEAN OF EACH MEDICAL SCHOOL**. Thus, these institutions had motive for the repeated attacks on my career and personal life. I discover their *modus operandi*. I exposed these issues to the US government: The *modus operandi* is simple. The universities are tax exempt and receive billions in Federal grants, etc. The Bayh Dole Act is abused via technology transfer of poorly regulated products, and the universities gain huge profits. Using the Bayh-Dole Act the universities do studies "*in vitro*" (in cells), then in animals, then in humans (clinical trials). The pharmaceutical companies and/or the universities' own biotechnology companies likely pay under the table for fast approval of the clinical trials in humans and to "avoid reporting severe adverse events" (SAEs). It is the function of the Dean of Medicine at each university medical school to approve the results these clinical trials. The Deans also are supposed to monitor what is called "**external activities**": specifically, what the investigators can do in advertising and/or speaking for the pharmaceutical companies. If these Deans are unethical or corrupted (as in the case of **Emory's former Dean Lawley**), conflicts of interest proliferate and false medical data is then sent to the FDA, the NIH and other governmental funding agencies for quick approval of the drugs and/or devices. The Offices of Technology Transfer are in the center of the process at the universities, and their attorneys specialize in patents. The following web site show the grants that Dr. Denis Liotta and Raymond Schinazi had received from the federal give them amounts, the years of financed and after reviewing these you cans ask Gilead, Pharmasset, Liotta, or Schinazi if they still have the nerve to say that "the federal government has not given them any dollars use for R&D in their medications for Hepatitis C, B and HIV". They Bayh-Dole Act entitles the federal government to maintain the licenses on patents, also the technology and most products should be manufactured on US to benefit the tax payer and Federal Government.

One possible mechanism for negotiating with Emory and BOR to negotiate our request settlement is to remind them that they are tax exempted and had abuse such using their foundations, and investments. They also receive training grants, Bayh Dole Act and technology transfer patent/royalty income, nontaxable endowment income, property and other tax exemptions as well as VA, Dep of Defense and NIH grants that can be stopped.

A qui tam action must be confidentially filed under seal in Federal district court in accordance with the Federal Rules of Civil Procedure. A copy of the complaint, with a written disclosure statement of substantially all material evidence and information in the plaintiff's possession, must be confidentially served on the US Attorney General and the US Attorney for the district in which the complaint is brought. An action under the False Claims Act must be filed on camera and under seal.

Potential recovery for the US government, taxpayers and others:

We are talking about:

1. **About 23 Trillion USDs** overcharged from US tax payers from falsely patented medications and 20 years of monopolies on these medications for HIV and hepatitis. The RECOVERY OF THIS MONEY **COULD PAY OFF THE ENTIRE US DEBT.** We had sent plenty of proof that the VA alone paid to Gilead almost 1.7 trillion USD (**Attach B.**)

2. **About 3 trillion USDs** against private health care companies such Kaiser Permanente, Blue Cross BlueShield, Aetna etc. This is an indirect damage for tax payers also because this illegal practices increase the price and copayments for tax payers via health insurances.

3. **About 100 trillion USDs** worldwide outside the US due fraudulent patents and monopolies in HIV and hepatitis medications for over 20 years.

The masterminds of the scam were: Dennis Liotta, PhD, Raymond F. Schinazi, PhD, DSc (Hon) (Triangle, Pharmasset, Emory and BOR), [(both at Emory and Board of Regents of the University System of Georgia (BOR))], John C Martin, (ex CEO of Gilead Sciences of Foster City, Calif.), Ex R &D of Gilead Dr. Norbert Bischofberger, Ex-Chief Executive Officer John Milligan, Gregg H. Alton, JD at Gilead, Steven D. Sencer (the current Chief Counsel for Emory for covering these criminal actions) helped to cover up the killing of hundreds of patients in sham clinical trials (in Romania, Mexico, two centers at South Africa and two centers in the USA) **with likely pay-offs at all levels.**

ACCORDING WITH THE JUSTICE MANUAL, 4 111 - DOJ DISMISSAL OF A CIVIL *QUI TAM* ACTION IS BASED ON THE FOLLOWING:

When evaluating a recommendation to decline intervention in a *qui tam* action, attorneys should also consider whether the government's interests are served, in addition, by seeking dismissal pursuant to 31 U.S.C. § 3730(c)(2)(A). While it is important to be judicious in utilizing § 3730(c)(2)(A), such dismissals also provide an important tool to advance the government's interests, preserve limited resources, and avoid adverse precedent.

When determining whether to seek dismissal, the Department should evaluate the following non-exhaustive list of factors that can serve as a basis for dismissal:

1. Curbing meritless *qui tams* that facially lack merit (either because the relator's legal theory is inherently defective, or the relator's factual allegations are frivolous). **We have factual, not frivolous allegations sent many times to the FBI, DOJ, VA, HHS, Dep of Defense among many federal agencies.**
2. Preventing parasitic or opportunistic *qui tam* actions that duplicate a pre-existing government investigation and add no useful information to the investigation. **We had led the federal agencies on this this investigation for years. We are not parasitic.**

3. Preventing interference with an agency's policies or the administration of its programs. **This does not apply.**
4. Controlling litigation brought on behalf of the United States, in order to protect the Department's litigation prerogatives. **We do not have access to the DOJ litigations on this matter, but consulted the antitrust and criminal DOJ websites for action against these defendants and have not found any information.**
5. Safeguarding classified information and national security interests. **This matter does not imply national security interest.**
6. Preserving government resources, particularly where the government's costs (including the opportunity costs of expending resources on other matters) are likely to exceed any expected gain. **This does not apply, we had shown that the VA alone paid almost 1.7 trillion USDs to Gilead using FOIA and several FOIAs to HHS, Federal Bureau of Prisons, FDA and to other agencies had been delayed for unknown reasons.**
7. Addressing egregious procedural errors that could frustrate the government's efforts to conduct a proper investigation. **The FBI had led efforts investigating this. There is no excuse for claiming these were our errors. This information below proof that our claims had been taking seriously by multiple federal agencies:**

Some accomplishments from this terrifying experience were that the U.S. Department of Health and Human Services, The Food and Drug Administration (FDA), Office of Good Clinical Practice (OGCP), Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Center for Devices and Radiologic Health (CDRH), Office of Regulatory Affairs (ORA) implemented sanction on September 2018 using new guidance's on failures on clinical trials by using civil money penalties relating to the ClinicalTrials.gov Data Bank to be use for FDA staff against responsible parties, and submitters of certain Applications and submissions to FDA <https://www.fda.gov/RegulatoryInformation/Guidances/ucm607652.htm>.

On May 14, 2018 new regulations were implemented to improve the Bayh-Dole Act and preventing abuse by institutions such Emory and others. The Patent and Trademark Law Amendments Act of 1980, commonly known as the "Bayh-Dole Act," governs the disposition of patent rights developed pursuant to three types of government funding arrangements: procurement contracts, grants, and cooperative agreements. The Secretary of Commerce has delegated to the National Institute of Standards and Technology (NIST) the authority to promulgate implementing the new regulations to favor the tax payers who at the ended funded these projects-patents.

Other positive changes as a result occurred in the Securities and Exchange Commission Act of 1934, including new amendments in Self-Regulatory Organizations, in Clearing Corporation Stress Testing and Clearing Fund methodology and reorganization and consolidation of clearing fund by-laws and rules.

The Department of Defense the General Services Administration, and the National Aeronautics and Space Administration updated rules including civilians and other companies' acquisitions updated its regulations in regard to the Federal Acquisition Regulations (FAR) on June 15, 2018: Federal Acquisition Circular (FAC)(Circular 2005-99).

At the National Institute of Health (NIH), positive changes were obtained including in the AIDS Study Section and Related Research (AARR) integrated review group (IRG), a cluster of study sections with a reorganization for September 2018. The NIH's Center for Scientific Review (CSR) will scientifically align the IRG with current and emerging areas of HIV/AIDS research and support their best practices for scientific breadth and meeting management. Six new study sections were created and will cover the areas of basic, translational, clinical, and population science: HIV Molecular Virology, Cell Biology, and Drug Development (HVCD), HIV Immunopathogenesis and Vaccine Development (HIVD), HIV Comorbidities and Clinical Studies (HCCS), HIV Coinfections and Associated Cancers (HCAC).

Other accomplishments beside the "retirement" of the top leaders at Gilead was that on September 24, 2018 Gilead announced a plan to introduce a generic version of their leading cures for Hepatitis C (HCV) in the United States. <http://www.gilead.com/news/gilead-subsiary-to-launch-authorized-generics-to-treat-hcv>

On Septembers 4, 2018 FDA approved generic medications for HIV: <https://aidsinfo.nih.gov/understanding-hiv-aids/fact-sheets/21/58/fda-approved-hiv-medicines>. FDA-Approved HIV Medicines. (Including the false patented by Emory and Gilead BOR).

HIV generics in Europe were also approved on June 2018.

On November 6, 2018, The Office of Inspector General (OIG), HHS update notice on the Federal Registry replacing all language in Part Q (Office of the Secretary) of the Statement of Organization, Functions, and Delegations of Authority for the Department of Health and Human Services (HHS or the Department). They updated rules in how to conduct and supervise audits, investigations, evaluations, and inspections relating to HHS programs and operations. Also updated identifying systemic weaknesses giving rise to opportunities for fraud and abuse in HHS programs and operations and makes recommendations to prevent their recurrence Agency/Docket Number:OIG-1810-N

On April 30, 2019, The Department of Justice (DOJ), Criminal Division released a new guidance document intended to assist prosecutors in evaluating corporate compliance programs and guide corporations in creating them. While written for prosecutors, the guidance provides a helpful roadmap for businesses reviewing and updating their compliance plans and should be considered mandatory reading for those operating in highly regulated industries, such as healthcare, life sciences, financial services, and energy. To that end, Part I of the document discusses various hallmarks of a well-designed compliance program relating to risk assessment, company policies and procedures, training and communications, confidential reporting structure and investigation process, third-party management, and mergers and acquisitions. Part II details features of effective implementation of a compliance program, including commitment by senior and middle management, autonomy and resources, and incentives and disciplinary measures. Finally, Part III discusses metrics of whether a compliance program is in fact operating effectively, exploring a program's capacity for continuous improvement, periodic testing, and review, investigation of misconduct, and analysis and remediation of underlying misconduct <https://www.justice.gov/opa/pr/criminal-division-announces-publication-guidance-evaluating-corporate-compliance-programs>.

On July 11, 2018, The House Committee on Oversight and Reform held a hearing of possible undeclared conflicts of interest by ex- Office of Management and Budget (OMB) Associate Director of Health Programs Joseph Grogan's apparent conflict of interest in developing a payment model and cancer treatment for a form his former employer, Gilead Sciences, Inc., Director <https://oversight.house.gov/news/press-releases/new-documents-raise-concerns-about-potential-conflict-of-interest-of-former-drug>.

The House Committee on Oversight and Reform held a hearing on May 15, 2019 about high drug prices on Gilead <https://oversight.house.gov/news/press-releases/committee-to-hold-hearing-on-gilead-s-exorbitant-price-for-hiv-prevention-drug>.

DOJ updated their rules on handling antitrust issues <https://www.justice.gov/opa/pr/departments-justice-hold-roundtable-antitrust-criminal-penalty-enhancement-reform-act>.

On May 13, 2019, the Department of Justice's antitrust division joins framework on competition agency procedures as founding member created a new Framework on Procedural Fairness in Antitrust Enforcement Will Come into Effect on May 15, 2019. <https://www.justice.gov/opa/pr/departments-justices-antitrust-division-joins-framework-competition-agency-procedures-founding>

The International Competition Network (ICN) held its 18th annual conference, hosted by Colombia's Superintendent of Industry and Commerce, on May 15-17, 2019, in Cartagena, Colombia. Nearly 500 delegates from more than 80 jurisdictions participated, including competition experts from international organizations and the legal, business, academic, and consumer communities. On May 17, 2019, the DOJ announced that they will host an ICN Adopts Framework for Competition Agency Procedures and Recommended Practices on Investigative Process, Announces U.S. on 2020 ICN Annual Conference. This with the goal of establishment a Framework on Competition Agency Procedures (CAP) that reflects the commitment by its participants to uphold fundamental procedural fairness principles and adopted Recommended Practices for Investigative Process that offer aspirational guidance and norm-setting principles on procedural fairness. <https://www.justice.gov/opa/pr/international-competition-network-adopts-framework-competition-agency-procedures-and>

On May 2019, The Federal Trade Commission also updated and changes several rules on this regard: <https://www.ftc.gov/about-ftc/bureaus-offices/bureau-competition>.

<https://www.ftc.gov/enforcement/premerger-notification-program>.

On May 2019 NIH updated the rules on Bayh-Dole Act and retrained the grantee institutions in their rights and obligations <https://regionalseminars.od.nih.gov/baltimore2019/sessions/00e/>,

<https://public.era.nih.gov/iedison/public/login.do?TARGET=https%3A%2F%2Fpublic.era.nih.gov%2Fiedison%2Finit.do>

On May 23, 2019 the Security and Exchange Commission (SEC) updated rules promoting the Sunshine Act: <https://www.sec.gov/news/closedmeetings/2019/ssamtg052319.htm>. Some of the

subject matters included: Institution and settlement of injunctive actions; Institution and settlement of administrative proceedings; Resolution of litigation claims; and Other matters relating to enforcement proceedings.

On May 9, 2019, Center for Disease Control (CDC) and DOJ DC negotiated with Gilead Sciences to give free Truvada pills to 200,000 uninsured people for the next 11 years to help prevent new HIV infections. Such likely as result of negotiation for less criminal, patents and antitrust charges. <https://www.nbcnews.com/feature/nbc-out/gilead-donate-hiv-prevention-drug-truvada-200k-uninsured-patients-n1004381>

On May 13, 2019 , the U.S. Supreme Court (SCOTUS), Extends Statute Of Limitations for Privately Initiated False Claims Act Lawsuits to 10 years. <https://www.drinkerbiddle.com/insights/publications/2019/05/us-supreme-court-extends-statute-of-limitations>

Special damage is claimed, based on description of precedent. An attached proposal settlement was also sent via Attorney Walter Brown, Civil Division DOJ and others and attached here again. For our precarious economic situation **we request immediately that the building** we used to rent at 1534 North Decatur Road NE Atlanta, GA, 30307 that was bought through a ghost buyer to destroy our practice (and we believe is held by either the FBI Atlanta and the DOJ (see **Attached files C and D**) be given immediately to Dr. Abreu and or be sold for 1 dollar, and that the defendants give Dr. Abreu immediately **\$ 500,000 USD** to gut it and move our practice there. Dr. Howard owes about **\$100,000 USD** in taxes. The DOJ can talk with IRS and immediately removed those past taxes and their interest and or give Dr. Howard that amount immediate to pay the past taxes. The 2018 taxes had not been filed yet. We also need immediately about **\$100,000** to fix the roof of our house, the drainage, put in a retention wall and other repairs that we have not being able to afford. Dr. Howard also owes Dr. Abreu **\$ 60,000 USDs**. We also request immediately that the DOJ as Gilead to give us our request settlement because we are aware of the negotiation of Truvada CDC, DOJ and Gilead from **Attach settlement E**.

From Attach E:

19. Gilead Sciences Inc. will give to the Atlanta Catholic Church Immaculate Heart of Mary **\$2,500,000 USD** and they will pay the taxes (if applicable). The money will be invested to pay the building debt and to fix the old church building. This will be effective one day after signing the agreement. The check will be given to Dr. Abreu to present to them directly. This church is located at 2855 Briarcliff Road NE, Atlanta, Georgia 30329.

22. Gilead Sciences Inc. will give to Dr. Abreu **\$5,000,000 USD** and to Dr. Howard **\$1,000,000 USD**, and they will pay the taxes on those, one day after signing this settlement. Gilead will also pay all State and Federal taxes on this amount at the approximate rate of 35%, (see 12, Tax


Indemnification), by electronic fund transfer pursuant to written instructions to be provided by the said sum. The payment with taxes will take place one day after signing the agreement into a specific bank account.

We are willing to wait some time for the rest of the settlement including **Attach D.**

Sincerely,



Ana Maria Abreu Velez, M.D., Ph.D., D.Sc. (signed electronically)
1192 Cumberland Road, NE; Atlanta, Georgia 30306
E-Mail: abreuvelez@yahoo.com.
Home Phone: 404-876-4897.
Cell phone: 404-660-5558.



Michael S. Howard, M.D., (signed electronically)
Georgia Dermatopathology Associates
2250 North Druid Hills Road, NE; Suite 124, Atlanta, Georgia 30329,
E-mail: mhoward@gadermpath.com
Work Phone: 404-371-0077, Cell: 404-431-9249

Exhibit 2

1

February 8, 2017

Jeff Sessions, United States Attorney General

RE: Dear Attorney General Sessions,

First, congratulations in your new role as US Attorney General. During the confirmation hearings, you presented yourself as a Southern gentleman, knowledgeable and respectful of Federal laws and our constitution. Your track record speaks for itself. We saw also viewed a television interview of several of your church friends and neighbors of Regents of the University System of Georgia, interviewed by Fox News from "Spot of Tea" in Mobile, Alabama. All of those interviewed spoke marvelous things about you. **WE ALSO SAW THE HORRIBLE BEHAVIOR OF SENATOR ELIZABETH WARREN AND OTHERS AGAINST YOU THAT WAS DESPICABLE.** Indeed she has been lobbying for Emory University and had visited them, and advocates for their causes for unknown reasons along with other senators because Emory has deep pockets.

We are sending this package through the White House Chief of Staff Mr. Reince Priebus, because Unfortunately, due to past experience with the courts and inside the current Department of Justice (DOJ) mail room in Washington, our mail has recently been "diverted" or has disappeared, due to the nature of our correspondence. Inside the enclosed USB, you will find important evidence with scanned documents.

Background: I HAVE EXPOSED THE LARGEST PHARMACEUTICAL SCAM IN US HISTORY AND THE MANSLAUGHTER/MURDER OF MULTIPLE PATIENTS IN CLINICAL TRIALS UNDER EMORY UNIVERSITY AND THE BOARD OF REGENTS OF THE UNIVERSITY SYSTEM OF GEORGIA IN THE USA AND IN SOUTH AFRICA. For exposing these issues and trying to get justice in two civil lawsuits (acting pro se because no attorney accepted my case due to the powerful forces these institutions have in the courts) we lost all our assets. I am jobless since June 2016, my husband's company is facing severe economic stress and have repeatedly asked these three entities to give us the settlement we deserve following over 56 attacks. **We are not sure HHS chief nominee tom price can help us, due to a possible relationship with Emory and BOR in Georgia.**

I lost my job in June 2016; and have applied to more than 50 positions, and have been unable to obtain a new position due to persecution because the negative gossip. My husband practice is facing bankruptcy and he owes more than 150,000 dollars in past taxes and other. Patients were **manslaughtered/murdered in clinical trials** for greed. Emory University and the BOR's top administrators and Trustees have also violated multiple rules of tax exempt organizations since at least 2005 to the present. **YOU HAVE HEARD PRESIDENT TRUMP SPEAKING ABOUT HOW "BIG PHARMA IS GETTING AWAY WITH MURDER"; HE IS REFERRING TO**

OUR CASE. WE SENT OUR INFORMATION TO MS. IVANKA TRUMP AND TO PRESIDENT ELECT TRUMP. He is speaking about what we expose

This biggest pharmaceutical scam in US history, resulting in no prosecution because of the severe conflicts of interest. We are specifically communicating information about Big Pharma fraud, including **Gilead Sciences Inc.** of Foster City, California. **Barack Obama's** Affordable Care Act (**Obamacare**) has also had a hidden agenda, by boosting the prices of Gilead Sciences' drugs and BIOGEN. These actions possibly represent the real reason **Ms. Loretta Lynch** has avoided prosecuting Gilead Sciences, by direct order of ex-President Obama.

In addition, Emory University (EU) in Atlanta, Georgia and the Board of Regents of the University System of Georgia (BOR) have been involved. As far as we know, this country has never experienced such a dark period in terms of Federal government and associated medical Big Pharma corruption (mostly Gilead Sciences) and attendant disrespect for American laws, citizens and patients.

We are facing severe financial stress. I have been without a job for almost 9 months, caused largely by retaliation for exposing these severe frauds and the murders of more than 12 innocent Georgia patients in 2004 clinical trials and several patients in South Africa. No body hires me for be a whistleblower. Please refer to our pertinent website: **Murders — Big Pharma Monster**

<https://www.bigpharmamonster.com/murders/>

For 12 years and three months, I, my family, my daughter, and our practice have suffered severe persecution, attacks and retaliations by the above institutions for exposing the death of multiple patients in 2004 MCG clinical trials and severe violations in the code of federal regulations. In addition I exposed severe antitrust violations by Gilead, never prosecuted by the current DOJ, besides sending them the information hundreds of times using Federal Express, US mail, phone calls and e-mail (of which I have proof). I also exposed severe violations of non-profit status by **EMORY UNIVERSITY, BOARD OF REGENTS OF THE UNIVERSITY SYSTEM OF GEORGIA** and their Trustees and top administrators. The IRS non-profit unit as well as the DOJ (which I copied) did nothing to recover billions of US Dollars. We lost our assets; I have been a victim of more than 56 attacks. **The DOJ, Ms. Loretta Lynch, Obama, Emory University, GILEAD Sciences Inc. and the BOARD OF REGENTS OF THE UNIVERSITY SYSTEM OF GEORGIA** top administrators and trustees tried by all means to destroy me and my family and practice (including physically attacking my minor daughter, who was hospitalized for one month after the attack).

Please refer to the pertinent website: **Big Pharma Monster. We lost all our assets fighting these monsters, and we hope that the current Trump administration with you leading the DOJ can give us an economical reward for exposing these crimes.**

<https://www.bigpharmamonster.com/murders>

We do not have the money or an attorney to request you guys either a Qui tam (filing *pro se*, because no attorneys want to help us, and the forms are very complicated for us as lay people) and do not know how other ways to recover all what we lost.

RE: A False Claims Act, 31 U.S.C. Sections 3729 through 3733. Qui tam, against Gilead Sciences Inc. (GILEAD), Emory University (EMORY UNIVERSITY), the Board of Regents of the University System of Georgia (BOARD OF REGENTS OF THE UNIVERSITY SYSTEM OF GEORGIA) and former Medical College of Georgia (MCG; currently Augusta University (AU) and its components for abuse/fraud against federal programs/and/ or contracts to sue the wrongdoer on behalf of the United States Government.

We tried by many ways via **Ms. Sally Q Yates, Loretta Lynch, John A Horn** (current US North Georgia Attorney) and top officers in the North Georgia US Attorney's Office (**Mr. Steven Grimberg**) as well as in the Southern Georgia US Attorney's office, including **Mr. Edward Tarver**. We contacted the OIG, and most US Federal regulatory agencies and they **DID NOTHING TO INVESTIGATE OR PROSECUTE THIS CASE.**

Here I present a summary of 12 years of our journey of harassment, discrimination and lack of justice for protecting patients, taxpayers and those affected by 1) HIV, and 2) Hepatitis B and C worldwide the Federal Government and the taxpayers. We document abuse of patients in 2004 clinical trials using taxpayer's money, abusing the Bayh-Dole Act and the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (Public Law 94-435, known commonly as the HSR Act by Big Pharma, some universities and professors using technology transfer thus creating a big pharma monopoly, all with the approval of the many top leaders of Federal Government.

They all conspired in the biggest pharmaceutical scam in US history, abusing the Federal government, the tax payer and being protected by the Obama administration and by very likely Ms Loretta Lynch and other top leaders at the DOJ.

I have exposed the biggest pharmaceutical scam in US and worldwide done by Emory University, Gilead Sciences and others, where Dr. Raymond Schinazi and Dr. Dennis Liotta at EMORY UNIVERSITY, along with GILEAD, and BOARD OF REGENTS OF THE UNIVERSITY SYSTEM OF GEORGIA have claimed false original patents (and thus false "genuine Bayh-Dole status") to sell products at huge profits like Emtriva (that is likely Lamivudine), Sovaldi (that is likely Tenofovir) and Harvoni (that is likely a first and or second generation NS5A or 5B inhibitor). The US taxpayers cost via Medicare, Medicaid and Tricare among other programs for these medications are in the high billions USDs from 2005 to today, and the US Supreme Court denied my certioraris(2009; 2016) in two failed civil lawsuits filed by me pro se since no attorney took my case.

GILEAD, EMORY UNIVERSITY, BOARD OF REGENTS OF THE UNIVERSITY SYSTEM OF GEORGIA and several people had paid off top administrators at the DOJ, and top administrators have been involved at the FBI, US Food and Drug Administration (FDA), the U.S. Securities and Exchange Commission (SEC), US Federal Trade Commission, United States Patent and Trademark Office (USPTO), United States Citizenship and Immigration Services (USCIS), and ex-President Obama. The root causes are the conflicts of interest generated by allowing Big Pharma firms to maintain a monopoly in this case, specifically in HIV as well as Hepatitis B and C medications, abusing the Bayh-Dole Act, using tax dollars from grants for research and development of these medications; they kept all the profits because universities and colleges are tax exempt. They also have violated multiple laws and disregarding human life in clinical trials.

The legal reasons are explained in the previously sent USB, and showing the lack of prosecution of this scam by these institutions. Our evidence would allow the putative recovery of hundreds of billions of US tax dollars. It shows the monopolies of Gilead Sciences, in medications for 1) Hepatitis B and C and 2) HIV worldwide by incorporations, acquiring other drug company's medications/patents, stealing or misidentifying medications to obtain higher profits, likely bribing US Senators and Congressmen and individuals within the U.S. Federal Trade Commission, FDA and US Patent Office, thus providing early termination of the waiting period for the global partnership agreements under The Hart-Scott-Rodino Antitrust Improvement Act of 1976. Under the Obama presidency, drug prices are the highest in US history because government grants Big Pharma a monopoly: see <http://thefreethoughtproject.com/harvard-study-govt-pharma-monopoly>.

Barack Obama's Affordable Care Act (Obamacare) has also had a hidden agenda, by boosting the prices of Gilead Sciences' drugs and BIOGEN. These actions possibly represent the real reason Loretta Lynch has avoided prosecuting Gilead Sciences, by direct order of ex- President Obama. Also Mr. Obama, Ms. Lynch and Gilead had been co-Defendants in a lawsuit made by an inmate that needed these medications and was denied

For as long as GILEAD has been making HIV and AIDS medications, it has been the target of AIDS groups over its pricing and availability of drugs. In the latest skirmish, the California company has brushed aside a lawsuit on a patent issue, but the healthcare group that accused it of **anticompetitive practices** says it will appeal and take the matter to the Supreme Court if necessary. The U.S. District Court for the Northern District of California last week granted Gilead's motion to dismiss the case, which had been filed in January, 2016. But the AIDS Healthcare Foundation (AHF), which spends millions of dollars a year on Gilead medications for its four dozen health centers, found enough encouragement in the judge's ruling to decide "this case is ripe for reconsideration by higher courts." Included should be antimonopoly and unfair competition considerations. In the multiple attached documents, we show their Modus Operandi and the **COVER UP BY THE DOJ, FOR MR OBAMA AND THE COURTS AND OTHERS**. These facts implicate OBAMACARE; a slew of new drug launches have occurred over the past 8 years, Emory University and biotechnology sectors have delivered eye-popping

returns, and some big stocks have hit prices not seen in a decade. That begs the question, is there any news not yet reflected in share prices? The answer: Ex-President **Barack Obama's Affordable Care Act**. Gilead Sciences Inc.(GILD).

We have asked repeatedly the DOJ, FBI and others for the prosecution of the people who **manslaughtered**/murdered the 2004 patients at the former Medical College of Georgia (MCG), and have not seen a response. O.C.G.A. 16-5-3 (2010), 16-5-3. Involuntary manslaughter THE LACK OF JUSTICE INDICATES SOME KIND OF CORRUPTION that is disgusting.

One hundred percent of the legal cases in all the US courts against GILEAD, EMORY UNIVERSITY and BOARD OF REGENTS OF THE UNIVERSITY SYSTEM OF GEORGIA are won by these institutions, which speaks to corruption and their millions if not billions of dollars in bribes and lobbying. Some of the reasons may be because top current and/or past leaders of the U.S. Securities and Exchange Commission (SEC) and DOJ in Georgia are part of the "Emory Trustees and or Board of the Visitors at Emory" such as Elizabeth (Lisa) Branch 94L, Judge, Georgia Court of Appeals, Paul Thomas Kim, Senior Counsel, US Securities and Exchange Commission, Shinji Morokuma, Program Director, Office of Court Professionals, Administrative Office of the Courts, G. Christopher Nunn 96C, Deputy Commissioner Department of Community Affairs State of Georgia, Elena Parent, State Senator, District 42, Georgia General Assembly, Robert S. (Bobby) Reeves 66C 69L, Judge Superior Court of Middle Georgia, Walter Jospin, Regional Director of SEC Atlanta (Emory alumni). One of the DOJ's top officers in the North Georgia US Attorney's Office (Mr. Steven Grimberg) IS AN ADJUNCT PROFESSOR AT EMORY (a **blatant conflict of interest**); AND MR. GRIMBERG NEVER INVESTIGATED any of my claims. Along with the ex- FBI Director in Atlanta, Mr. Grimberg blocked many of the communications we sent to Ms. Sally Q Yates.

Patients were **manslaughtered/murdered in clinical trials for greed**. Emory University and the BOARD OF REGENTS OF THE UNIVERSITY SYSTEM OF GEORGIA's top administrators and Trustees have also violated multiple rules of tax exempt organizations since at least 2005 to the present. Thus, the recovery would include the 35% exemption abused by them, and involving this sum over multiple years. One portion of a possible recovery is that the current **Emory endowment totals about 7 billion US dollars, and Emory secretly and separately manages 28 billion USD in real estate and equity** that 1) is not on the books, nor 2) in the pertinent IRS Forms 990 from 2007 to 2014! Mary Cahill and other top administrators at Emory including many VPs and trustees, also took unfair advantage of Emory staff personnel via their retirement funds management using the companies of the Trustees such the Rollins family companies(see the money laundering area of the web site, and Modus Operandi). I ALSO ASKED REPEATEDLY FOR A FEDERAL GRAND JURY INVESTIGATION, WHICH HAS NEVER OCCURRED.

Dr. Abreu uncovered and reported that, as a result of the failure of MCG staff to properly perform the clinical trials, the following patients, named here with their study number, died and/or suffered with no reported severe adverse events (SAE). **The name of some of the murder patients are here:** (1)Cheryl Hill MCG-001115258; (2) Edna Jones MCG-5870227;(3) Bobbie Chick 379354; (4) Theresa Tucker 471667; (5) Lessie Hamilton 0419098; (6) Eleanor Gibson 00486244; (7) Rolig Bragg 001078755; (8) Lamar Brown 0330111; (9)Pamela Dumm

0250362; (10) Bobby Carr 000437338; (11) James Duncan 001039894, (12) Mary Cothorn 001015115; (13) Jorge Cue 515800; (14) Lula Boyd 000523270; (15) Ollie Johnson 000339084; and (16) Vivian Hilton 000135165. All these patients were part of one study: Protein Kinase C- β Inhibitor-Diabetic Retinopathy Study (PKC-DRS2), A Phase 3 Clinical LY333531. For 12 years, Dr. Abreu has contacted the two Georgia governors and Attorney Generals, warning them about the severity of these actions, with no answer; thus reflecting a lack of ethics and cover ups.

The patients that died in the clinical trials in South Africa were done by Emory University professors Dr. Raymond Schinazzi and Dennis Liotta, in one of their biotechnology companies (Triangle Pharmaceutical). The studies were terminated in the study of the HIV treatment Coviracil (emtricitabine) after discussions with the US Food and Drug Administration, and following the receipt of a letter from the South African Medicine Control Council via South Africa's Health Minister, Mantombazana Tshabalala-Msimang. The firm reported that there was a higher than expected incidence of liver toxicity in the study, which resulted in two fatalities.

What was behind the 12 years of retaliation and attacks, including federal crimes on immigration, against Dr. Abreu, her family and practice? Dr. Abreu alleges that it is trillions of dollars (**A PUTATIVE RECOVERY OF TRILLIONS OF DOLLARS TO BUILD THE WALL WITH MEXICO**) resulting from white collar crime against the federal government and the taxpayers. Dr. Abreu is one of the few people in the world with training in basic sciences, clinical trials and the medical field, who is capable to figure out the *modus operandi* (M.O.). She reported to the FBI and others that Drs. Raymond F. Schinazi and Dennis Liotta at Emory University supposedly "discovered" Emtricitabine, abused the Bayh-Dole Act (the Patent and Trademark Law Amendments Act, Pub.L. 96-517 12/12/1980) (BDA); created companies abusing the Offices of Technology Transfer (OTT) at Emory University which manages the intellectual property rights for the university, other universities and colleges which are a part of BOR, and AU, and their respective foundations; and sold Emtriva with false marketing to Gilead Sciences, Inc. (Gilead) for 540 million USD in 2005. Gilead's CEO has also lobbied to several U.S. representatives and senators, and paid exorbitant sums of money to make Sovaldi® and other medicines part of the "essential medications" for Medicare and Medicaid. They "developed these medications using tax payers including the patent of Emtrivacina (patent No 5914331), The US government has right into this invention because the funded grants NIH # A1-26055, A1-28731, NIH 5-21935 as well as by VA Merit Awards. This means the US Government should have royalties on this and they were never paid by Emory.

How did it start? Dr. Abreu informed that Dr. Thomas Lawley, ex-dean of the School of Medicine at Emory University, and Gilead ex-CEO John C. Martin had "worked together since 2000," advising the National Institute of Allergy and Infectious Diseases (NIAID), that belongs to the National Institute of Health (NIH), to give grants to Emory University where all these medicines supposedly were discovered. Dr. Abreu also discovered and averred in her 2013 Lawsuit that, about the same time or one year earlier, Drs. Schinazi and Liotta and Dr. Woo-Baeg Choi, also with Emory University, held patents derived from NIH-funded research. Dr. Abreu suggests that these may become a liability to Emory University if ongoing investigations prove that Racemic BCH-189 [the minus enantiomer known as Lamivudine (3TC), invented by Dr. Bernard Belleau while working at McGill University and the Montreal-based IAF Biochem International Inc. in 1988] may INDEED be Emtricitabine (Emtriva®) (FTC). Dr. Abreu finds it

quite abnormal that several publications comparing these two drugs (including multiple publications by the World Health Organization (WHO) in June 2012, found the data they did; these are antiretroviral drugs included in current WHO Model Lists of Essential Medicines and various international guidelines for the treatment of HIV infection. Specifically, The WHO evaluated 3TC and FTC and considered them very similar. Indeed, Dr. Abreu's research has revealed that these three professors from Emory University stole the patent from Dr. Belleau (Emory's patent for 3TC/Epivir® Lamivudine® was invalidated by the U.S. Patent Office); and, then, Emory University bought the rights of 3TC from Glaxo Wellcome, Inc., which merged with these small companies, and a large settlement was paid by Emory University to cover all this. Dr. Abreu believes it is likely these doctors have stolen many other patents on drugs to treat HIV and Hep C worldwide to maintain, along with Gilead, the monopoly and to manipulate the patent system. Dr. Abreu suggests that they manipulate the patent system by not allowing the patents to expire and generics to enter the market, which would help to lower the prices, and by preventing competition and abusing the provisions of the Hatch-Waxman Act, The Drug Price Competition and Patent Term Restoration Act, Pub.L. 98-417, that encourage generic competition. Dr. Abreu notes that multiple antitrust lawsuits have been filed against Gilead and Emory University by many companies, and patient's advocates, among others, and that these dirty practices block affordable access to lifesaving HIV and Hep C drugs. In fact, Dr. Abreu notes that in late 2015, Emory University lost a wrongful death case arising out of a sleep study which proves to her that money is more important to Emory University than the safety of its patients.

Dr. Abreu notes that Pharmasset Inc. was founded in 1998 by Emory University professors Drs. Schinazi and Liotta. The company was initially incorporated in Barbados (as Pharmasset, Ltd.) and separately in Georgia; however, the company was redomiciled as a Delaware corporation on June 8, 2004. Drs. Schinazi and Liotta have received millions of dollars in grants at Emory University from the NIH and other federal agencies including, this year, the Defense Threat Reduction Agency. Later, the same group was involved in many lawsuits based on "merging and buying companies" to maintain the monopoly on HIV, Hep C, Hep B, and other antiviral treatments and medications worldwide, violating antitrust laws, and related to the drug Emtricitabine.

Violations:

Knowingly presenting (or causing to be presented) to the federal government a false or fraudulent claim for payment in the medications for HIV, and Hepatitis C such Emtriva®, Sovaldi, and Harvoni.

Knowingly using (or causing to be used) a false record or statement to get a claim paid by the federal government: Emtriva® may in fact be Lamivudine. The Lamivudine patent was stolen from Professor Belleau in Canada by Dr. Raymond Schinazi and Dr. Liotta from EMORY UNIVERSITY who later bought their rights from Glaxo. Harvoni® likely is Ledipasvir, and Sovaldi® is very likely to be Tenofovir. In lay terms, Dr. Abreu points out that the U.S. government and the taxpayer had been paying for over 12 years for 30 capsules of Emtricitabine 200mg from 543 USD to 637 USD in different pharmacies instead of paying for what Dr. Abreu believes is in fact Lamivudine, Generic Epivir (about 87 USD). The price of Emtricitabine has dropped, but, in the first two years, more than 10 billion USD was

paid for a medication that generically possibly would cost a maximum of 100 million USD per year.

Manslaughter/Murders in clinical trials

Conspiring with others to get a false or fraudulent claim paid by the federal government; GILEAD, EMORY UNIVERSITY, and BOARD OF REGENTS OF THE UNIVERSITY SYSTEM OF GEORGIA made claims for the medications mention above for programs such **Medicaid, Medicare, Tricare** among many other federal programs selling medications that should cost only some millions of dollars, pretending to be “newly discover medications”: and instead the government has spent billions of dollars. The recovery of these funds could pay for the building of the wall between Mexico and USA, and also to pay a large portion of the US debt.

Knowingly using (or causing to be used) a false record or statement to conceal, avoid, or decrease an obligation to pay money or transmit property to the Federal government by abusing the following acts and/or laws: **The Sherman Antitrust Act in 1890, the Massachusetts Antitrust Act., The Clayton Antitrust Act of 1914, The Robinson-Patman Act of 1936., 18 U.S.C.). The Securities Act of 1933, The Securities Exchange Act of 1934, The Tax evasion (Section 7201 of the Internal Revenue Code, 26 U.S.C. §§ 7201-7217, The “Responsible Corporate Officer” (RCO) doctrine, The Bank Secrecy Act of 1970, and the Money Laundering Acts.**

These institutions, as well as possibly several top administrators of the Obama administration DOJ, in Washington DC as well as in Atlanta, and Augusta_Georgia had incurred violations in: **Obstruction of Justice 18 U.S.C. §§ 1501-1521, the Racketeering Influenced and Corrupt Organizations Act (RICO) (18 U.S.C. §§ 1961-1968),** had abused and retaliated against me and my daughter’s immigration violating **The Immigrations and Naturalization Acts via Paul Onyango at Atlanta Northlake USCIS office, a relative of ex-president Obama. BOR and Gilead attacked us was by damaging my and my daughter’s USCIS applications for work visas, Green Cards and citizenship. All were jeopardized illegally, and or cancelled, trying to make me leave the USA. My Green Card applications were jeopardized at least 5 times as EB1, EB2 status and others by PAUL ONYANGO AT USCIS ATLANTA (HE IS EITHER A COUSIN AND/OR HALF-BROTHER OF EX-PRESIDENT OBAMA).** We discovered the connections using FOIAs from the USCIS, as well as the USCIS OIG. They both demonstrated **MR ONYANGO DID THIS “INTERNAL JOB” AND NO PROSECUTION HAPPENED BECAUSE OF HIS RELATIONSHIP TO EX-PRESIDENT OBAMA.** We beg you guys to speak with the new DHS Secretary, and order an investigation and the human resources files on Paul Onyango, the current staff director at Atlanta Northlake USCIS; he could reveal who paid him off to destroy our immigration. Mr. Onyango use to have a relative of his working in Human Resources at Emory University (Partrica Rubera Onyango); we believe this is the connection.

Based on our experience, one way to recovery trillions of dollars for US tax payers is considering making the colleges and universities pay appropriate taxes. Large medical universities currently have MASSIVE income from 1) tuition and fees, 2) training grants, 3) payments for staffing outside training hospitals, 4) gifts and donations, 5) Bayh Dole technology transfer patent/royalty income, 6) endowment income and 7) property and other tax exemptions. As an example, Emory University in Atlanta is by far DeKalb County, Georgia's largest employer and landowner, and pays NO county property taxes! The combined US university endowments (non-taxable, with many improper contracts) total in the trillion dollar range.

Implications of this case in tax exemptions laws for universities, their foundations, hospital endowments [IRC §§509(a) (1) and 170(b) (1) (A) (i)] and the Bayh-Dole Act for the U.S.


The following folders are included in the USB Drive: The last events are in the Folder name "last attempt to get justice"

- **11th 2009 Court horrible clinical trials.** This folder contains all the communications with the courts in the first lawsuit, all proofs, the MCG lied committed perjury, falsified documents and the judges oversaw all the proofs.
- **Attacks:** The attacks on us.
- **Batson:** This was my crooked attorney in Augusta whom received out of the blue "400,000" heritage from a none existing uncle and did removed files from my lawsuit. He never presented, I have to travel to Augusta and pay the sheriff to serve it. I fired him after that.
- **Bayh-Dole Act.** It shows all the crooked actions on this abused act.
- **Emory Board of Trustees and ex- president Carter.** All communications we sent to them (when we were so naïve thinking that they really were trustees for the good of Emory and the society. No one answer us back either. We realized alter the conflicts of interest of many trustees and most of Carter center money is managed by Emory.
- **Busqued trabajo after MCG firing:** I trying to get a job after MCG fired me illegally for exposing the horrible clinical trials.
- **Certorati 2009:** All, documents in my first certiorati.
- **Certorati 2016.** All, documents in my second certiorati.
- **Clinical trials compliances:** a recompilation of the rules in clinical trials compliances.
- **Dr. Marcus 3 small claims judgements again:** Dr. Dennis Marcus the guy who did the horrible clinical trials in Augusta GA has had 3 lawsuits against him.
- **E-mails with FBI and others.** The name is explicative of contains.
- **Emory:** Multiple violations committed by Emory.
- **MCG Faculty Senate By-laws:** when MCG was changing the by-laws and I figures out why.
- **Federal and state authorities I have contacted:** Self-explanatory, exposing all these civil and criminal violations.

- **Fix the courts:** Some ideas how to improve the judiciary system in USA.
- **FOIA and SEC answers.** All the bogus answer to multiples agencies of our FOIA request (BS) Self-explanatory.
- **Fraud lawsuits vs. Emory and MCG-BOARD OF REGENTS OF THE UNIVERSITY SYSTEM OF GEORGIA:** A compilation I made of multiple lawsuits and violations from these entities.
- **Gilead Emtriva Emory:** self-explanatory.
- **Immigration.**
- **Immigration Manuela and Ana:** the previous one and this one all the violations we caught again me and my daughter
- **LAST ATTEMPTS TO GET JUSTICE.** Self-explanatory include the lasts events including the communications with you guys.
- **Lobbying:** Dirty lobbying issues from the Emory and Gilead and some changes that happens at MCG after I left.
- **Marcus:** Shows the horrible clinical trials at MCG, forging of documents, conflicts of interest etc.
- **MCG Foundation:** All the crooked things that happened at the MCG foundation.
- **The last three files are** me asking to remove Dr. Swerlick and Dr. Lawley from the Society of Investigative Dermatology and American Academy of Dermatology.

I also have about 22 large ups boxes with documents proving my claims, both copies and originals, as well as three boxes the size of copier paper I will be glad to give to you, but someone that you trust needs to pick up them in a place we agree on in Atlanta, Georgia. Now Emory University is trying silently to change many of their trustees trying **to cover up these severe violations of the laws.** Please feel free to ask me anything to help you. It is easy for me via e-mail.


Sincerely,


Ana María Abreu Velez, M.D., Ph.D., Dr.Sc.
1192 Cumberland Road, NE; Atlanta, Georgia 30306
E-Mail: abreuuvelez@yahoo.com.
Phone: 404-876-4897.
Cell phone:404-660-5558.

11

A handwritten signature in cursive script, reading "Michael S. Howard, M.D.", written in dark ink.

Michael S. Howard, M.D.
Georgia Dermatopathology Associates
Work: 1534 North Decatur Road NE; Suite 206
Atlanta, Georgia 30307.
E-mail: mhoward@gadermpath.com.
Work Phone: 404-371-0077.
Cellular: 404-431-9249.

CLAIM FOR DAMAGE, INJURY, OR DEATH		INSTRUCTIONS: Please read carefully the instructions on the reverse side and supply information requested on both sides of this form. Use additional sheet(s) if necessary. See reverse side for additional instructions.		FORM APPROVED OMB NO. 1105-0008	
1. Submit to Appropriate Federal Agency: Department of Justice, HHS, FTC			2. Name, address of claimant, and claimant's personal representative if any. (See instructions on reverse). Number, Street, City, State and Zip code. Ana Maria Abreu Velez and Michael S Howard. 1192 Cumberland Road NE, Atlanta, GA 30306		
3. TYPE OF EMPLOYMENT <input type="checkbox"/> MILITARY <input checked="" type="checkbox"/> CIVILIAN		4. DATE OF BIRTH 05/22/1965	5. MARITAL STATUS Single	6. DATE AND DAY OF ACCIDENT these past years	
7. TIME (A.M. OR P.M.) N/A					
8. BASIS OF CLAIM (State in detail the known facts and circumstances attending the damage, injury, or death, identifying persons and property involved, the place of occurrence and the cause thereof. Use additional pages if necessary). We had submitted to the DOJ (multiple divisions), to HHS, FTC evidence of the biggest pharmaceutical scam in US and world system done by Gilead Science Inc, Emory University, ex-employees of Gilead and the BOR. They had for 20 years the monopoly on HIV and Hepatitis medications abusing of tax payers for about 23 trillion dollars. They also filed false patents pretending to be new medications but are generics using and abusing of the Bay-Dole Act. They manslaughter patients. .					
9. PROPERTY DAMAGE					
NAME AND ADDRESS OF OWNER, IF OTHER THAN CLAIMANT (Number, Street, City, State, and Zip Code). Drs Abreu and Howard, 1192 Cumberland Road NE, Atlanta, GA 30306.					
BRIEFLY DESCRIBE THE PROPERTY, NATURE AND EXTENT OF THE DAMAGE AND THE LOCATION OF WHERE THE PROPERTY MAY BE INSPECTED. (See instructions on reverse side). The DOJ and others didnt prosecute these crimes, destruction of our lifes, properties, our profession, immigration et					
10. PERSONAL INJURY/WRONGFUL DEATH					
STATE THE NATURE AND EXTENT OF EACH INJURY OR CAUSE OF DEATH, WHICH FORMS THE BASIS OF THE CLAIM. IF OTHER THAN CLAIMANT, STATE THE NAME OF THE INJURED PERSON OR DECEDENT. We had presented more than 70 attacks to the FBI Atlanta, to AG Barr, to ex attorneys Rosenstein, Yates, Lynch, Panussio and more than a 100 people at DOJ and HHS. Ana Abreu, Michael Howard, Manuela Villa all had been injure for these criminals. They had not recover multiple trillions of USD.					
11. WITNESSES					
NAME		ADDRESS (Number, Street, City, State, and Zip Code)			
Special agent William Share, Atlanta Police o		FBI Atlanta and Atlanta and Dekalb police in Georgia			
12. (See instructions on reverse). AMOUNT OF CLAIM (in dollars)					
12a. PROPERTY DAMAGE At least 10 million USD		12b. PERSONAL INJURY At least 20 million USD		12c. WRONGFUL DEATH At least 30 million USD	
12d. TOTAL (Failure to specify may cause forfeiture of your rights). At least 30 million USD					
I CERTIFY THAT THE AMOUNT OF CLAIM COVERS ONLY DAMAGES AND INJURIES CAUSED BY THE INCIDENT ABOVE AND AGREE TO ACCEPT SAID AMOUNT IN FULL SATISFACTION AND FINAL SETTLEMENT OF THIS CLAIM.					
13a. SIGNATURE OF CLAIMANT (See instructions on reverse side).  CIVIL PENALTY FOR PRESENTING FRAUDULENT CLAIM			13b. PHONE NUMBER OF PERSON SIGNING FORM 4048764897		14. DATE OF SIGNATURE 05/30/2019
The claimant is liable to the United States Government for a civil penalty of not less than \$5,000 and not more than \$10,000, plus 3 times the amount of damages sustained by the Government. (See 31 U.S.C. 3729).			CRIMINAL PENALTY FOR PRESENTING FRAUDULENT CLAIM OR MAKING FALSE STATEMENTS Fine, imprisonment, or both. (See 18 U.S.C. 287, 1001.)		

INSURANCE COVERAGE

In order that subrogation claims may be adjudicated, it is essential that the claimant provide the following information regarding the insurance coverage of the vehicle or property.

15. Do you carry accident insurance? ☐ Yes If yes, give name and address of insurance company (Number, Street, City, State, and Zip Code) and policy number. ☒ No

16. Have you filed a claim with your insurance carrier in this instance, and if so, is it full coverage or deductible? ☐ Yes ☒ No 17. If deductible, state amount.

18. If a claim has been filed with your carrier, what action has your insurer taken or proposed to take with reference to your claim? (It is necessary that you ascertain these facts).

N/A

19. Do you carry public liability and property damage insurance? ☐ Yes If yes, give name and address of insurance carrier (Number, Street, City, State, and Zip Code). ☐ No

N/A

INSTRUCTIONS

Claims presented under the Federal Tort Claims Act should be submitted directly to the "appropriate Federal agency" whose employee(s) was involved in the incident. If the incident involves more than one claimant, each claimant should submit a separate claim form.

Complete all items - Insert the word NONE where applicable.

A CLAIM SHALL BE DEEMED TO HAVE BEEN PRESENTED WHEN A FEDERAL AGENCY RECEIVES FROM A CLAIMANT, HIS DULY AUTHORIZED AGENT, OR LEGAL REPRESENTATIVE, AN EXECUTED STANDARD FORM 95 OR OTHER WRITTEN NOTIFICATION OF AN INCIDENT, ACCOMPANIED BY A CLAIM FOR MONEY

Failure to completely execute this form or to supply the requested material within two years from the date the claim accrued may render your claim invalid. A claim is deemed presented when it is received by the appropriate agency, not when it is mailed.

If instruction is needed in completing this form, the agency listed in item #1 on the reverse side may be contacted. Complete regulations pertaining to claims asserted under the Federal Tort Claims Act can be found in Title 28, Code of Federal Regulations, Part 14. Many agencies have published supplementing regulations. If more than one agency is involved, please state each agency.

The claim may be filled by a duly authorized agent or other legal representative, provided evidence satisfactory to the Government is submitted with the claim establishing express authority to act for the claimant. A claim presented by an agent or legal representative must be presented in the name of the claimant. If the claim is signed by the agent or legal representative, it must show the title or legal capacity of the person signing and be accompanied by evidence of his/her authority to present a claim on behalf of the claimant as agent, executor, administrator, parent, guardian or other representative.

If claimant intends to file for both personal injury and property damage, the amount for each must be shown in item number 12 of this form.

DAMAGES IN A SUM CERTAIN FOR INJURY TO OR LOSS OF PROPERTY, PERSONAL INJURY, OR DEATH ALLEGED TO HAVE OCCURRED BY REASON OF THE INCIDENT. THE CLAIM MUST BE PRESENTED TO THE APPROPRIATE FEDERAL AGENCY WITHIN TWO YEARS AFTER THE CLAIM ACCRUES.

The amount claimed should be substantiated by competent evidence as follows:

(a) In support of the claim for personal injury or death, the claimant should submit a written report by the attending physician, showing the nature and extent of the injury, the nature and extent of treatment, the degree of permanent disability, if any, the prognosis, and the period of hospitalization, or incapacitation, attaching itemized bills for medical, hospital, or burial expenses actually incurred.

(b) In support of claims for damage to property, which has been or can be economically repaired, the claimant should submit at least two itemized signed statements or estimates by reliable, disinterested concerns, or, if payment has been made, the itemized signed receipts evidencing payment.

(c) In support of claims for damage to property which is not economically repairable, or if the property is lost or destroyed, the claimant should submit statements as to the original cost of the property, the date of purchase, and the value of the property, both before and after the accident. Such statements should be by disinterested competent persons, preferably reputable dealers or officials familiar with the type of property damaged, or by two or more competitive bidders, and should be certified as being just and correct.

(d) Failure to specify a sum certain will render your claim invalid and may result in forfeiture of your rights.

PRIVACY ACT NOTICE

This Notice is provided in accordance with the Privacy Act, 5 U.S.C. 552a(e)(3), and concerns the information requested in the letter to which this Notice is attached.

A. **Authority:** The requested information is solicited pursuant to one or more of the following: 5 U.S.C. 301, 28 U.S.C. 501 et seq., 28 U.S.C. 2671 et seq., 28 C.F.R. Part 14.

B. **Principal Purpose:** The information requested is to be used in evaluating claims.

C. **Routine Use:** See the Notices of Systems of Records for the agency to whom you are submitting this form for this information.

D. **Effect of Failure to Respond:** Disclosure is voluntary. However, failure to supply the requested information or to execute the form may render your claim "invalid."

PAPERWORK REDUCTION ACT NOTICE


This notice is solely for the purpose of the Paperwork Reduction Act, 44 U.S.C. 3501. Public reporting burden for this collection of information is estimated to average 6 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to the Director, Tort Branch, Attention: Paperwork Reduction Staff, Civil Division, U.S. Department of Justice, Washington, DC 20530 or to the Office of Management and Budget. Do not mail completed form(s) to these addresses.


May 30, 2019

Federal Tort Claims Act Section
Torts Branch, Civil Division
U.S. Department of Justice
1331 Pennsylvania Ave, N.W., National Place
Suite 800 North, Washington, DC 20004
Telephone: (202) 616-4400
Fax: (202) 616-5200
RE: Federal Tort Claims

Based on the act enacted on August 2, 1946(Federal Tort Claims Act 28 U.S.C. § 1346(b)), we are submitting the attached claims due to NEGLIGENCE BY MULTIPLE PEOPLE AT THE DOJ, HHS and FTC etc. FOR NOT INVESTIGATING AND PROSECUTING THE LARGEST PHARMACEUTICAL CRIME IN US AND WORLD HISTORY, COSTING US TAXPAYERS MULTIPLE TRILLIONS OF DOLLARS. For many years we filed all the whistleblower forms, we contacted dozens of DOJ divisions, the AGs, Deputy AGs, the Office of Professional Responsibility and the Office of the DOJ Inspector General. The only meaningful answer was that there was no crime. We have proof of sending e-mails, FedEx packages, USPS certified packages, and calls. For being whistleblowers we loss all our assets, they injured our daughter; we lost much of our work, our office and our professional reputation. All this after negligent or wrongful acts or omissions by MULTIPLE employees of the Government at the DOJ, HHS, FDA, USPTO, ETC. while acting within the scope of THEIR office or employment(and under circumstances where the United States, if a private person, would be liable to the claim in accordance with the law at the place where the act or omission occurred). We previously requested the DOJ to provide our proposed settlement(attached) and DOJ has not done so despite such being requested multiple times.

Sincerely,


Ana Maria Abreu Velez, M.D., Ph.D., D.Sc.
1192 Cumberland Road NE Atlanta, Georgia 30306.
E-mail: abreuvelez@yahoo.com.
Phone at home: 404-876-4897.
Cell: 404-660-5558.


Michael S. Howard, M.D.
Georgia Dermatopathology Associates
Work: 2250 North Druid Hills Road, NE; Suite 124
Atlanta, Georgia 30329
E-mail: mhoward@gadermpath.com
Work Phone: 404-371-0077
Cell: 404-431-9249



U.S. Department of Justice

Civil Division, Torts Branch
Federal Tort Claims Act Staff

*Post Office Box 888
Benjamin Franklin Station
Washington, D.C. 20044*

GKJ:HLSwann:hls
157-0-32-16
157-0-32-23

July 8, 2019

Ms. Ana Maria Abreu Velez
Mr. Michael S. Howard
1192 Cumberland Road NE
Atlanta, GA 30306

Re: Administrative Tort Claim of Ana Maria Abreu Velez and Michael S. Howard

Dear Ms. Velez and Mr. Howard:

This is in response to your administrative tort claim dated May 30, 2019, which you submitted to the Department of Justice (Department). The Department received the claim on June 6, 2019. I have examined your claim and it lacks a sum certain, thus rendering it invalid.

In addition, because your claim involves the U.S. Department of Health and Human Services and the Federal Trade Commission, you should submit your revised claim to those agencies at the following addresses:

Mr. William Biglow
Acting Deputy Associate General Counsel
General Law Division
U.S. Department of Health and Human Services
330 C Street, S.W.
Switzer Building, Suite 2600
Washington, D.C. 20201

Mr. David Shonka
Acting General Counsel
Federal Trade Commission
601 Pennsylvania Avenue, N.W.
Room 568
Washington, D.C. 20580

Because your claim is invalid, this office cannot process it. Therefore, I am returning the claim to you.

Very truly yours,

A handwritten signature in cursive script that reads "Hope L. Swann".

HOPE L. SWANN
Paralegal Specialist
Civil Division, Torts Branch

Enclosure

**U.S. Department of Justice**

Washington, D.C. 20530

January 11, 2019

Ana Maria Abreu Velez
1192 Cumberland Road, NE
Atlanta, GA 30306-2263

Dear Friend:

Thank you for your recent letter to the Attorney General. We reviewed the information you provided and it appears that this matter does not involve Federal law and/or the Department of Justice. Accordingly, we are returning your correspondence to you. If you need to pursue the matter, we suggest that you consult a private attorney to determine what legal avenues are open to you.

Sincerely,

Mail Referral Unit
Department of Justice

Enclosure
Incoming Letter

SUMMARY OF HARASSMENTS AND ATTACKS PERPETRATED AGAINST ANA MARIA ABREU VELEZ, M.D., Ph.D. DrSC AND MICHAEL S. HOWARD, M.D. IN AUGUSTA/COLUMBIA COUNTY AND ATLANTA/DEKALB COUNTY, GEORGIA, 2002-2019.

Background information: Ana Maria Abreu Velez, M.D., Ph.D., D.Sc an internationally distinguished physician and scientist, is a witness to alleged Federal crimes including the deaths of patients in Theragenics Corporation (Buford, Georgia) clinical trials (and subsequent mismanagement and cover up of these incidents) as a clinical trial coordinator at the Medical College of Georgia (MCG) in Augusta. Dr. Abreu Velez believes she was discriminated against as a result of informing her supervisor, Dr. Dennis Marcus, about these issues, resulting in her dismissal from her position in November, 2004. Due to the seriousness and number of individuals involved in her MCG allegations (as well as previous, severe problems in clinical trial management at MCG in 1997-98 involving Drs. Richard Borison and Bruce Diamond), selected, pertinent data was reported by Dr. Abreu Velez to enforcement officers of multiple agencies of the US Federal Government in early December, 2007. During 2008-10, numerous MCG administration officials retired or were forced out, including the President (Daniel Rhan, M.D.), Provost (Barry Goldstein, Ph.D.), Director of Clinical Trials (George Shuster, D.D.S.) and Chief of the MCG Physician's Practice Group (John Steinhaus, M.D.). In addition, Dr. Dennis Marcus was forced out of MCG during this period, and the MCG Foundation was restructured.

Dr. Abreu lived in Augusta, Georgia from September, 2001 until September, 2005, at which time she moved to DeKalb County and has been a continuous resident of the county since that time. She worked at Emory University from September, 2005 until December, 2006 and since that time has worked at the North Decatur Road offices of Georgia Dermatopathology Associates (GDA), a private practice skin pathology laboratory located near the Emory University campus. In Augusta, four separate incidents of violent harassment were perpetrated against Dr. Abreu and/or her family members.

Augusta Incident 1: Occurred on January 31, 2002 at Dr. Abreu Velez' apartment in Martinez, Columbia County, Georgia, a suburb of Augusta. Her address was 4101 Old Petersburg Road, Apartment G51, Martinez, Georgia 30907. During the day while Dr. Abreu Velez was working at MCG, a person or persons broke into her apartment and stole her personal computer tower, keyboard, monitor, printer, scanner and a small white storage basket. No other items of value, i.e., jewelry, radios, television sets, etc. were stolen, despite being present in full view within the apartment. The incident was reported to Columbia County Sheriff's Office on January 31, Officer Wadis Broxton and Investigator Timothy Burnley, **Columbia County Case 2002-00003704.**

Augusta Incidents 2 and 3: Occurred during her residence in Augusta, on two separate occasions, when an individual or individuals came to the door of her residence during the day and pounded their fists as hard as possible for approximately one to two continuous minutes on the door of the residence. Augusta Incident 2 occurred in 2002-2003 at a separate apartment from Augusta Incident 1, specifically at the Lakeside Apartments in Evans, Columbia County, Georgia, Apartment 51. Augusta Incident 3 occurred in the 2003-2005 period at Dr. Abreu Velez' house, with the address provided in Augusta Incident 4 below. One of these incidents involved as perpetrators a tall Caucasian male, and a second, shorter person. **These incidents were possibly (not certain) reported to the Columbia County Sheriff's Department.**

Augusta Incident 4: Occurred after Dr. Abreu Velez had moved to Atlanta, but still owned her house at 609 Blue Ridge Crossing Drive, Evans, Columbia County, Georgia 30809. At night on approximately July 30, 2006, a person or persons attacked Dr. Abreu Velez' house mailbox with explosives, completely destroying the mailbox. No one was living in the house at the time of the incident, and no further items were stolen from the house or yard. Incident was reported on July 31 to Columbia County Sheriff's Office, Officer Ronald Koch, **Columbia County Case 2006-30987.**

With this Augusta background information, we now report a sustained pattern of criminal harassment against Dr. Abreu and Dr. Michael Howard in DeKalb County, Georgia from 2006 until the present.

DeKalb Incident 1: Occurred from early 2006 until December 2006, during Dr. Abreu Velez's postdoctoral fellowship in the Department of Radiation Oncology of the Winship Cancer Institute within Emory University Medical Center in Atlanta. Dr. Abreu Velez had notified the Emory Medical Center administration in late 2005 that she was filing a civil lawsuit against the Medical College of Georgia in Augusta regarding her 2004 experiences as a clinical trial coordinator in poorly regulated Theragenics Corporation (CEO Christine Jacobs; Buford, Georgia) clinical trials, specifically under Dennis Marcus, M.D. in the Department of Ophthalmology at MCG. Dr. Abreu Velez **did not know at this time** that Dr. Thomas Lawley, Dean of Emory Medical School, was the medical chief of Theragenics clinical trials in 2004 at Emory and at all other sites (including MCG). Dr. Abreu noticed that she began to be watched and/or followed within Winship by Otis Brawley, M.D., a Winship administrator also on the board of Theragenics Corporation in 2006. Dr. Abreu **did not know at this time** that Dr. Brawley had this association, and was surprised that Dr. Brawley showed this level of interest in her activities within Winship. **Incident was not reported to DeKalb County Police.**

DeKalb Incident 2: Occurred at approximately 5 pm on March 30, 2006 near Dr. Abreu Velez's home apartment at the Conservatory Apartments, specifically 3448-T North Druid Hills Road, Decatur, Georgia 30033. Attempted kidnapping and aggravated assault was perpetrated on Dr. Abreu Velez' dependent 16 year old daughter, Manuela Villa Abreu, with the shouted threat "You and your Mom had better watch out!!". The perpetrator was a Caucasian male, 25-40 years old, 5'10" and approximately 180 pounds, with dark hair. Reported to DeKalb Police March 30, 2006. Note that at the time of this incident, the alleged perpetrator and Dr. Abreu Velez both worked at Emory Medical Center but had never met; the medical center was headed by Dean Thomas Lawley (see note following DeKalb Incident 10). Further, note that Dr. Lawley and Dr. Abreu Velez practice in the same medical specialty AND subspecialty. DeKalb Police Report Case 06-044063, Detective Ferreira. Also reported to Special Agent William Share, Atlanta Division FBI, (404) 679-9000.

DeKalb Incident 3: Occurred over the January to August 2007 period at Emory University Medical Center, specifically in the Department of Radiation Oncology and possibly within Emory Human Resources. Dr. Abreu Velez experiences a significant delay in delivery of a request for evidence (RFE) letter pertinent to her pending, December 2006 citizenship EB2 application and sent to Emory by the US Citizenship and Immigration Service (USCIS). The RFE request letter from USCIS was held for several months by Emory before being delivered from Ms. Patricia Mouan to Dr. Abreu Velez's new, 1192 Cumberland Road home address, arriving in a box with a handwritten note placed on her front porch during August, 2007. Dr. Abreu Velez had changed her home address in late January, 2007; her forwarding information was present at the old home address US post office in Decatur, Georgia during this time. Based on the timeline and outcomes of Dr. Abreu Velez's USCIS applications, Emory Human Resources may have further interfered with her application during the 2007-2011 period (see Appendix C). **Incident was not reported to DeKalb Police.**

DeKalb Incident 4: Occurred in three parts on February 14, 2007(8 am); February 19(12 noon) and February 21(12 noon) at or near the offices of Georgia Dermatopathology Associates (GDA), 1534 North Decatur Road, Suite 206, Atlanta, Georgia 30307, Telephone (404) 371-0077. A "Mr. Brian A. Zimmerman" entered the offices on the first day, stating that he owned a business and needed to expand his working space. Mr. Zimmerman met with Mr. Jonathan Jones and Dr. Abreu Velez simultaneously on February 14; he specifically asked Dr. Abreu Velez her name twice, and where she was from. Dr. Abreu Velez was very uncomfortable with her interactions with Mr. Zimmerman. Mr. Zimmerman claimed he sought to rent or sublet space in the Georgia Dermatopathology Associates building, and provided his card to be given to Michael S. Howard, M.D. Laboratory Director and Dr. Abreu Velez' supervisor. In addition, because Dr. Howard was not present, Mr. Zimmerman was given Dr. Howard's card and instructed to call back to discuss this matter directly with Dr. Howard. Mr. Zimmerman's card gave his name as Brian A. Zimmerman, with the contact information of 815 Harold Avenue, SE, Atlanta, Georgia 30316, Telephone (404) 659-8909. No further information was provided on his business card. Mr. Zimmerman presented as a Caucasian male, approximately 50 years of age, approximately 6'5" tall and 220 pounds, with blond hair and blue eyes (note his physical description does **NOT** match the assailant in DeKalb Incident 2). A public records search by Dr. Abreu on 2/14/07 yielded a birthdate for a Brian Anderson Zimmerman of December 27, 1956 and previous Atlanta addresses of 850 Ralph McGill Boulevard, Apartment 3, Atlanta 30306 and 2233 Edison Avenue, NE, Atlanta 30305 for a Brian A Zimmerman, and confirmed the then current Harold Avenue address listed on the business card. Mr. Zimmerman also has a previous driver's license number of 256506156368 in January, 2003, documented on public records search due to a speeding violation; in addition, two civil judgments against him are recorded in Saint Louis, Missouri in 1993.

On February 19 and 21, 2007, Mr. Zimmerman was observed and positively identified from inside the GDA offices by Jonathan Jones suspiciously loitering and looking at the GDA offices from the nearby CVS parking lot on North Decatur Road, at approximately 12 noon on both days. Mr. Zimmerman did not come to the building to inquire regarding sublet space from Dr. Howard on these dates, despite the fact that Dr. Howard was working and present in the offices. Dr. Howard has not called or contacted Mr. Zimmerman at any time regarding the sublet space issue, and Mr. Zimmerman has not contacted any member of the laboratory for legitimate purposes since February 14, 2007. A 411 Nationwide information call in August, 2008 confirms a listing for a Brian Zimmerman in Atlanta, matching the above address and telephone contact information. **On February 22, 2007, these three events involving Mr. Zimmerman at Georgia Dermatopathology Associates were reported to DeKalb County Police, as well as to Special Agent William Share, Atlanta FBI, who instructed Dr. Abreu Velez to file the DeKalb County Police Report.**

DeKalb Incident 5: Occurred on the night of May 19-20, 2007, when Dr. Abreu Velez's 2002 Toyota Corolla was parked in the driveway of her residence at 1192 Cumberland Road, NE, DeKalb County, City of Atlanta, Georgia 30306. A person or persons threw a large rock through the passenger side door window of the car; the rock matched stones from a decorative wall in the front yard of the residence. The entire window was shattered and necessitated complete replacement. No items of value were stolen from the car, despite the passenger door lock being left unlocked overnight and a small amount of cash being present in full view on the passenger side seat of the car. **On May 20, 2007, the incident was reported to City of Atlanta Police, Officer Ed Baker, Case 07-1400633.**

DeKalb Incident 6: Occurred between 5 pm on August 24 and 3 pm on August 25, 2007; a person or persons entered the Georgia Dermatopathology offices on North Decatur Road, to vandalize a business

directory sign near the front outside door and for the likely purpose of making plastic molds of the interior door locks. Specifically, when Dr. Howard and Dr. Abreu entered the offices on August 25 at 3 pm, Dr. Howard's office door lock had a plastic substance in it, and the business directory vandalism had also occurred. Other, similar internal vandalism incidents had occurred involving the business name sign on dates preceding August 24. No materials were stolen from the GDA offices. **On August 27, the incidents were reported to DeKalb Police, Officer J.S. Johnson, see Case 07-112909.**

DeKalb Incident 7: Occurred during the June 3-9, 2008 period at the offices of Georgia Dermatopathology Associates on North Decatur Road. Dr. Howard was contacted by telephone by Steven Budnick, M.D., an oral pathology faculty member at Emory Medical School regarding possible employment at GDA. Dr. Budnick stated that he "had not been able to obtain requested Friday time off" from his department chair, specifically Tristram Parslow, M.D. in the Department of Pathology and Laboratory Medicine. He asked Dr. Howard to keep the call confidential and asked if Dr. Howard would be willing to hire him as an associate, if Dr. Budnick were to leave his Emory faculty position. Dr. Budnick stated that he was interested in working at GDA because he lived near GDA, and because it would take time for Dr. Budnick to set up his own practice, with him having only a few years remaining until reaching age 65. Dr. Budnick had previously served on medical school committees for Dr. Lawley, and was and remains a direct back-door neighbor of Dr. Lawley at home (Dr. Lawley on Oxford Road, Dr. Budnick on Springdale Road). **Drs. Howard and Abreu Velez later suspected that** Dr. Budnick may have been offered a full Emory retirement by Dr. Lawley, and asked to "infiltrate" GDA for Dr. Lawley (with or without knowledge of Dr. Lawley's true intentions). The purpose of the "infiltration" would be for Dr. Lawley to politically cover up any future action by GDA vis-a-vis the attack on Dr. Abreu Velez's daughter outlined in DeKalb Incident 2. Dr. Howard discussed this matter with Dr. Abreu Velez and called Dr. Budnick back on Monday, June 9 to state that he and Dr. Abreu Velez were not interested in hiring him. **Incident was not reported to DeKalb Police.**

DeKalb Incident 8: Occurred on the night of August 20-21, 2008, between 10 pm and 8 am, when a person or persons entered the Georgia Dermatopathology Associates offices, apparently with key access, i.e., no signs of forced entry were noted on the outside locked doors of the building, or on any interior locked office doors. The persons entering committed acts of vandalism on the business directory sign, very similar to the vandalism occurring the preceding August in DeKalb Incident 6. In addition, these individuals had specifically entered Dr. Abreu Velez' two separate locked offices without signs of forced entry, and had placed handwritten paper signs reading "MCG" on both of her two work computer keyboards, one in each office. In addition, GDA information technology officer Chris Griffin (404-488-9694) investigated the incident with computer forensic analysis on the night of August 21 and determined that a probable, unsuccessful attempt was made at one of Dr. Abreu Velez' computer keyboards to log onto the GDA computer network at 11:30 pm, August 20. No materials were stolen from the offices. Thus, the perpetrator of this crime (DeKalb Incident 8) 1) knew the location of Dr. Abreu Velez' two specific offices out of a total of eight separate GDA offices (relevant name/office identification is not present on the exterior of the offices or on the business name directory), 2) that she had an association with MCG, and 3) possessed keys to these offices. Extensive investigation inside Georgia Dermatopathology Associates revealed only three individuals, i.e., Drs. Abreu Velez and Howard and Jonathan Jones, who had the keys to commit this act inside the company; all of these three employees had excellent alibis and believed the August 2007 and August 2008 DeKalb incidents (Numbers 6 and 8) were likely connected directly or indirectly to the "Mr. Brian Zimmerman" of DeKalb Incident 4. On August 21, this incident was reported to DeKalb Police, Case 08-112522, Officer C.W. Fraser, with Crime Scene Fingerprinting at the GDA offices performed on

August 22, 2008. DeKalb Incidents 2, 5, 6 and 8 were also discussed with Lt. D. A. Lillard of the DeKalb Police Detective Unit on August 22, at Telephone (770) 724-7781.

DeKalb Incident 9: Occurred on the afternoon of August 19, 2009, at approximately 4:50 pm at the GDA offices on North Decatur Road. Vandalism to the GDA building internal name sign had occurred on the previous weekend of August 15-16, similar to the August vandalism of the preceding two years. A Caucasian male was observed by Dr. Howard attempting to gain access to the front door of the building at this time. Given that the door was already locked for the afternoon, the perpetrator immediately went to the back of the GDA parking lot, possibly to try to gain access to the locked rear door. At approximately 5:05 pm, the same individual was observed by Dr. Howard walking out of the GDA parking lot, and was followed by Dr. Howard (on a hot and humid day), without the individual of interest realizing he was being followed. The individual crossed to the south side of North Decatur Road, and proceeded east on North Decatur Road, stopping to look into store windows and make or receive a cell phone call in front of the Rise and Dine restaurant (1565 North Decatur Road) at approximately 5:10 pm (NOTE: the identity of the perpetrator could hopefully be traced with this information, utilizing cell phone tower call time/location records; Dr. Howard and Abreu Velez currently believe this perpetrator was likely involved in DeKalb Incidents 5, 6, 8, 9, 10, 14 and 20). He proceeded east to the Glenn Memorial Church After School Building at 1669 North Decatur Road, where visual contact was lost at approximately 5:20 pm, with the individual located at the front yard fence gate on the west side of the property.

According the school staff director (Kathy P. Wells, 404-320-9528; Cell 404-583-7652), no individual matching his description had been seen entering the building from the nearby front door (her offices are immediately inside the front door). A search of the building and rear parking lot by Dr. Howard failed to locate the individual on the property. A tan, recent model, economy size sedan was leaving the parking lot approximately 8 minutes after contact with the individual was last made, but the driver could not be positively identified, nor the license plate number obtained. The individual was a clean shaven, thin Caucasian male, approximately 5'8" and 135 pounds, 20-40 years old, short brown hair, black horn-rim sunglasses, blue short sleeve tee shirt and light green opaque(non-camouflage) army fatigue pants and unknown color sneakers. **Incident was not reported to DeKalb police.**

Note: On March 20, 2010, Thomas Lawley, M.D., Dean of Emory Medical School, under pressure from Atlanta private practice dermatologists, presents a keynote lecture on "Universities and the Public Trust" at the annual Emory Dermatology Day lectures on campus. Drs. Howard and Abreu Velez did not attend, and have not attended any Emory dermatology departmental events since the April 28, 2007 Emory Dermatology Day until 2017. The three most recent department Chairs in the Emory Department of Dermatology are: 1) Thomas Lawley, M.D. (1988-1996; also Dean of Emory Medical School 1996 to 2013); 2) Wright Caughman, M.D.(1996-2007) and 3) Robert Swerlick, M.D.(2007 to the present).

DeKalb Incident 10: Occurred in two parts on the afternoon of May 17 and morning of May 18, 2010, near the offices of Georgia Dermatopathology Associates. On the afternoon of May 17 at approximately 5 p.m., a Caucasian male matching the description of the individual in DeKalb Incident 9 was observed face to face by Dr. Abreu Velez riding a bicycle into the GDA office parking lot driveway entrance. Upon recognizing Dr. Abreu Velez at the driveway entrance, the individual seem startled and scared, and immediately drove his bicycle to the rear of the parking lot and waited approximately 3 minutes. The individual was then seen by Dr. Abreu exiting the parking lot via the driveway on his bicycle, and proceeding rapidly west on North Decatur Road. The individual was

wearing sunglasses, a bicycle touring top and pants, and sneakers. On the morning of May 18 at 8 a.m., the same individual was waiting on his bicycle for Dr. Abreu (as she walked from home to work) at the intersection of North Decatur Road and Springdale Road. When asked by Dr. Abreu why he entered the office parking lot of GDA the previous afternoon, the individual stated that he was "not riding his bicycle the previous day". He subsequently, without probing from Dr. Abreu, uttered the statement "What have they done to you?" twice before Dr. Abreu Velez left, walking to work east on North Decatur Road. Simultaneously with her leaving the intersection, the individual also was observed by Dr. Abreu Velez leaving the intersection on his bicycle, and proceeding south on Springdale Road.

Both May 17 and 18 incidents were not reported to DeKalb police. However, on June 2, 2010, DeKalb Police CID was called at (770) 724-7850(Sergeant Stafford) by Dr. Howard, to report a likely visual ID by Dr. Abreu Velez on Micah Chrenek of the Emory Medical Center Department of Ophthalmology, the alleged perpetrator of DeKalb Incident 2. Having received no follow-up call from DeKalb Police, the call was repeated to the same number on June 22, 2010 by Dr. Abreu Velez, who spoke to Captain Detective Richards regarding Micah Chrenek.

IMPORTANT NOTE: On June 5, 2010, Drs. Howard and Abreu write via FedEx to FBI Director Robert Mueller, Atlanta FBI Special Agent William Share and US Senator Charles Grassley of Iowa regarding their suspicions that Dean Lawley at Emory Medical School may have sent Micah Chrenek to attack Manuela Villa Abreu on March 30, 2006, and that Dean Lawley may be involved in many or all of the other DeKalb County Incidents. Senator Grassley was instrumental in investigating the unprofessional behavior of Charles Nemeroff, M.D. of the Emory Psychiatry Department in 2008-09, and in the course of his investigation interfaced with both Dean Lawley and Emory President James Wagner. Dr. Nemeroff was forced out at Emory in 2009 and is now in the Department of Psychiatry at the University of Miami Medical Center, Miami, Florida.

DeKalb Incident 11: Occurred on June 9, 2010 at the GDA offices on North Decatur Road. An "emergency" fire inspection was conducted by the DeKalb County Fire Department, specifically within the GDA offices inside the Darden Research Building. The laboratory had last been inspected when Dr. Howard set up the slide production area of the laboratory in August, 2004. Three (3) fire department inspectors arrived in a medium sized pumper fire truck, with sirens on in the middle of the workday. Other tenant offices within the Darden Building were not inspected. The inspectors asked for GDA to install 1) fire extinguisher brackets and 2) fire extinguisher signs within the laboratory. The inspectors left after approximately one hour, telling Drs. Howard and Abreu that they would follow-up their inspection at a later date to determine if these changes had been made. Drs. Howard and Abreu made the requested improvements, but no follow-up calls or visits from the DeKalb Fire Department occurred. **Incident was not reported to DeKalb Police.**

DeKalb Incident 12: Occurred on June 10, 2010, when Dr. Abreu was called by telephone by Wendy Gao, M.D., a physician in the laboratory of Hans Grossniklaus, M.D. at the Emory University Medical Center Department of Ophthalmology. Dr. Grossniklaus and Dr. Gao had collaborated in research with GDA during both 2009 and early 2010, in both Emory Ophthalmology and GDA venues. Significantly, a large research paper had been published in the March, 2010 issue of the *Journal of the American Academy of Dermatology* co-authored by Drs. Abreu, Howard, and Grossniklaus, with Dr. Gao mentioned in the article for her excellent technical assistance; Drs. Thomas Lawley and Robert Swerlick of Emory dermatology consistently read this journal. The specific paper reference is Abreu Velez AM, Howard MS, Hashimoto T, Grossniklaus HE. JAAD 62(3): 437-447(2010). Dr. Gao called to report that Micah Chrenek (possibly involved in DeKalb Incident 2) had been suspiciously following

her, and to ask advice on how to handle the problem. Dr. Howard sent Dr. Gao an email (to her personal email) the same day introducing her to Special Agent William Share of the Atlanta FBI office (and copying him), and providing both individuals with contact information to reach each other. **Incident was not reported to DeKalb Police by GDA. Later in the summer, Dr. Gao experienced vandalism to one of her car tires, specifically a nail driven into an outer lateral side of the tire and discovered following work within her Emory parking deck.**

Note: According to sources inside Emory Medical Center, Dr. Robert Swerlick, Chair of Dermatology, began having public angry outbursts and temper tantrums in the presence dermatology and pathology residents and fellows within the department during June and July, 2010. The same sources report that Dr. Swerlick was considering leaving the position of Chair, and that the administration might be interested in bringing back Alvin R. Solomon, M.D. as Chair, a former dermatology faculty member and full Professor who left Emory for Oregon Health Sciences Center in Portland in 2008. During this period, Dr. Swerlick panicked and publicly informed numerous Atlanta private practice dermatologists that "Dean Lawley had done something horrible, and was responsible for directing an attack on Dr. Abreu Velez's daughter". Later in the year, different, scaled down versions of this story were circulated among Atlanta and Georgia private practice dermatologists by Dr. Swerlick and a close Lawley/Swerlick ally in private practice, Harold J. Brody, M.D. In addition, in response to Dr. Swerlick's original statements and in professional sympathy for Drs. Howard and Abreu, the Atlanta Dermatological Association (primarily private practice dermatologists) hosted two special speakers at their monthly meetings in August and September, 2010 (specifically Hans Grossniklaus, M.D. of Emory Ophthalmology, a research collaborator with Drs. Howard and Abreu and Jean Bolognia, M.D., a Yale University dermatopathologist, respectively). The Atlanta Dermatological Association also moved some of their 2010-2011 monthly meetings off the Emory campus at this time. Due to their desire for privacy during this time, Drs. Howard and Abreu did not attend the Grossniklaus or Bolognia lectures. Dr. Swerlick, the only Emory Medical Center Chair (out of 18 total) NOT to hold the rank of full Professor in June, 2010, was then suddenly promoted to full Professor during the summer, and Dr. Swerlick continued on as dermatology Chair. Dean Lawley had not see fit to promote (for unknown reasons) Dr. Swerlick from Associate Professor to Professor during Dr. Swerlick's entire previous tenure as Chair of Dermatology, specifically from April, 2007 until the summer of 2010.

DeKalb Incident 13: Occurred on June 29, 2010 when Dr. Abreu Velez attempted to attend a free June 29-July 1 Zeiss Microscopy Seminar, open to the public 10am to 2 pm each day and hosted within the Winship Cancer Institute at Emory Medical Center. Upon arrival at the seminar, Dr. Abreu spoke to Adam Marcus, Ph.D., director of the Microscopy Core nearby on the fifth floor of Winship, who was attending the seminar. Dr. Marcus remembered Dr. Abreu from her 2005-2006 postdoctoral fellowship at Winship, and for no discernable reason contacted Emory Security to report that Dr. Abreu was attending the seminar. He stated to Dr. Abreu that she was "not supposed to be here". Shortly thereafter, two(2) armed, plainclothes Emory security officers appeared at the seminar, and began to watch and follow Dr. Abreu Velez as she attended the seminar. Dr. Abreu was very uncomfortable being watched and followed in this manner and left the seminar before noon, to return to GDA. She attended no further seminar sessions. **Incident was not reported to DeKalb Police.**

DeKalb Incident 14: Occurred in Dr. Abreu Velez's auxiliary lab office at GDA on the morning on July 12, 2010. It was discovered that a person or persons had entered Dr. Abreu laboratory without permission and had written "MCG" in black felt tip pen block letters on the card of Mr. Ron Gazaway, a representative for Optisystems Corporation of Canton, Georgia (Office 678-493-8922; Cell 678-296-9282). The Optisystems card was located on Dr. Abreu Velez's computer monitor stand, immediately

in front of her sitting position at the microscope. Thus, the location of this “MCG” inscription was very close to one of the “MCG” signs left in this office in DeKalb Incident 8 (the Incident 8 sign was located approximately one foot lower, placed on the computer keyboard). The style of lettering was very similar in the Incident 8 and Incident 14 writings. Mr. Gazaway had last visited this specific GDA lab on May 27, 2010 to install a special fluorescent light bulb into Dr. Abreu Velez’s auxiliary lab microscope. The Optisystems card involved was given to Dr. Abreu Velez by Mr. Gazaway at that time, and posted into position on the computer monitor stand. Thus, we believe the laboratory was entered and the Optisystems card written on between May 27 and July 12. Dr. Howard called Mr. Gazaway by telephone on the morning of July 12; Mr. Gazaway denied having written “MCG” on any Optisystems card given to Dr. Abreu Velez at any time. No signs of forced entry were noted on the outside doors of the building, or on the door of the auxiliary lab. No materials were stolen from the GDA offices. **Incident was not reported to DeKalb Police by GDA, but Incident was reported by Dr. Howard via email to Special Agent William Share of the Atlanta FBI office on July 12, 2010.**

DeKalb Incident 15: Occurred in three parts on August 2 and 3, 2010. First, at approximately 6:20 am on August 2, Dr. Abreu logged onto her home computer email at 1192 Cumberland Road, NE, Atlanta 30306. After a few minutes of normal performance, her computer experienced a massive, multiple phase virus attack, originating from her yahoo email account (abreuvelez@yahoo.com), and coming from multiple IP addresses simultaneously. The attacking viruses seemed to be attempting to determine or steal Dr. Abreu Velez’s username and password information. Dr. Abreu shut down and unplugged her computer, and contacted GDA IT support Chris Griffin (404-488-9694) regarding this issue. Secondly, at approximately 8:30 am August 2, Lynn Nabers, HT, HTL was staffing the GDA main laboratory within the GDA offices. Ms. Nabers received a call from a caller identifying herself as “Tonya”, stating that she was employed at ADP payroll services, and that her contact at GDA was “Michael”. The caller ID on the GDA laboratory telephone listed the caller as “Unknown number”. Ms. Nabers asked the caller if by “Michael” she meant “Dr. Michael Howard”, and received no reply. The caller then asked Ms. Nabers if she knew how many people worked at GDA, and about GDA workmen’s compensation arrangements in the front office within the company. Ms. Nabers did not answer these questions, and instructed the caller to call back and speak to Dr. Howard beginning at 10 am, August 2. Dr. Howard received no follow up call from ADP or “Tonya” on August 2 or 3. A call to ADP’s Atlanta payroll office (770-226-6522) at 4 pm August 3 by Dr. Howard confirmed that no calls regarding employees or workmen’s compensation policies were documented on ADP’s GDA account as having been made to GDA on August 2, or to be made.

In addition, the Atlanta office stated that calls of this nature (i.e., workmen’s compensation calls) were classically made to clients by ADP only at the client’s prior request. Third, on August 3 at approximately 12 noon, Dr. Abreu Velez experienced an additional virus attack originating from her yahoo email account, and affecting her main GDA work computer tower. On August 9, 2010, Chris Griffin reported that computer forensic analysis had determined the home computer attack of August 2 was caused by spyware and NOT by a denial of service (DOS) attack from multiple servers. **Incidents were not reported to DeKalb County Police, but communicated by Dr. Howard via email to Special Agent William Share of the Atlanta FBI office late on August 3, 2010.**

DeKalb Incident 16: Occurred on the afternoon of Friday, August 27, 2010. Dr. Howard, needing to discuss research issues with Hans Grossniklaus, M.D. in the Department of Ophthalmology at Emory Medical Center, sent an email to Dr. Grossniklaus requesting a time for a telephone call. The time was agreed on as approximately 5pm, and Dr. Howard called Dr. Grossniklaus at that time. Dr. Howard was present in his GDA office (404-371-0077 or 404-371-0027), and Dr. Grossniklaus was present in

his Emory Eye Laboratory office (404-778-4611) during the call. Dr. Howard and Dr. Grossniklaus spoke for approximately 30 minutes, and discussed 1) mutual research activities, and 2) the June harassment of Dr. Wendy Gao outlined in DeKalb Incident 12. Dr. Howard suspected later (i.e., following DeKalb Incident 17 five days later) that this call may have been illegally recorded or listened to by Emory, and reported to Dr. Lawley. **Incident was not reported to DeKalb Police.**

DeKalb Incident 17: Occurred on the evening of September 1, 2010, at the GDA offices on North Decatur Road. At approximately 9:50 pm, well after nightfall, Jonathan Jones, HT was returning to the laboratory after leaving at 4:00 pm to work a second, evening shift job at a different company. The last person to leave the building was Dr. Howard at 6:30 pm, with all doors locked and no one in the building. After entering the GDA parking lot and driving to a location near the north end of the building, Mr. Jones witnessed a Caucasian male, exiting the GDA building rear door landing and looking out at his approaching GMC Sierra white 2008 pickup truck. The individual then ran quickly (in front of the truck headlights) across the path of the truck, exiting the GDA building parking lot on its northeast corner, and running north into a wooded area along the west bank of Peavine Creek towards Oxford Road and Emory University. Mr. Jones did not hear splashing from the individual (from the possibility of running in the creek itself), and did not pursue the individual into the woods. Mr. Jones screamed at the individual to stop, but to no avail. No suspicious cars, bicycles, etc. were present in the GDA parking lot. Upon inspection by Mr. Jones, the back door of the building was locked and did not appear to have been tampered with. Upon inspection inside the GDA offices, no items had been stolen from the offices, and no evidence existed of any of the offices having been forced open or entered into. The individual of interest was a Caucasian male, approximately 30-40 years old and approximately 6'2" and 210 pounds, with short, unknown color hair, a sun tan and unknown color eyes. The individual did NOT appear to match the description of the perpetrators in earlier DeKalb Incidents. He was dressed in a plain black baseball cap, long sleeve black sweater and long black pants, with black leather work boots (inappropriate clothing for a hot, humid summer evening).

Note that this attack on the GDA building occurred at a similar time of year as attacks on the building in August of the preceding THREE years (DeKalb Incidents 6, 8 and 9). Note that this exact date (September 1, 2010) represented the first day that Wright Caughman, M.D. began serving as Dr. Thomas Lawley's boss (i.e., Chief of the Woodruff Health Sciences Center, or WHSC), and further that Dr. Lawley served as Dr. Caughman's boss 1996-2007. Dr. Lawley's boss from 2007-2010 was WHSC Chief Fred Sanfilippo, M.D., Ph.D., who did not have a previous relationship with Dr. Lawley. Many on the campus believed that Dr. Sanfilippo had a very short, three year WHSC Chief tenure due to 1) the stress of the Grady Hospital/Emory management crisis in 2007, 2) the Charles Nemeroff, M.D. Emory crisis of 2008-09, 3) Dr. Lawley's behavior during this period and 4) the failure of the Emory University Administration to back Dr. Sanfilippo in firing or disciplining Dr. Lawley. On September 2, 2010, this incident was reported to DeKalb County Police, Officer J. Jamison, DeKalb Police Report Case 10-104133. In addition, the incident was reported by email to Special Agent William Share at the Atlanta FBI offices on September 2, 2010.

DeKalb Incident 18: Occurred on the evening of Monday, February 21, 2011 at the residence of Michael Howard, M.D. and Ana Maria Abreu Velez, M.D., Ph.D., 1192 Cumberland Road, NE; DeKalb County, City of Atlanta, Georgia, 30306. After dark at 7:55 pm, Dr. Howard was watching television in the front first floor living room of the house; Dr. Abreu Velez was upstairs in the house. The front porch lights were turned off. Multiple knocks were heard at the front door; Dr. Howard turned on the front porch lights, and looked out of the front door window. A young Caucasian male

was present outside the door, approximately 6'2" and 180 pounds, and approximately 20-25 years old. He was dressed in a red warm-up top and grey warm-up pants. The visitor announced his name as "Mike" and held up a cardboard box containing a game; the game may have been Monopoly (?). The caller stated that he wished to talk to Dr. Howard about "a product in the box". Dr. Howard did not open the door, sternly replied that it was not a good time to engage in such a conversation, and asked the caller to leave the property. Dr. Howard turned off the outside porch light to emphasize that he wished the visitor to leave. The visitor then walked off of the property, and disappeared into the darkness on Cumberland Road. No car was identified as belonging to the caller in the street. **The incident was very similar to an incident that occurred on the night of August 29, 2010, at the home of Jonathan Jones, HT, an employee of GDA, near McDonough, Georgia.** In the Jones incident, a tall, Caucasian male visitor knocked on his front residence door at approximately 10 pm on a Sunday night, well after dark. The Jones visitor was approximately 30 years old, 6'2", 180 pounds, held a sales folder, and was dressed in a non-company golf shirt and slacks. The Jones visitor stated that he wished to speak to Mr. Jones about a "new company product". Mr. Jones did not open the door, instructed the caller to leave the property at once, and stated that otherwise he would call the Henry County Sheriff's office. The caller then left the property. **The Jones and Howard incidents were not reported to Henry County Sheriff's office or to Atlanta Police, respectively. However, the Jones and Howard incidents were communicated by email to Special Agent William Share at the Atlanta FBI offices on February 22, 2011.**

DeKalb Incident 19: Occurred on May 12, 2011, when Dr. Abreu received a 1) returned request first class mail, 2) faxed and 3) emailed letter from Alastair Carruthers, MD, Chair of the Membership Committee at the American Academy of Dermatology(AAD), regarding her Affiliate category membership in the AAD. **Dr. Carruthers has previously published articles with Dr. Robert Swerlick, current Chair of the Emory Dermatology Department; Dr. Swerlick has verbally attacked Dr. Abreu Velez verbally multiple times over the last 4 years, probably at the request of Dean Lawley. Dr. Swerlick may have met Dr. Carruthers and Dean Lawley at the recent 2011 Society for Investigative Dermatology(SID) Annual Meeting(May 4-7, 2011) in Phoenix, Arizona.** Dr. Carruthers' current letter was similar to one received by Dr. Abreu Velez in early 2010, requesting her current US medical license for membership in that category. When Dr. Abreu researched the issue in 2010, she was provided with the membership criteria for the Affiliate category, which **DID NOT** state that the Affiliate must hold a current US medical license. Dr. Abreu confirmed with the AAD that she had sent all relevant documents for Affiliate membership (i.e., her Colombian dermatology board certification and other documents) into the AAD at that time. In the 2011 letter, sections of the wording of the letter are contradictory. Specifically, it states in the first paragraph that "Based on the information we received, it was determined that you may not meet the current criteria for the Affiliate membership category...."; this statement directly contradicts the Affiliate membership discussion vis-à-vis Dr. Abreu Velez in the previous year, as well as the current 2011 Affiliate category membership criteria, literally provided in the 2011 letter (the 2011 criteria are identical to the 2010 criteria). The 2011 Affiliate membership eligibility statement was thus received as harassing, and a waste of Dr. Abreu Velez's time. Later in the 2011 letter, Dr. Abreu is given the option of joining a new Adjunct Researcher category (and saving \$300 annually in membership fees, while giving up the right to vote on Academy matters), versus remaining in the Affiliate category. The 2011 letter ends with a request to Dr. Abreu Velez: "If you would like to maintain the Affiliate membership category we request that you provide us with a copy of your US or Canadian medical license." Again, this statement is also contradictory and harassing, for the reasons previously described. Dr. Abreu Velez elected in 2011 to remain in the Affiliate category. Incident was not reported to DeKalb County Police, but was reported by email to Special Agent William Share on May 13 and 16, 2011. Similar harassments were reported

by email to Special Agent Share in the summer and fall of 2010 involving 1) Drs. Howard and Abreu Velez not receiving their CME certificates from the SID following their attendance at the May 5-8, 2010 national meeting in Atlanta until September 29, 2010, despite asking the society throughout the summer (expected turnaround time was 8 weeks); and 2) Dr. Howard not receiving several prepaid issues of the Journal of Investigative Dermatology, published by the SID, from February 2010 until September, 2010, with a "failed mailout" of these back issues following email confirmation between Dr. Howard and Tracy Martin at the SID in August. Dr. Lawley was SID president 2006-07, and Dr. Swerlick was Secretary Treasurer of the SID in 2009-2010.

Note: On June 7, 2011, Dr. Abreu Velez visited the offices of James Wagner, Ph.D., President of Emory University without a prior appointment. Dr. Wagner was not present at the time of her visit. Dr. Abreu Velez left a copy of the summary of most of these attacks and harassments for Dr. Wagner to review. Drs. Abreu Velez and Howard, despite their status as Emory alumni and living and working near the Emory campus, have not received any response from Dr. Wagner or Emory since that time regarding her concerns vis-a-vis Dean Lawley and Micah Chrenek, nor about any past, ongoing or future investigation into these matters within Emory University. On both May 31 and June 7, Dr. Abreu Velez also spoke directly to the Atlanta FBI offices about her concerns regarding the ongoing harassments, and about what she regarded as inadequate investigation of these events by the DeKalb County Police Department, especially given the data presented to them in June, 2010.

DeKalb Incident 20: Occurred in two parts on July 9 and 13, 2011. On July 13 at the GDA offices, a person or persons had entered the front door of the GDA Darden Research building, likely during the workday, and again vandalized Dr. Howard's name on the building directory sign (very similar to the directory harassments in the Augusts of 2007-09 (see DeKalb Incidents 6, 8 and 9). Dr. Howard's name was specifically vandalized, out of four (4) total names on the directory. The vandalism was observed and noted by Jonathan Jones inside the company. Drs. Howard and Abreu Velez had personally seen Dr. Lawley four days earlier (on Saturday morning, July 9) while grocery shopping at the Sage Hill Kroger store, located approximately 1 mile from GDA. Drs. Howard and Abreu Velez approached Dr. Lawley together upon seeing him, smiled, and Dr. Abreu Velez said "Dr. Lawley, hi". Dr. Lawley looked at Drs. Howard and Abreu Velez, smiled, and said "Hi". Dr. Lawley then walked away into the store after showing no further interest or emotional response, and without any further words spoken by any of the three physicians. **Incident was not reported to DeKalb Police, but was reported by email by Dr. Howard to Special Agent William Share of the Atlanta FBI late on July 13, 2011.**

DeKalb Incident 21: Occurred at 4:30 pm on the afternoon of July 18, 2011, near the GDA offices. Dr. Howard had walked out of the offices on a hot, humid afternoon to make a billing shipment via a FedEx box on Oxford Road. As he walked through the nearby CVS parking lot, he noticed he was being directly watched by a Caucasian male, sitting in the driver's seat of a dark color, parked, recent year small sedan within the parking lot. The car's driver seat window was rolled down, and the car engine was not running. The driver was a heavy-set, serious man, dressed in a dark shirt and wearing sunglasses. His hair was of average length and white; he appeared approximately 55-70 years old, and about 6 feet tall and 240 pounds. After Dr. Howard passed the car, he looked back and saw the driver appear to briefly (2-3 seconds) speak into a hand-held device, i.e., a small cell phone or walkie-talkie. Dr. Howard recorded the license plate number of the car as Georgia, Fulton County BKY 1719, and did not speak to the driver. A Vanderbilt University decal was present on the car's upper rear window. Dr. Howard next proceeded on to the FedEx box, located less than a tenth of a mile away and beyond sight of the car. On Dr. Howard's return trip through the CVS parking lot 5-10 minutes later, the dark car was gone **Note:** If the preceding sentences (DeKalb Incident 21) represented Atlanta FBI surveillance

vis-à-vis DeKalb Incident 20, we appreciate any such protection; however, we also respectfully feel that such is an inefficient use of FBI personnel (given the overall context of the case), and that it is now time to address the root causes of these incidents with a thorough investigation. Also, three(3) separate emails sent from Dr. Abreu (abreuvelez@yahoo.com) to Dr. Howard (mhoward@gadermpath.com) regarding Dr. Lawley seemed to be intercepted and never arrived on July 17, 18 and 19(one each day), despite being indicated as "Sent". Incidents were not reported to DeKalb Police, nor to the Atlanta FBI.

DeKalb Incident 22: Occurred on July 25, 2011 at the GDA offices on North Decatur Road. A person or persons had entered the front door of the GDA Darden Research Building, and again vandalized the building directory sign (very similar to DeKalb Incidents 6, 8, 9 and 20). Dr. Howard discovered the vandalism at approximately 12 noon. Jonathan Jones witnessed the vandalism within the company. **Incident was not reported to DeKalb Police, but was communicated by email to William Share of the Atlanta FBI office late on July 25, 2011.**

DeKalb Incident 23: Occurred on August 24, 2011 at the GDA offices on North Decatur Road. A person or persons had again entered the front door of the GDA Darden Research Building, and again vandalized the building directory sign (similar to DeKalb Incidents 6, 8, 9, 20 and 22). Dr. Howard discovered the vandalism at 4 pm. Jonathan Jones witnessed the vandalism inside the company. **Incident was not reported to DeKalb Police, but was communicated by email to William Share of the Atlanta FBI office late on August 24, 2011.**

Note: In November, 2011, following an investigation by North Georgia US Attorney Sally Yates and the Atlanta FBI, Dr. Lawley was forced out as Dean of Emory University Medical School. The most likely reason for his forced retirement were violations of Federal law due to direct interference with the USCIS immigration applications of Dr. Abreu Velez, 2006-2011(See Appendix C). The public announcement of Dr. Lawley's resignation was made in the Emory Wheel via Wright Caughman, M.D. on November 18, 2011. Dr. Lawley's resignation date was originally targeted for August 31, 2012. However, in September 2012, a public announcement was made in the Emory Wheel that more time was needed to find and approve a new Dean. Dr. Lawley finally resigned and was replaced by Christian Larsen, M.D. as Dean on January 15, 2013. Why was this additional time needed for Emory to replace Dr. Lawley as Dean? Was he extorting the university in any way?

DeKalb Incident 24: Identical to Incident 23 on December 22, 2011, with additional missing "Y".

Note: On December 18, 2013, Dr. Abreu Velez filed a civil lawsuit in US District Court, Northern District of Georgia, Atlanta Division, for damages 2004-2013 against defendants 1) Board of Regents of the University System of Georgia; 2) Georgia Regents University; and 3) Emory University; Case File Number 1:13-CV-4187-WBH.

DeKalb Incident 25: Occurred on July 1, 2014, at the GDA offices on North Decatur Road. A person or persons had again entered the Darden Building and vandalized the building directory sign. Dr. Howard discovered the vandalism at 12 noon. **Evidence was photographed by Dr. Abreu Velez, and sent via email to Special Agent William Share at the Atlanta FBI offices on July 1.**

DeKalb Incident 26: Occurred on July 11, 2014 at the Saba Restaurant in Emory University Village. Dr. Abreu Velez encountered Dr. James Wagner, President of Emory University at 12 noon while picking up a takeout lunch at the restaurant. Dr. Abreu Velez asked Dr. Wagner why Emory University had not apologized or offered a just settlement over 8 years after the attack on Manuela

Villa Abreu on March 30, 2006. Dr. Wagner offered no apology, nor a plan for a settlement. **Incident was reported by email to Special Agent William Share of the Atlanta FBI on July 11, 2014.**

DeKalb Incident 27: Occurred on July 30, 2014 at the GDA offices on North Decatur Road. A person or persons had again entered the Darden Building and vandalized the building directory sign. Dr. Howard discovered the vandalism at 9 am. **Incident was reported by email to Special Agent William Share of the Atlanta FBI on July 30, 2014.**

DeKalb Incident 28: Occurred on August 8, 2014 at the GDA offices on North Decatur Road. A person or persons had again entered the Darden Building and vandalized the building directory sign. Dr. Howard discovered the vandalism at 5:30 pm, and had specifically noted a perfect building directory sign (without damage) on arrival at work at 9:45 am. **Incident was reported by email to Special Agent William Share of the Atlanta FBI on August 9, 2014.**

DeKalb Incident 29: Occurred early on August 13, 2014 at the GDA offices on North Decatur Road. A person or persons had again entered the Darden Building and vandalized the building directory sign. Dr. Howard discovered the vandalism at 9:30 am when arriving for work. Dr. Howard had observed the sign to be in excellent condition on August 12 when leaving work at 5:30 pm. **Incident was reported by email to Special Agent William Share of the Atlanta FBI on August 13, 2014.**

Note: On August 14, 2014, Wright Caughman, M.D. announced his retirement from Emory Medical Center, effective upon finding a replacement for his position of Chief of WHSC. See note between DeKalb Incidents 17 and 18. The information was communicated by email to Special Agent William Share of the Atlanta FBI on August 21, 2014.

DeKalb Incident 30: Occurred early on August 15, 2014 at the GDA offices on North Decatur Road. A person or persons had again entered the Darden Building and vandalized the building directory sign. Dr. Howard discovered the vandalism at 10:00 am when arriving for work. Dr. Howard had observed the sign to be in excellent condition on August 14 when leaving work at 5:30 pm. **Incident was reported by email to Special Agent William Share of the Atlanta FBI on August 15, 2014.**

DeKalb Incident 31: Occurred later on August 15, 2014 at the GDA offices on North Decatur Road. Dr. Abreu Velez received a very strange email, allegedly from her fired ex-attorney John Batson of Augusta, Georgia (served 2005-2006, during her 2005-2009 Board of Regents civil legal case). Mr. Batson stated that he needed Dr. Abreu Velez to wire funds to him, in order to assist him to travel home from Amman, Jordan. **Incident was reported by email to Special Agent William Share of the Atlanta FBI on August 15, 2014.**

DeKalb Incident 32: Occurred early on August 22, 2014 at the GDA offices on North Decatur Road. A person or persons had again entered the Darden Building, and vandalized the building directory sign. Dr. Howard discovered the vandalism at 9:45 am when arriving for work. Jonathan Jones witnessed the vandalism inside the company. Dr. Howard had observed the sign to be in excellent condition on August 21 when leaving work at 5:30 pm. **Incident was reported by email to Special Agent William Share of the Atlanta FBI on August 22, 2014.**

DeKalb Incident 33: Occurred early on August 29, 2014 at the GDA offices on North Decatur Road. A person or persons had again entered the Darden Building, and vandalized the building directory sign. Dr. Howard discovered the vandalism at 9:45 am when arriving for work. Dr. Howard had observed the

sign to be in excellent condition on August 28 when leaving work at 5:30 pm. **Incident was reported by email to Special Agent William Share of the Atlanta FBI on August 29, 2014.**

DeKalb Incident 34: Occurred at noon on September 8, 2014 at the Saba Restaurant in Emory University Village. Dr. Abreu Velez encountered Dr. James Wagner, President of Emory University. In their discussion, Dr. Wagner seemed genuinely remorseful for the past actions of Emory vis-à-vis Dr. Abreu Velez, and acknowledged that the time had come for Emory to “do the right thing” in regards to these matters. **Incident was reported by email to Special Agent William Share of the Atlanta FBI on September 10, 2014.**

DeKalb Incident 35: Occurred early on September 10, 2014 at the GDA offices on North Decatur Road. A person or persons had again entered the Darden Building, and vandalized the building directory sign. Dr. Howard discovered the vandalism at 9:10 am when arriving for work. Dr. Howard had observed the sign to be in excellent condition on September 9 when leaving work at 5:45 pm. At that time, no other persons were in the building and all doors were locked. The sign vandalism was observed by Jonathan Jones within the company. **Incident was reported by email to Special Agent William Share of the Atlanta FBI on September 10, 2014.**

DeKalb Incident 36: Occurred at 4 pm on September 15, 2014 at the GDA offices on North Decatur Road. Dr. Abreu Velez was driving out of the GDA parking lot when leaving work. As she drove out through the driveway, a tall Caucasian male, approximately 25-30 years old, drove into the driveway on a bicycle from the west (non-Emory Village) side of the driveway. The man had black, curly hair and hazel eyes, and did not have a bike helmet on. He was dressed in a casual blue shirt and blue jeans, and had a small, black nylon backpack on. His bicycle was blue. Upon seeing and recognizing Dr. Abreu, the man panicked, immediately turned his bike around and drove off west on North Decatur Road towards Lullwater Road. He did not say anything to Dr. Abreu Velez, nor did she say anything to him. Dr. Abreu immediately stopped, did not pursue the man and called Dr. Howard. **Incident was reported by email to Special Agent William Share of the Atlanta FBI on September 16, 2014.**

DeKalb Incident 37: Occurred early on October 3, 2014 at the GDA offices on North Decatur Road. A person or persons had again entered the Darden Building, and vandalized the building directory sign. Dr. Howard discovered the vandalism at 10:15 am when arriving for work. Dr. Howard had observed the sign to be in excellent condition on October 2 when leaving work at 5:30 pm. **Incident was reported by email to Special Agent William Share of the Atlanta FBI on October 3, 2014.**

DeKalb Incident 38: Occurred early on November 7, 2014 at the GDA offices on North Decatur Road. A person or persons had again entered the Darden Building, and vandalized the building directory sign. Dr. Howard discovered the vandalism at 9:45 am when arriving for work. Dr. Howard had observed the sign to be in excellent condition on November 6, when leaving work at 5:30 pm. Later in the day, three additional GDA company signs were discovered or discussed to have been recently inverted. Specifically, these signs included 1) an emergency exit direction sign at the top of the front stairwell; 2) an OSHA sign for employees on the auxiliary laboratory external door face and 3) a maintenance sign within the men’s restroom. **Incident was reported by email to Special Agent William Share of the Atlanta FBI on November 7, 2014.**

Note: On November 8, 2014, the 2014 DeKalb Incidents were reported to DeKalb County Police, Officer Tom Green, Case Number 14-111763. Dr. Thomas Lawley was identified as the alleged

perpetrator of the DeKalb 2014 GDA Incidents. Special Agent William Share of the Atlanta FBI was informed by email of the DeKalb Police Report on November 8, 2014.

DeKalb Incident 39: Occurred November 7-17, 2014. USCIS Atlanta AMAV Missing Application for Green Card. AMAV notifies MSH on November 14. Website application back up on November 17.

DeKalb Incident 40: One week after successfully correcting the USCIS website application, the application disappears again. Was present on Saturday, November 22 and missing on Monday, November 24. **Dr. Abreu Velez notifies SA William Share by email on November 24.**

DeKalb Incident 41: Occurred on December 19, 2014 at the Saba Restaurant in Emory University Village. Dr. Abreu Velez again encountered Dr. James Wagner, President of Emory University, approaching the restaurant at 12 noon. Dr. Abreu Velez discussed her case with Dr. Wagner, and he invited her to visit him and further discuss the matter. **Meeting was reported by Dr. Abreu Velez by email to Special Agent William Share of the Atlanta FBI on December 19, 2014. Dr. Abreu Velez was later denied access to talk with Dr. Wagner in his office, as had been offered verbally.**

DeKalb Incident 42: Occurred on the morning of September 14, 2015 in the Emory University Administration Building office of Steven Sencer, Emory Chief Counsel. Dr. Abreu Velez visited Mr. Sencer's office to introduce herself. Mr. Sencer immediately became angry and acted in an unprofessional manner towards her, requesting Dr. Abreu-Velez to leave the building. Incident was witnessed by an Emory paralegal assistant. **Incident was reported by email to Special Agent William Share of the Atlanta FBI on September 14, 2015.**

DeKalb Incident 43: Occurred over the weekend of September 11-14, 2015 and on September 14 at the GDA offices on North Decatur Road. A person or persons had again entered the Darden Research Building, and vandalized the building directory sign. Dr. Howard discovered the vandalism at 10 am on Monday, September 14 when arriving for work. Dr. Howard had noted the sign to be in excellent condition on Friday, September 11 at 5 pm when leaving work. Photographs were taken of the vandalism by Dr. Abreu. Also, Dr. Abreu noted all of her tire pressures in her 2012 Toyota RAV-4 to be normal (32 psi) when driving to work on the morning of September 14; on her return home at 4 pm, her tire pressure caution light was on. On arrival at home, all 4 of the tires had decreased pressures (20 psi) when checked with a pressure gauge. **These incidents were reported by email to Special Agent William Share of the Atlanta FBI (with the attached relevant sign photos) on September 14, 2015.**

Note: On September 11, 2015, James Wagner announced his resignation as President of Emory University, effective upon finding a replacement and at the end of the current academic year in 2016.

DeKalb Incident 44. On October 23-29, 2015, Dr. Abreu tried to apply to become member at the Atlanta Dermatological and Surgery Society (<http://www.atlantaderm.org>). She e-mailed initially on October 23, then again on October 27. Receiving no response, she then again sent an e-mail to the Atlanta Dermatological and Surgery Society on October 29, telling them that she had been treated unfairly because Dr. Robert Swerlick had attacked her and Dr. Michael Howard's reputations. **In the October 29 email, Dr. Abreu included a copy of the attacks she and her family had suffered, and copied the e-mail of Atlanta FBI Special Agent William Share.** Dr. Swerlick has had a very close friendship with the Atlanta Dermatological Association staffers, specifically Maryann McGrail-

Executive Director.maryann@theassociationcompany.com; Karrie Kirwan – Association Coordinator & Director of Membership/Database Management karrie@theassociationcompany.com, and Karen Manning – Director of Marketing/Corporate Support karen@theassociationcompany.com.

DeKalb Incident 45: Occurred on October 28, 2015 at the Darden Research Building on North Decatur Road. A lack of heat in the building led to an HVAC consultation, and the discovery that natural gas had been deliberately cut off outside the building. Mr. Claibourne Darden consulted with the Atlanta Gas Light Company, and was informed that the gas had been cut off in August, 2015. Mr. Darden stated to Dr. Howard that he had not requested a cutoff, and that his gas bills had been paid in a timely manner. The Atlanta Gas Light Company informed Mr. Darden that no reason could be found for the cutoff in company records, nor the identities of any specific technologists that had performed such a cutoff. Because a commercial building gas cutoff requires special tools, who cut off the gas to the Darden Building? Gas service to the building was restored on October 28. **Incident was and copied the e-mail of the Special Agent William Share of the Atlanta FBI by email from Dr. Abreu Velez on October 29, 2015.**

DeKalb Incident 46. On November 25, 2015, Dr Abreu e-mailed the president of the Atlanta Association for Dermatology and Dermatologic Surgery, Petra Milde, M.D., in regard to an answer from the society as to acceptance of her application (see DeKalb Incident 44); a copy was provided to Ms. Maryann McGrail. Dr. Milde replied more than once over the next two weeks that she was still waiting on Ms. McGrail to answer her. **Incident was and copied the e-mail of Special Agent William Share of the Atlanta FBI by email from Dr. Abreu Velez on December 11, 2015.**

DeKalb Incident 47. On November 3, 2015, we sent a FedEx package outlining our concerns about the GDA attacks to Laura Jones Hardman, Secretary of the Emory Board of Trustees. The FedEx was addressed to her personally via the Office of the Vice President, Attention Tara Davis, Room 407 in the Administration Building at Emory University. The FedEx tracking number was 8047 7305 1610, and delivered on November 4, 2015. On December 13, 2015, we personally visited Laura Jones Hardman and her husband John B. Hardman, M.D. at their home in Atlanta. Ms. Hardman stated that she had never received our November 4 FedEx, due to being not in the area at the time. She stated that the FedEx had been received by Allison Dykes, Emory University Secretary, and then "taken care of" according to the Administration. We informed Ms. Hardman that, as best we could determine, Ms. Dykes never forwarded copies of our FedEx to the full Board of Trustees as requested. We informed her that, in our opinion, a cover-up had been perpetrated by the Administration in this context, likely via Allison Dykes, Steven Sencer and James Wagner. Dr. Hardman informed us that within the last month, Ms. Hardman had retired from the Board of Trustees due to mandatory retirement at age 70. We informed her that we would be communicating our concerns to former US President Jimmy Carter, at the Carter Center of Emory University in Atlanta. Ms. Hardman stated that she would think about ways she could help us in communicating this information to the full Board of Trustees. On December 14, our FedEx to President Carter was received at the Carter Center (FedEx tracking number 8047 7305 1551). **An incident summary was sent via email to Special Agent William Share of the Atlanta FBI on December 14, 2015.**

In DeKalb Incidents 48, and 49 and 50, the tires were new. Dr. Abreu-Velez car found tires were deflated in March, and April 2016 in different occasions and places (at work and at the entrance of the home) and the incidents were reported to the Atlanta FBI by the e-mails of Special agent Share.

DeKalb Incident 51. Occurred in Dr. Abreu Velez's USCIS immigration interview at the USCIS Atlanta Northlake Field Office on Monday, May 16, 2016. Part of her documents at Atlanta USCIS were "missing again" according to Agent Bessar, after these having being sent with copies to Sally Q Yates, and by certified Fedex and in person to the Northlake office using an INFOPASS. According to Agent Bessar, following my successful examination, suddenly "part of my file was not complete". By definition, the interview should not have occurred until all the records were complete, and thus someone at Atlanta Northlake USCIS removed them.-

DeKalb Incident 52: Occurred on Saturday, June 25, 2016 at the USCIS Atlanta Northlake Field Office. Dr. Abreu Velez's daughter Manuela Villa Abreu came to USCIS Northlake for her immigration interview (see her application number inside this package). All her documentation was in her file, and she passed her oral examination. Then, suddenly, the USCIS agent "didn't want to approve her citizenship". Please search for the agent that performed this interview. The agent said that she needed more time to further review Manuela's file. By definition, the interview should not have occurred until all the records were complete. Dr. Abreu daughter was understandably very upset

DeKalb Incident 53: Occurred over the years 2014-2016. We believe that the Ex-Director of the Atlanta FBI, Mr. Britt Johnson, was using the Atlanta FBI Special Agent William Share e-mail address (given to Dr. Abreu in 2006 for confidential reporting by Special Agent William Share) to tip off Emory University, the Board of Regents of the University System of Georgia and Gilead Sciences Inc., and help cover up evidence Dr. Abreu was providing to the FBI.

DeKalb Incident 54. On December 15, 2016, Dr. Abreu sent for review for publication a research study of her entitled: "Patients affected by a new variant of endemic pemphigus in El Bagre, Colombia have autoantibodies to blood/lymphatic vessels and their cell junctions, which colocalize with MYOZAP, ARVCF, desmoplakins I -II AND p0071 JAAD-D-16-01771 to the Journal of the American Academy of Dermatology. The Editor, Dr. Bruce Thiers (a close friend of Drs. Swerlick and Lawley at Emory) claimed this article was "not suitable for the journal". In fact, many publications of this nature have been published in the journal, including a similar article by Dr. Abreu Velez in 2010.

DeKalb Incident 55. As of February 5, 2017, for over 2 years Dr. Abreu has been without a full time job, and Dr. Howard's practice at GDA is facing significant financial hardship because of the destruction of their reputations by these evil institutions.

DeKalb Incident 56: During recent years we noticed multiple IT companies have been following Dr. Abreu and Howard's names, accomplishments and erased any web site that praised our work, trying to destroy our professional reputation. Some examples I exposed are following in internet my name, my publications, my research, my accomplishments and leaving only negative reports about me. Recent examples: One of my latest publications was named as the best 30 immunofluorescence in the world. The article was erased (yellow).

immunofluorescence staining - Top 30 Publications

Immunofluorescence staining - Top 30 Publications

immunofluorescence staining - Top 30 Publications - PubTransformer. www.pubtransformer.com/Pubmed/ShortPubsGivenKeyword?keyword. Patients with a new variant of endemic pemphigus foliaceus have autoantibodies against arrector pili muscle, colocalizing with MYZAP, p0071, desmoplakins 1 and 2 and ARVCF. ... Flow cytometry analysis and immunofluorescence staining revealed that PA-induced ROS and cell apoptosis were reversed by BA.

Another example:

JournalTOCs - ICBL - Heriot-Watt University. www.icbl.hw.ac.uk › HOME › Browse by PublisherAbstract: BackgroundWe previously described a new variant of endemic pemphigus foliaceus in El Bagre, Colombia (El Bagre-EPF). ... The autoreactivity was polyclonal, and the patient's antibodies colocalized with commercial antibodies to desmoplakins I and II, p0071, ARVCF, and MYZAP (all from Progen Biotechnik.

DeKalb Incident 57: The top people at the DOJ in the Obama and Trump administrations (with the exception of Mr. Jeff Sessions) as far as we know have received: Loretta Lynch (300 million USDs) Sally Q Yates (unknown amount, but favor from Emory and BOR for likely not prosecuting the biggest pharmaceutical scam in US history (about 23 trillion USDs) and worldwide (about 100 trillion USDs); for covering the Gilead monopolies on HIV and Hepatitis medications, blocking generics and the products to produce them (API products)). The lack of prosecution happened for over 12 years, allowing the manslaughter of more than 479 people in clinical trials including innocent pregnant women and children.

DeKalb Incident 58: Abuse of power by Mr. Rod Rosenstein; within the DOJ and the FBI; we believe he used the e-mail account of FBI Special Agent William Share to tip off Gilead Sciences Inc., Emory and BOR about our research and findings over several years. Rosenstein likely ordered erasing any evidence that the DOJ had received from us about this evil case, by using high tech companies. When Dr. Abreu sent the evidence to President Trump, WH Chief of Staff Kelly and Sessions in May 10-11, 2018, she gave the FedEx number 8130 2518 9816 in advance, “supposedly” via email to FBI Agent Share. The FEDEX WAS THEN DELAYED FOR 2 DAYS. Dr. Abreu communicated this to General Mattis and General Kelly by a private channel, and resent the information via certified mail

DeKalb Incidents 59-60. A black rose was put in the front of GDA on May 23, 2018. Dr. Abreu’s daughter’s citizenship “disappeared from the federal records”. Both reported to the FBI Atlanta. This is so painful, enduring 14 years of harassment for protecting the patients in Georgia and the taxpayers.

Dekalb incident 61. “OUT OF THE BLUE” ON AUGUST 16, 2018 WE WERE TOLD BY THE OWNER OF THE BUILDING WE HAVE BEEN RENTING FOR OUR MEDICAL PRACTICE GA DERMATOPATHOLOGY ASSOCIATES) FOR OVER 16 YEARS (AT 1534 NORTH DECATUR ROAD NE, ATLANTA, GA 30307) THAT HE WOULD SELL THE BUILDING HE OWNS AS “DARDEN RESEARCH CORPORATION” ON AUGUST 23, AND INDEED IT HAPPENED. IT WAS SOLD BY CLAIBOURNE DARDEN JR THE BUILDING IS PARCEL ID: 1805302028, DECATUR, GA. TAX DISTRICT 04 UNINCORPORATED.

The building was sold to Atlanta attorney Matthew B. Stoddard, Office 404-800-1152, or Cell 919-280-4925. Business address: 5447 Roswell Road Suite 204 Atlanta, GA 30342. E-mail: matt@thestoddardfirm.com. We also know one person directly involved in the sale was David Aynes (687-665-3283; Atlanta Leasing & Investment/Commercial Real Estate). Before the sale, one of the

two appraisal firms is attached in this package); also before the sale, the property was visited by a geologist for a survey, i.e., Mr. John Salvino: jhonsalvino619@gmail.com. **Importantly, during the summer months this year, FOUR of the top Gilead executives have left Gilead in California (Martin, Bitschofburger and Gilligan), all of whom had been at Gilead approximately 30 years.**

Thus, given this pertinent criminal background involving Emory and Gilead, we are concerned that the SALE OF THE DARDEN BUILDING WAS AN ORCHESTRATED, CONSPIRACY RETALIATION TO DESTROY OUR MEDICAL PRACTICE, ORIGINATING WITH DR. MARTIN IN CALIFORNIA, AND/OR DR. RAYMOND SCHINAZI AND/OR MR. STEVEN SENCER AT EMORY, WITH MR. AYNES AND/OR OTHERS PLAYING A CRUCIAL FRONTING ROLE IN ATLANTA. Following a basic investigation of Mr. Stoddard, we believe is very strange that this young attorney (about 35 years old; who bought his current house at 1658 East Clifton Road, NE in Atlanta for about \$800,000 last year) ALSO had the resources and could obtain via financing (with Iberia Bank, 2970 Peachtree Road, NW; Suite 200; Atlanta, Georgia 30305; Ms. Elizabeth Bresnahan) the sale price of 2 million dollars by the time of the sale. His wife is a veterinarian that works at CDC. He asked all the tenants of the building to vacate the property in writing, within 70 days, on the date of the sale (August 23). By his own account, he is planning to gut and refurbish the entire building under the ownership firm Lullwater Wharf, LLC as upscale commercial property (we estimate the refurbishment will cost an additional \$500,000) beginning in November, 2018.

DeKalb Incident 62. On October 17th, 2018 the entire Darden Building garbage dumpster contents (filled with assorted papers) was found spread over the rear parking lot. At 10:10 am, a man with a black bicycle was observed sorting through the papers. The guy said his name was John Ergene; that he was homeless, and lived in Midtown Atlanta. He seemed to be under the influence of drugs. He stated that he did not spread the papers in the parking lot. He stated that he was "riding his bike around Midtown to check whether the tires were properly inflated", and "had no idea how he came all the way to our location". He stated that he pulled in the parking lot, then noted the papers and "wanted to search for something to write on" when asked why he was sorting through the papers. We took pictures of him, then called the FBI and also reported the incident to DeKalb Police, Case No. 18-165295. The man appeared to be a Middle Eastern male, about 35 years old and of slender build, with black hair, brown eyes, a prominent nose, about 5 foot 11 and 160 pounds. The man and the scattered papers were also witnessed by GDA UPS driver Jamila Edwards, cell phone: 678-964-0735.

Atlanta incidents 63 and others: Multiple people had come to the new office and calling us to get us in trouble pretending they were clients. We do not see patients, we are a laboratory.

SETTLEMENT TERMS AND CONDITIONS

1. Emory University (EU), Board of Regents of the University System of Georgia (BOR), Augusta University (AU) (A.K.A. Medical College of Georgia/MCG) and BOR including some "retired people" and current personnel/Trustees from Emory University (EU), BOR-AU are permanently prohibited from negative and defamatory speech, regarding Dr. Abreu, Dr. Howard, their careers, family, and Georgia Dermatopathology Associates (GDA). This request will take place one day after signing the agreement.

2. No further physical, verbal or emotional OR PROFESSIONAL attacks on Dr. Abreu and her family, nor Dr. Howard REPUTATION AND GDA.

2. Relator calls for the termination of 1) Dr. Robert Swerlick, Chair of Dermatology at EU, Dr. Thomas Lawley, Professor of same Department, 2) Micah A. Chrenok researcher at the EU Department of Ophthalmology (for physically attacking Dr. Abreu's daughter) and the 3) EU VP for legal affairs Mr. Stephen D. Sencer for cover this, paid off with the courts, abuse of the Emory none profit status, for cover for the death of many innocent people in the Africa clinical trials done with the HIV medications by Drs. Dennis Liotta and Raymond Schinazi (they also need to be fired immediately). We also request that Mr. Peter Barnes, Vice President for Human Resources of Emory University, to be removed from his position for allowing damage on Dr. Abreu and her daughter green card and citizenships application. This request will take place one day after signing the agreement.

3. EU and BOR-MCG should erase any negative documents from Dr. Abreu's Human Resources files due to the false nature of them. This request will take place one day after signing the agreement. All these should be stated in writing.

4. EU and BOR-AU shall pay Dr. Michael S. Howard the sum of two million, five hundred thousand dollars (\$2,500,000 USD), (split in 2/3 Emory, and 1/3 BOR) for all the damages against him and EU and BOR will also pay all State and Federal taxes on this amount at the approximate rate of 35%, (see 12, Tax Indemnification), by electronic fund transfer pursuant to written instructions to be provided by the said sum. The payment with taxes will take place one day after signing the agreement into a specific bank account.

5. EU and BOR shall pay Dr. Abreu's past attorney and paralegal fees in the amount of sixty thousand dollars (\$60,000 USD) and EU, BOE UA will also pay also pay all State and Federal taxes on this amount at the approximate rate of 35%, (see 12, Tax Indemnification), for 13 years of litigation fees. The payment with taxes will take place one day after signing the agreement.

6. Emory will pay the amount of \$11,739.97 USD plus \$99.90 USD for the cost of the appeal plus the accrued interest paid by Dr. Abreu from July 27, 2008 until today. RE: DOAS file number: LI06196020, Civil Action number: 1-CV-05-186, and appeal number: 09-11365-C. With the annual interest, the sum will be approximately \$13,165.95 USD, and BOR will pay the

taxes (both Federal and State), on this amount at the approximate rate of 35%, plus the interest accrued at a fair annual rate (see 12, Tax Indemnification). The payment with taxes will take place one day after signing the agreement.

7. BOR-AU will pay Dr. Abreu the amount of two million dollars (\$2,000,000 USD), for damages and will also pay all State and Federal taxes on this amount at the approximate rate of 35%, (see 12, Tax Indemnification), by electronic funds transfer pursuant to written instructions to be provided by the said sum. The payment and taxes will take place one day after signing the agreement.

8. BOR-AU will pay Dr. Abreu's lost wages, benefits, and other remunerations with all fringe benefits that were in place which she was employed at MCG (Dr. Abreu's annual salary at firing was \$32,200 USD, non-used annual leave, accrued vacation, fringe and health benefits and interest, multiplied by 14 years and 4 months equals about \$500,040 USD, plus annual increase, interest accrued at a fair annual rate of approximate 1.5% from Nov 22, 2004 to the effective date of this Settlement and fringe benefits. This also includes non-taken vacations and salary increase from former MCG from 10/22/2004 to the date of signing the agreement for BOR). The payment will take place one day after signing the agreement. BOR-AU will also pay all State and Federal taxes for this amount plus interest (see 12, Tax Indemnification).

9. EU will pay Dr. Abreu's lost wages, benefits, and other remunerations with all fringe benefits that were in place which she was employed at EU as a post-doctoral fellow and was illegally terminated in December, 27, 2006 (Dr. Abreu's annual salary at firing was \$37,080 USD, annually compensation, non-used annual leave, accrued vacation, fringe and health benefits and interest multiplied by 12 years and 2 months equals about \$444,960 USD, plus interest accrued at a fair annual rate of about 1.5% to the effective date of this Settlement. Dr. Abreu understands that the post-doctoral fellow's salaries in 2019 are about \$44,107/ USD/year. (The pay will include fringe benefits, rate agreements, non-taken vacations and salary increase from EU). The payment will take place one day after signing the agreement EU and BOR and AU will also pay all State and Federal taxes for this amount plus interest (see Tax Indemnification).

10. EU and BOR will agree to allow Drs. Abreu and Dr. Howard use of their Core Facilities and other facilities as "institutional user rates", and will allow full and unrestricted cooperation in academic and research activities. This will be take place one day after signing this agreement.

11. Drs. Abreu and Howard will have free access to Emory and BOR libraries and accounts to request online articles including interlibrary loans document per life at none charge, and both EU and BOR will pay for those request articles. This will be taking place one day after signing the agreement.

12. EU and BOR will allow Dr. Abreu to travel about two times a year to Colombia for research-academic activities go to the endemic area of endemic pemphigus foliaceus in El Bagre, Colombia, as part of her research activities for periods of about one or two weeks per visit; or, in lieu of such bi/annual visits, allow her to participate volunteer free medical missions including Doctors without Borders and/or other non-profit organizations. This will be taking place one day after signing the agreement.

13. EU and BOR will pay into Dr. Abreu's past retirement (directly into her 401K) using the same system as when illegally fired. The payment will take place one day after signing the agreement.

14. EU and BOR will pay any and all moving expenses for Drs. Abreu and Dr. Howard GDA laboratory inside metro Atlanta, GA. The payment will take place one day after signing the agreement.

15. EU, AU will name Dr. Howard as a half-time tenure-track full professor of Dermatopathology at EU and BOR-AU, with the salary of \$150,000 USD, yearly plus benefits, split by Emory and BOR, and allowed to work the other part time in his private laboratory at GDA. EU and BOR will pay his fringe benefits. This will be take place one day after signing this agreement. Dr. Howard will negotiate his salary Both EU and BOR will pay Dr. Howard's salary (half- half). This will be taking place one day after signing the agreement. Emory will give Dr. Howard two entire weeks' paid before start working to be able to rest. This time will not be part of his coming tenure.

16. EU and BOR will pay Dr. Abreu's and Dr. Howard yearly membership fees to the American Academy of Dermatology, The Atlanta and the Georgia Societies of Dermatology and Dermatologic Surgery, The Society for Investigative Dermatology and the American Association of Immunologists (the AAI only for Dr. Abreu). EU and BOR will also pay for Dr. Abreu and Dr. Howard to attend two or three national and/or international professional meetings a year covering registration, hotel, food and travel expenses in the regular business class. This will not be part of the start-up package. If for any reason Dr. Abreu end working at CDC, Emory and BOR will have to pay for those fees until Dr. Abreu retirees from CDC by reimbursing CDC and or other company.

17. Both Emory and Augusta University will immediately (one day after signing this agreement) give Dr. Abreu the Honorary Medical Degrees, as well as the degrees in Dermatology, and they will get the Medical and Dermatology Licenses at the State of Georgia with their respective certifications. This will be taking place one day after signing the agreement. The ordinary degree of Doctor of Medicine is conferred by an institution of competent authority on persons who are supposed to have acquired, by diligent study and careful instruction, a sufficient amount of medical knowledge and skill to constitute them safe practitioners of the science and art of medicine. The attainments of the person applying for the degree are ascertained by a proper examination, conducted by the teachers in the institution by which the degree is given. The possession of the degree is evidenced by a diploma, which, after the person who holds it has complied with certain governmental requirements, assures to him all the rights and privileges of a member of the medical profession. But such institutions may also confer, without an examination, the additional honorary degree of Doctor of Medicine on persons already in the profession, who have publicly demonstrated their attainment of such a degree of learning and skill in medicine as would make the conferring it on them to be an act of such undoubted propriety as to be acknowledged without question by all. This can be done by conferring it only on persons of good character and high attainments. The Georgia State Board of Health diploma must be presented for registration. (THE HONORARY DEGREE OF DOCTOR OF

MEDICINE) JAMA. 1885;IV(11):287-288. doi:10.1001/jama.1885.02390860007001b, E. INGALS, M.D., CHICAGO, ILL, JAMA, March 14, page 285, 1985). This will be taking place one day after signing the agreement. If Dr. Abreu decides to take the USMLE steps and become physician in USA, she will be entitled to an internship and a dermatology residency at either EU and or AU; if during this time she reads the immunodermatology tests, and performs active research her salary will be accordingly with her salary as a faculty member.

19. EU-BOR-AU will provide her a \$7,250,000 USD as a startup package split between EU (2/3) and BOR (1/3) and such will be administrated and audited through Georgia Tech. If Dr. Abreu starts working at CDC and or other company, she will be allow to taking one year sabbatical paid by Emory and AU the START UP PACKAGE will be administrated by CDC and or the other company for Dr. Abreu research. If at the end of the sabbatical year Dr. Abreu decided to continue working at CDC and or other company, both Emory and BOR will paid her salaries and benefits until the age of 70 years old with the forecast increase per those years.

19. Gilead Sciences Inc. will give to the Atlanta Catholic Church Immaculate Heart of Mary \$2,500,000 USD and they will pay the taxes (if applicable). The money will be invested to pay the building debt and to fix the old church building. This will be effective one day after signing the agreement. The check will be given to Dr. Abreu to present to them directly. This church is located at 2855 Briarcliff Road NE, Atlanta, Georgia 30329.

22. Gilead Sciences Inc. will give to Dr. Abreu \$5,000,000 USD and to Dr. Howard \$1,000,000 USD, and they will pay the taxes on those, one day after signing this settlement. Gilead will also pay all State and Federal taxes on this amount at the approximate rate of 35%, (see 12, Tax Indemnification), by electronic fund transfer pursuant to written instructions to be provided by the said sum. The payment with taxes will take place one day after signing the agreement into a specific bank account.

23. Each institution EU and BOR will donor \$10,000 USD each (each institution) one in January 10, per year for the next ten years to **Life/Line Animal Project** (lifelineanimal.org/) in Atlanta, Georgia (none profit). The first money will be to buy a new heat and HVAC systems for the Avondale facility at 129 Lake Street, Avondale States, GA 30002, Phone: 404.292.8800. The rest will be determining by them. And to **HOPE HIV** Atlanta, phone: 404-817-7070, (<https://hopeatlanta.org/im-homeless-with-hiv/>) (none profit). A copy of each year donation for Emory and BOR to each entity needs to be sent by e-mail or mail to Dr. Abreu.

24. BOR/former MCG “**MUST find and return to Dr. Abreu**” the irreplaceable collection of skin biopsies and microscopy slides of patients affected by a new variant of endemic pemphigus in El Bagre that “disappeared” in Fall 2004 as well as other materials that were in that UPS package. It is likely Drs. Andrew Mellor and or David Munn at EU may have them.

25. If Dr. Abreu is rehired by EU and BOR at Georgia Institute of Technology (Georgia Tech), she will be entitled to take 2 months accumulated past vacation for moving and to finish some personal issues.

26. EU and BOR, and Georgia Institute of Technology (GT) will provide parking passes in

visitor parking to attend academic activities to Drs. Abreu and Howard.

27. EU and BOR, will hire Dr. Abreu as a tenure track full time professor at the George W. Woodruff School of Mechanical Engineering, Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology (Georgia Tech) (based on her credentials), with shared appointments in dermatology, immunology/autoimmune Centers at EU and AU.

28. Dr. Abreu's office and laboratory will be allowed to be in the GDA building. She will teach students, and receive fellows in any needed locations. The rehiring will take place one day after signing the agreement. Dr. Abreu's yearly salary will be based on that of a person with similar education and experience credentials and 29 years of experience. Dr. Abreu will participate in all academic activities as well read immunofluorescence, ELISAs etc. of the skin for AU and help EU, and will help in research. Thus, an approximate yearly salary of three hundred thousand dollars (\$300,000) yearly (full professor's salaries range from 180 to 380K) and of course will receive fringe benefits and the regular increments. Both EU and BOR will pay Dr. Abreu salary (half-half). The earned money from the testing will go the respective institutions, either BOR or EU. The students, residents and fellows will be able to learn from the specimen studies. The skin biopsies can be sent to Dr. Abreu from Augusta, and or other satellite medical facilities belonging to the BOR by FedEx/UPS/USPS. If Dr. Abreu works at CDC these samples and materials will be sent to CDC,

29. **Emory University/Attorney Matthew B. Stoddard/Lullwater Wharf, LLC**, will sell for \$1 dollar to Dr. Abreu and/or give as a gift the Darden Research Corporation building at 1534 NORTH DECATUR ROAD NE, ATLANTA, GA 30307) and provide \$500,000 USD to gut and refurbish the entire building. Emory will pay the tax on this amount the day after we sign this agreement. They will also pay for the closing cost, and will provide the survey, the two existing copies of the appraisal, the geological survey, the application of the DeKalb County, Georgia Certificate of Appropriateness application by Ms. Linda I Dunlavy, the answered denial, as well as the architectural proposed modifications by Mr. Robert Scott at R.G. Scott and Associates Inc. and the original blueprints of the building. This will happen one day after signing the agreement.

Note: Fringe Benefits and health insurance for EU and MCG will be based on their official rates over their past years as show below. Fringe rates are developed in order to cover the costs of fringe benefits offered by the University. The rate is determined by creating a pool of benefit costs, and dividing by the salary base. Emory uses three categories of employees when developing fringe rates: Faculty/Staff/Postdoc, Residents, & Part-Time. For each of these categories, a federal and non-federal rate is developed. The federal rate excludes certain unallowable costs for the government, per OMB circular A-21. The federal rates are negotiated

with the government in advance for a fiscal year and any over- or under-recovery is included as an adjustment in a subsequent rate proposal.

EMORY UNIVERSITY						
Fiscal Year	Faculty/Staff/Postdoc		Resident		Part-Time	
	Federal	Non-Fed	Federal	Non-Fed	Federal	Non-Fed
FY17	24.70	27.25	14.90	20.00	7.65	7.65
FY16	23.90	26.25	15.10	20.00	7.65	7.65
FY15	24.60	25.75	21.20	20.00	7.65	7.65
FY14	23.50	26.50	17.10	20.00	7.65	7.65
FY13	30.00	27.50	15.50	20.00	7.65	7.65
FY12	27.30	27.50	13.20	20.00	7.65	7.65
FY11	22.40	27.25	19.5	20.00	7.65	7.65
FY10	26.10	27.00	20.70	20.00	7.65	7.65
FY09	25.00	26.80	17.40	20.00	7.65	7.65
FY08	25.60	26.80	16.20	20.00	7.65	7.65
FY08	XX	XX	XX	XX	XX	XX

Costs in the Fringe Benefit Rate include: Employer Taxes & Insurance, Retirement Benefits, Health Benefits, Human Resources & Benefits Administration, and Transportation Subsidies.

Please add the values for AU as in the table for EU.

30. EU and BOR will paid the rent for a one year lease, the down deposit (\$1,538.00) and the moving and packing expenses (\$3,300) in the monthly amount of \$1538.00 to: BRUNTWOOD ESTATES, INC., from the 10th day of November 2018 (the "Commencement Date") and end at 5:00 p.m. on the last day of November, 2019, unless terminated sooner by Landlord. EU and BOR will pay Dr. Howard until he moves back, and the PAYMENT OF MOVING BACK TO GDA WHEN THE REMODLING IS DONE AND WE OBTAIN THE DARDEN BUILDING. In addition to that we paid \$500 to movers for the Revco and the Cryostat and to remove the Freon, and remove the sink from the laboratory. We paid \$340 dollars to the movers of the HAVC/heat units donated to Lifeline in Avondale and several desks and tables donated to Goodwill. We paid \$800 to the microscope company OptiSystem to disassemble/assemble the microscopes. We paid \$4,000 plus tips (around \$4,300) to the movers (twice). We paid \$800 to the plumber, \$800 to the Southeast Pathology to calibrate the equipment following the moving.

We paid AT&T for the installation of internet, phone and faxes \$500 (twice). We lost the initial deposit because the odors at the new place (\$1,538.00), (\$200 moving out excess of furniture). We also paid \$3,000 to the commercial real state agent. All these expenses are about \$18,500 (Grossly)

31. Any evidence of further harassment or discrimination against Dr. Abreu, Dr. Howard, their families or GDA (confirmed by an independent party) and committed by EU, or BOR-AU will warrant a ten million dollar (\$10,000,000) penalty per episode, and the Federal and State tax penalty for each incident, paid out to the party that is the victim of each such offense.

32. **The University of Heidelberg and Progen in Germany** will contribute about \$10,250 USD yearly, split between both, directly to the patients affected by the new variant of endemic pemphigus foliaceus in El Bagre, Colombia, South America (<https://www.facebook.com/Endemic.Pemphigus.Foliaceus.in.ElBagre/>). The contribution will be until Dr. Abreu retires at the age of about 70. The money will be used to buy one air ticket from the city of Atlanta to Medellin, round trip, once or twice a year to visit the patients in the endemic area of El Bagre. On May, 2019, one round trip ticket cost about \$ 1,850 USD. Usually the banks in Colombia pay less than the official amount. The money will be sent to the Mineros SA Foundation (an independent Foundation that is located in the endemic area, and belongs to Mineros SA). Dr. Abreu has worked with them over 29 years. The money will also be used to buy groceries in the local market for 60 patients-families in an about rate of \$70,000 Colombian pesos, twice a year that will be about \$8,400,000 Colombia pesos, or about \$300 USD for two visits to the endemic area. This money will also buy for the patient's sun protector, medications, clothes, shoes and necessities. The patients are extremely poor. The Mining Company Foundation will buy the tickets for the voluntary doctors as well as the food and clothes for the patients, and will send copies of the receipts to Dr. Abreu and to BOR and Emory twice a year after each medical/volunteer mission. The rest will be maintained in the Mineros SA Foundation, and will cover the fees of the transaction of the banks that are obligatory to be paid when any amount is transfer between banks and institutions and/or checks are issued (4 Colombian pesos pay for each \$1,000 transfer of Colombian pesos/per transaction between banks), (0.4%) of the value of the transaction), and also if any patient need some emergency medical treatment or for other emergencies. Each year there will be an increase of the amount of 6.77%., based on the increase of life expenses in Colombia per year. They will pay the respective taxes (federal and state and overseas transfers).

ILLEGAL COMMERCIALIZATION AND PATENTS OF THE PATIENTS AFFECTED BY A NEW FORM OF ENDEMIC PEMPHIGUS FOLIACEUS IN EL BAGRE, COLOMBIA, SOUTH AMERICA:

The Department of Justice, EU, BOR and AU will help Dr. Abreu to legally recover the rights of the autoantibodies commercialized illegally by Dr. Werner W. Franke, ex-professor at Heidelberg University in Germany and others, from the patients affected by a new variant of Endemic pemphigus foliaceus in El Bagre.

The DOJ and/or President Trump administration can speak directly to chancellor Angela Merkel and make her to convince Dr. Wegner et al to do this immediately since most of their grant

money came from the German government. Included are all Heidelberg University autoantibodies that were created, immortalized and/or commercialized from Dr. Abreu's patient's serum without Dr. Abreu's permission, nor the permission of the patients from El Bagre, Colombia affected by endemic pemphigus foliaceus. I will accept: Free antibodies and other products commercialized, until Dr. Abreu scientific life ends, from Progen. We also request that Drs. Franke, Frey and others to add Dr. Michael S. Howard and Dr. Abreu as co-authors on each of the pertinent publications (complete list attached; Document 2). Any further publication using these antibodies will include Drs. Abreu and Howard as coauthors, and Dr. Abreu will review and make recommendations on them. El Bagre EPF patient autoantibodies precisely colocalize with Progen commercial antibodies against plakophilins 2 and 4, ARVCF, desmoplakin I-II by different methods. Possibly also Myoscape, cardiac-enriched FHL2-interacting protein (CEFIP), and others to be identified. Likely stolen and immortalized antibodies commercialized illegally by Progen include: anti-desmoglein 1/2 mouse monoclonal, DG 3.10, (Cat No:61002,) anti-Desmoplakin 1/2 mouse monoclonal, DP-2.15 + DP-2.17 + DP-2.20, (DI-DPII), (Cat no 65146). The armadillo repeat gene deleted in velocardiofacial syndrome (ARVCF) anti-ARVCF guinea pig polyclonal, serum (Cat. no. GP155), anti-p0071, multi-epitope cocktail mouse monoclonal, 406.3.1 + 433.10.3 + 7.7.9, (Cat No. 651166), anti-Myozap mouse monoclonal, 517.67, supernatant, (Cat No 651169): Anti-Plakoglobin (N-terminus) guinea pig polyclonal, serum, (Cat No: GP57), anti-Plakophilin 1 guinea pig polyclonal, serum, (Cat No. GP-PP1). Anti-Plakophilin 2 guinea pig polyclonal, serum, (Cat No: GP-PP2). Anti-Perilipin 1 (N-terminus) mouse monoclonal, PERI 112.17, supernatant (Cat. No. 651156), anti-Perilipin 2 (N-terminus aa 1-29) guinea pig polyclonal, serum, sample (Cat. No. GP40S), anti-Perilipin 3 (N-terminus) guinea pig polyclonal, serum, sample (Cat. No. GP30S), Anti-Perilipin 4 (C-terminus) guinea pig polyclonal, serum, sample, (cat. No. GP34S), anti-Perilipin 5 (C-terminus) guinea pig polyclonal, serum, sample Cat. No. GP31S, anti-Symplekin mouse monoclonal, Sym-TJ-E150, supernatant, Cat No: 651100, anti-Cingulin guinea pig polyclonal, serum, Cat No:GP26, LUMA)or TMEM43originally claimed to function as "p53 apoptosis effector related to PMP-22" and thus abbreviated as protein "PERP" (TP53 apoptosis effector, isoform CRA_a) [Homo sapiens] or (p53 apoptosis effector related to PMP-22)

Perp "PMP-22/gas3 family",

Protein PERP	a) mAb m (26.3.30)	Progen Biotechnik
	b) mAb, m (8.2.9)	Progen Biotechnik
	c) mAb, m (26.2.22)	Progen Biotechnik
	d) As, gp (PERP-1A-4B)	Progen Biotechnik


and others.

If DOJ, EU and BOR do not want to perform this request, they will pay the legal fees for Dr. Abreu and Howard to hire an independent intellectual law firm and/or ask the US Department of Justice to contact their counterpart in Germany and "persuade the people involved to do the right thing".

Sincerely,



Ana Maria Abreu Velez, M.D., Ph.D., D.Sc.
1192 Cumberland Road NE Atlanta, Georgia 30306.
E-mail: abreuvelez@yahoo.com
Phone at home: 404-876-4897.
Cell: 404-660-5558.



Michael S. Howard, M.D.
Georgia Dermatopathology Associates
Work: 1534 North Decatur Road NE; Suite 206
Atlanta, Georgia 30307.
E-mail: mhoward@gadermpath.com
Work Phone: 404-371-0077
Cellular: 404-431-9249

PUBLICATIONS OF INTEREST

1. Moll R, Sievers E, Hämmerling B, Schmidt A, Barth M, Kuhn C, Grund C, Hofmann I, Franke WW. Endothelial and virgular cell formations in the mammalian lymph node sinus: endothelial differentiation morphotypes characterized by a special kind of junction (complexus adhaerens). *Cell Tissue Res.* 2009 Jan;335(1):109-41. Epub 2008 Nov 18. Review. PMID: 19015886.
2. Hofmann I, Kuhn C, Franke WW. Protein p0071, a major plaque protein of non-desmosomal adhering junctions, is a selective cell-type marker. *Cell Tissue Res.* 2008 Dec;334(3):381-99. Epub 2008 Nov 13. PMID: 19005682.
3. Rickelt S, Franke WW, Doerflinger Y, Goerdts S, Brandner JM, Peitsch WK Subtypes of melanocytes and melanoma cells distinguished by their intercellular contacts: heterotypic adherens junctions, adhesive associations, and dispersed desmoglein 2 glycoproteins. *Cell Tissue Res.* 2008 Dec;334(3):401-22. Epub 2008 Oct 31. PMID: 18975006.
4. Pieperhoff S, Schumacher H, Franke WW. The area composita of adhering junctions connecting heart muscle cells of vertebrates. V. The importance of plakophilin-2 demonstrated by small interference RNA-mediated knockdown in cultured rat cardiomyocytes. *Eur J Cell Biol.* 2008 Jul;87(7):399-411. doi: 10.1016/j.ejcb.2007.12.002. Epub 2008 Feb 7. PMID:18261826.
5. Pieperhoff S, Schumacher H, Franke WW. The area composita of adhering junctions connecting heart muscle cells of vertebrates. V. The importance of plakophilin-2 demonstrated by small interference RNA-mediated knockdown in cultured rat cardiomyocytes. *Eur J Cell Biol.* 2008 Jul;87(7):399-411. Epub 2008 Feb 7. PMID: 18261826.
6. Walter B, Schlechter T, Hergt M, Berger I, Hofmann I. Differential expression pattern of protein ARVCF in nephron segments of human and mouse kidney. *Histochem Cell Biol.* 2008 Nov;130(5):943-56. doi: 10.1007/s00418-008-0456-1. Epub 2008 Jul 4.
7. Pieperhoff S, Franke WW. The area composita of adhering junctions connecting heart muscle cells of vertebrates. VI. Different precursor structures in non-mammalian species. *Eur J Cell Biol.* 2008 Jul;87(7):413-30. Epub 2008 Apr 16. PMID: 18420304.
8. Pieperhoff S, Borrmann C, Grund C, Barth M, Rizzo S, Franke WW. The area composita of adhering junctions connecting heart muscle cells of vertebrates. VII. The different types of lateral junctions between the special cardiomyocytes of the conduction system of ovine and bovine hearts. *Eur J Cell Biol.* 2010 May;89(5):365-78. doi: 10.1016/j.ejcb.2009.11.025. Epub 2010 Feb 2. PMID: 20129695.
9. Pieperhoff S, Bennett W, Farrell AP. The intercellular organization of the two muscular systems in the adult salmonid heart, the compact and the spongy myocardium. *J Anat.* 2009 Nov;215(5):536-47. doi: 10.1111/j.1469-7580.2009.01129.x. Epub 2009 Jul 22. PMID: 19627390.
10. Boda-Heggemann J, Régnier-Vigouroux A, Franke WW. Beyond vessels: occurrence and regional clustering of vascular endothelial (VE-) cadherin-containing junctions in non-endothelial cells. *Cell Tissue Res.* 2009 Jan;335(1):49-65. Epub 2008 Nov 11. PMID: 19002500.

11. Hofmann I, Schlechter T, Kuhn C, Hergt M, Franke WW. Protein p0071 - an armadillo plaque protein that characterizes a specific subtype of adherens junctions. *J Cell Sci.* 2009 Jan 1;122(Pt 1):21-4. PMID: 19092057.
12. Walter B, Berger I, Hofmann I. The proteins ARVCF and p0071 in renal cell carcinomas and their potential use in the diagnosis of renal tumours. *Histopathology.* 2009 Dec;55(6):761-4. doi: 10.1111/j.1365-2559.2009.03444.x. No abstract available. PMID: 20002775.
13. Barth M, Schumacher H, Kuhn C, Akhyari P, Lichtenberg A, Franke WW. Cordial connections: molecular ensembles and structures of adhering junctions connecting interstitial cells of cardiac valves in situ and in cell culture. *Cell Tissue Res.* 2009 Jul;337(1):63-77. Epub 2009 May 28. PMID: 19475424.
14. Rickelt S, Winter-Simanowski S, Noffz E, Kuhn C, Franke WW. Upregulation of plakophilin-2 and its acquisition to adherens junctions identifies a novel molecular ensemble of cell-cell-attachment characteristic for transformed mesenchymal cells. *Int J Cancer.* 2009 Nov 1;125(9):2036-48. PMID: 19551809.
15. Franke WW, Rickelt S, Barth M, Pieperhoff S. The junctions that don't fit the scheme: special symmetrical cell-cell junctions of their own kind. *Cell Tissue Res.* 2009 Oct;338(1):1-17. doi: 10.1007/s00441-009-0849-z. Epub 2009 Aug 14. PMID: 19680692.
16. Pieperhoff S, Borrmann C, Grund C, Barth M, Rizzo S, Franke WW. The area composita of adhering junctions connecting heart muscle cells of vertebrates. VII. The different types of lateral junctions between the special cardiomyocytes of the conduction system of ovine and bovine hearts. *Eur J Cell Biol.* 2010 May;89(5):365-78. doi: 10.1016/j.ejcb.2009.11.025. Epub 2010 Feb 2.
17. Walter B, Krebs U, Berger I, Hofmann I. Protein p0071, an armadillo plaque protein of adherens junctions, is predominantly expressed in distal renal tubules. *Histochem Cell Biol.* 2010 Jan;133(1):69-83. doi: 10.1007/s00418-009-0645-6. Epub 2009 Oct 15. PMID: 19830446.
18. Breuninger S, Reidenbach S, Sauer CG, Ströbel P, Pfitzenmaier J, Trojan L, Hofmann I. Desmosomal plakophilins in the prostate and prostatic adenocarcinomas: Implications for diagnosis and tumor progression.. *Am J Pathol.* 2010May;176(5):2509-19. doi: 10.2353/ajpath.2010.090737. Epub 2010 Mar 26. PMID:20348237.
19. Seeger TS, Frank D, Rohr C, Will R, Just S, Grund C, Lyon R, Luedde M, Koegl M, Sheikh F, Rottbauer W, Franke WW, Katus HA, Olson EN, Frey N. Myozap, a novel intercalated disc protein, activates serum response factor-dependent signaling and is required to maintain cardiac function in vivo. *Circ Res.* 2010 Mar 19;106(5):880-90. doi: 10.1161/CIRCRESAHA.109.213256. Epub 2010 Jan 21. PMID: 20093627.
20. Pieperhoff S, Barth M, Rickelt S, Franke WW. Dermatol Res Pract. Desmosomal molecules in and out of adhering junctions: normal and diseased States of epidermal, cardiac and mesenchymally derived cells. 2010;2010:139167. doi: 10.1155/2010/139167. Epub 2010 Jun 30. PMID: 20671973.
21. Rickelt S, Rizzo S, Doerflinger Y, Zentgraf H, Basso C, Gerosa G, Thiene G, Moll R, Franke WW. A novel kind of tumor type-characteristic junction: plakophilin-2 as a major protein of adherens junctions in cardiac myxomata. *Mod Pathol.* 2010 Nov;23(11):1429-37. doi: 10.1038/modpathol.2010.138. Epub 2010 Aug 6. PMID: 20693980.

22. Rickelt S, Moll I, Franke WW. Intercellular adhering junctions with an asymmetric molecular composition: desmosomes connecting Merkel cells and keratinocytes. *Cell Tissue Res.* 2011 Oct;346(1):65-77. doi: 10.1007/s00441-011-1260-0. Epub 2011 Oct 19. PMID:22006253.
23. Fabritz L, Hoogendijk MG, Scicluna BP, van Amersfoort SC, Fortmueller L, Wolf S, Laakmann S, Kreienkamp N, Piccini I, Breithardt G, Noppinger PR, Witt H, Ebnet K, Wichter T, Levkau B, Franke WW, Pieperhoff S, de Bakker JM, Coronel R, Kirchhof P. Load-reducing therapy prevents development of arrhythmogenic right ventricular cardiomyopathy in plakoglobin-deficient mice. *J Am Coll Cardiol.* 2011 Feb 8;57(6):740-50. doi: 10.1016/j.jacc.2010.09.046. PMID:21292134.
24. Franke WW, Rickelt S. Mesenchymal-epithelial transitions: spontaneous and cumulative syntheses of epithelial marker molecules and their assemblies to novel cell junctions connecting human hematopoietic tumor cells to carcinomatoid tissue structures. *Int J Cancer.* 2011 Dec 1;129(11):2588-99. doi: 10.1002/ijc.26227. Epub 2011 Aug 17. PMID:21647878.
25. Rickelt S, Kuhn C, Winter-Simanowski S, Zimbelmann R, Frey N, Franke WW. Protein myozap--a late addition to the molecular ensembles of various kinds of adherens junctions. *Cell Tissue Res.* 2011 Dec;346(3):347-59. doi: 10.1007/s00441-011-1281-8. Epub 2011 Dec 11. PMID: 22160502.
26. Barth M, Rickelt S, Noffz E, Winter-Simanowski S, Niemann H, Akhyari P, Lichtenberg A, Franke WW. The adhering junctions of valvular interstitial cells: molecular composition in fetal and adult hearts and the comings and goings of plakophilin-2 in situ, in cell culture and upon re-association with scaffolds. *WW.Cell Tissue Res.* 2012 May;348(2):295-307. doi: 10.1007/s00441-011-1315-2. PMID:22290634.
27. Medvetz DA, Khabibullin D, Hariharan V, Ongusaha PP, Goncharova EA, Schlechter T, Darling TN, Hofmann I, Krymskaya VP, Liao JK, Huang H, Henske EP. Folliculin, the product of the Birt-Hogg-Dube tumor suppressor gene, interacts with the adherens junction protein p0071 to regulate cell-cell adhesion.. *PLoS One.* 2012;7(11):e47842. doi: 10.1371/journal.pone.0047842. Epub 2012 Nov 6. PMID: 23139756.
28. Rickelt S, Pieperhoff S. Mutations with pathogenic potential in proteins located in or at the composite junctions of the intercalated disk connecting mammalian cardiomyocytes: a reference thesaurus for arrhythmogenic cardiomyopathies and for Naxos and Carvajal diseases. *Cell Tissue Res.* 2012 May;348(2):325-33. doi: 10.1007/s00441-012-1365-0. Epub 2012 Mar 27. Review. PMID: 22450909.
29. Pieperhoff S, Rickelt S, Heid H, Claycomb WC, Zimbelmann R, Kuhn C, Winter-Simanowski S, Kuhn C, Frey N, Franke WW. The plaque protein myozap identified as a novel major component of adhering junctions in endothelia of the blood and the lymph vascular systems. *J Cell Mol Med.* 2012 Aug;16(8):1709-19. doi: 10.1111/j.1582-4934.2011.01463.x. PMID: 21992629.
30. Pieperhoff S. Gene Mutations Resulting in the Development of ARVC/D Could Affect Cells of the Cardiac Conduction System. *Front Physiol.* 2012 Feb 17;3:22. doi: 10.3389/fphys.2012.00022. eCollection 2012. PMID: 22363295.
31. Rangrez AY, Bernt A, Poyanmehr R, Harazin V, Boomgaarden I, Kuhn C, Rohrbeck A, Frank D, Frey N. Dysbindin is a potent inducer of RhoA-SRF-mediated cardiomyocyte hypertrophy. *Cell Biol.* 2013 Nov 25;203(4):643-56. doi: 10.1083/jcb.201303052. PMID: 24385487.

32. Franke WW, Heid H, Zimbelmann R, Kuhn C, Winter-Simanowski S, Dörflinger Y, Grund C, Rickelt S. Transmembrane protein PERP is a component of tessellate junctions and of other junctional and non-junctional plasma membrane regions in diverse epithelial and epithelium-derived cells. *Cell Tissue Res.* 2013 Jul;353(1):99-115. doi: 10.1007/s00441-013-1645-3. Epub 2013 May 21. PMID: 23689684.
33. Rangrez AY, Bernt A, Poyanmehr R, Harazin V, Boomgaarden I, Kuhn C, Rohrbeck A, Frank D, Frey N.J. Dysbindin is a potent inducer of RhoA-SRF-mediated cardiomyocyte hypertrophy. *Cell Biol.* 2013 Nov 25;203(4):643-56. doi: 10.1083/jcb.201303052. PMID: 24385487.
34. Frank D, Rangrez AY, Poyanmehr R, Seeger TS, Kuhn C, Eden M, Stiebeling K, Bernt A, Grund C, Franke WW, Frey N. Mice with cardiac-restricted overexpression of Myozap are sensitized to biomechanical stress and develop a protein-aggregate-associated cardiomyopathy. *J Mol Cell Cardiol.* 2014 Jul;72:196-207. doi: 10.1016/j.yjmcc.2014.03.016. Epub 2014 Mar 31. PMID: 24698889.
35. Rappe U, Schlechter T, Aschoff M, Hotz-Wagenblatt A, Hofmann I. Nuclear ARVCF protein binds splicing factors and contributes to the regulation of alternative splicing. *J Biol Chem.* 2014 May 2;289(18):12421-34. doi: 10.1074/jbc.M113.530717. Epub 2014 Mar 18. PMID: 24644279
36. Franke WW, Dörflinger Y, Kuhn C, Zimbelmann R, Winter-Simanowski S, Frey N, Heid H. ProteinLUMA is a cytoplasmic plaque constituent of various epithelial adherens junctions and composite junctions of myocardial intercalated disks: a unifying finding for cell biology and cardiology. *Cell Tissue Res.* 2014 Jul;357(1):159-72. doi: 10.1007/s00441-014-1865-1. Epub 2014 Apr 29. PMID:24770932.
37. Domke LM, Rickelt S, Dörflinger Y, Kuhn C, Winter-Simanowski S, Zimbelmann R, Rosin-Arbesfeld R, Heid H, Franke WW. The cell-cell junctions of mammalian testes: I. The adhering junctions of the seminiferous epithelium represent special differentiation structures. *Cell Tissue Res.* 2014 Sep;357(3):645-65. doi: 10.1007/s00441-014-1906-9. Epub 2014 Jun 8. PMID: 24907851.
38. Frank D, Rangrez AY, Poyanmehr R, Seeger TS, Kuhn C, Eden M, Stiebeling K, Bernt A, Grund C, Franke WW, Frey N. Mice with cardiac-restricted overexpression of Myozap are sensitized to biomechanical stress and develop a protein-aggregate-associated cardiomyopathy. *J Mol Cell Cardiol.* 2014 Jul;72:196-207. doi: 10.1016/j.yjmcc.2014.03.016. Epub 2014 Mar 31. PMID: 24698889.
39. Rangrez AY, Eden M, Poyanmehr R, Kuhn C, Stiebeling K, Dierck F, Bernt A, Lüllmann-Rauch R, Weiler H, Kirchof P, Frank D, Frey N. Myozap Deficiency Promotes Adverse Cardiac Remodeling via Differential Regulation of Mitogen-activated Protein Kinase/Serum-response Factor and β -Catenin/GSK-3 β Protein Signaling. *J Biol Chem.* 2016 Feb 19;291(8):4128-43. doi: 10.1074/jbc.M115.689620. Epub 2015 Dec 30. PMID: 26719331.
40. Franke WW. Discovering the molecular components of intercellular junctions--a historical view. *Cold Spring Harb Perspect Biol.* 2009 Sep;1(3):a003061. doi: 10.1101/cshperspect.a003061.
41. Barth M, Rickelt S, Noffz E, Winter-Simanowski S, Niemann H, Akhyari P, Lichtenberg A, Franke WW. The adhering junctions of valvular interstitial cells: molecular composition in fetal and adult hearts and the comings and goings of plakophilin-2 in situ, in cell culture and upon re-association with scaffolds.

- Cell Tissue Res. 2012 May;348(2):295-307. doi: 10.1007/s00441-011-1315-2. PMID: 22290634.
42. Rickelt S, Moll I, Franke WW. Intercellular adhering junctions with an asymmetric molecular composition: desmosomes connecting Merkel cells and keratinocytes. *Cell Tissue Res.* 2011 Oct;346(1):65-77. doi: 10.1007/s00441-011-1260-0. Epub 2011 Oct 19. PMID: 22006253.
 43. Rickelt S, Rizzo S, Doerflinger Y, Zentgraf H, Basso C, Gerosa G, Thiene G, Moll R, Franke WW. A novel kind of tumor type-characteristic junction: plakophilin-2 as a major protein of adherens junctions in cardiac myxomata. *Mod Pathol.* 2010 Nov;23(11):1429-37.
 44. Rickelt S, Winter-Simanowski S, Noffz E, Kuhn C, Franke WW. Upregulation of plakophilin-2 and its acquisition to adherens junctions identifies a novel molecular ensemble of cell-cell attachment characteristic for transformed mesenchymal cells. *Int J Cancer.* 2009 Nov 1;125(9):2036-48.
 45. Rickelt S. Plakophilin-2: a cell-cell adhesion plaque molecule of selective and fundamental importance in cardiac functions and tumor cell growth. *Cell Tissue Res* 348, 281–294 (2012).
 46. Fischer-Kešo R, Breuninger S, Hofmann S, Henn M, Röhrig T, Ströbel P, Stoecklin G², Hofmann I. Plakophilins 1 and 3 bind to FXR1 and thereby influence the mRNA stability of desmosomal proteins. *Mol Cell Biol.* 2014 Dec 1;34(23):4244-56. doi: 10.1128/MCB.00766-14. Epub 2014 Sep 15.
 47. Straub BK, Rickelt S, Zimbelmann R, Grund C, Kuhn C, Iken M, Ott M, Schirmacher P, Franke WW. E-N-cadherin heterodimers define novel adherens junctions connecting endoderm-derived cells. *J Cell Biol.* 2011 Nov 28;195(5):873-87. doi: 10.1083/jcb.201106023. Epub 2011 Nov 21.
 48. Franke WW, Rickelt S, Zimbelmann R, Dörflinger Y, Kuhn C, Frey N, Heid H, Rosin-Arbesfeld R. Striatins as plaque molecules of zonulae adhaerentes in simple epithelia, of tessellate junctions in stratified epithelia, of cardiac composite junctions and of various size classes of lateral adherens junctions in cultures of epithelia- and carcinoma-derived cells. *Cell Tissue Res.* 2015 Mar;359(3):779-97. doi: 10.1007/s00441-014-2053-z.
 49. Franke WW, Dörflinger Y, Kuhn C, Zimbelmann R, Winter-Simanowski S, Frey N, Heid H. Epub 2014 Dec 12. Protein LUMA is a cytoplasmic plaque constituent of various epithelial adherens junctions and composite junctions of myocardial intercalated disks: a unifying finding for cell biology and cardiology. *Cell Tissue Res.* 2014 Jul;357(1):159-72. doi: 10.1007/s00441-014-1865-1.
 50. Franke WW, Dörflinger Y, Kuhn C, Zimbelmann R, Winter-Simanowski S, Frey N, Heid H. Protein LUMA is a cytoplasmic plaque constituent of various epithelial adherens junctions and composite junctions of myocardial intercalated disks: a unifying finding for cell biology and cardiology. *Cell Tissue Res.* 2014 Jul;357(1):159-72. doi: 10.1007/s00441-014-1865-1. Epub 2014 Apr 29.
 51. Franke WW, Heid H, Zimbelmann R, Kuhn C, Winter-Simanowski S, Dörflinger Y, Grund C, Rickelt S. Transmembrane protein PERP is a component of tessellate junctions and of other junctional and non-junctional plasma membrane regions in diverse epithelial and epithelium-derived cells. *Cell Tissue Res.* 2013 Jul;353(1):99-115. doi: 10.1007/s00441-013-1645-3. Epub 2013 May 21.

52. Franke WW, Pape UF. Diverse types of junctions containing tight junction proteins in stratified mammalian epithelia. *Ann N Y Acad Sci.* 2012 Jun;1257:152-7. doi: 10.1111/j.1749-6632.2012.06504.x.
53. Schulte K1, Berger K, Boor P, Jirak P, Gelman IH, Arkill KP, Neal CR, Kriz W, Floege J, Smeets B, Moeller MJ. Origin of parietal podocytes in atubular glomeruli mapped by lineage tracing. *J Am Soc Nephrol.* 2014 Jan;25(1):129-41. doi: 10.1681/ASN.2013040376. Epub 2013 Sep 26.
54. Eden M, Meder B, Völkers M, Poomvanicha M, Domes K, Branchereau M, Marck P, Will R, Bernt A, Rangrez A, Busch M, Hrabě de Angelis M, Heymes C, Rottbauer W, Most P, Hofmann F, Frey N. Erratum: Myoscape controls cardiac calcium cycling and contractility via regulation of L-type calcium channel surface expression. *Nat Commun.* 2016 May 26;7:11835. doi: 10.1038/ncomms11835
55. Eden M, Meder B, Völkers M, Poomvanicha M, Domes K, Branchereau M, Marck P, Will R, Bernt A, Rangrez A, Busch M; German Mouse Clinic Consortium, Hrabě de Angelis M, Heymes C, Rottbauer W, Most P, Hofmann F, Frey N. Myoscape controls cardiac calcium cycling and contractility via regulation of L-type calcium channel surface expression. *Nat Commun.* 2016 Apr 28;7:11317. doi: 10.1038/ncomms11317.PMID:27122098.
56. Heid H, Rickelt S, Zimbelmann R, Winter S, Schumacher H, Dörflinger Y, Kuhn C, Franke WW. On the formation of lipid droplets in human adipocytes: the organization of the perilipin-vimentin cortex. *PLoS One.* 2014 Feb 28;9(2):e90386. doi: 10.1371/journal.pone.0090386. eCollection 2014.
57. Heid H, Rickelt S, Zimbelmann R, Winter S, Schumacher H, Dörflinger Y. Lipid droplets, perilipins and cytokeratins--unravelling liaisons in epithelium-derived cells. *PLoS One.* 2013 May 21;8(5):e63061. doi: 10.1371/journal.pone.0063061.
58. Straub BK, Stoeffel P, Heid H, Zimbelmann R, Schirmacher P: Differential pattern of lipid droplet-associated proteins and de novo perilipin expression in hepatocyte steatogenesis. *Hepatology* 47, 1936-1946 (2008).
59. Straub BK, Herpel E, Singer S, Zimbelmann R, Breuhahn K, Macher-Goeppinger S, Warth A, Lehmann-Koch J, Longerich T, Heid H, Schirmacher P: Lipid-droplet-associated PAT-proteins show frequent and differential expression in neoplastic steatogenesis. *Modern Pathology* 23, 480-492 (2010).
60. Westhoff CC, Mrozinski J, Riedel I, Heid HW, Moll R. Perilipin 1 is a highly specific marker for adipocytic differentiation in sarcomas with intermediate sensitivity. *J Cancer Res Clin Oncol.* 2017 Feb;143(2):225-232. doi: 10.1007/s00432-016-2263-
61. Straub BK [Lipid droplet-associated proteins. Importance in steatosis, steatohepatitis and hepatocarcinogenesis]. *Pathologe.* 2015 Nov;36 Suppl 2:146-52. doi: 10.1007/s00292-015-0082-3. PMID:26400566
62. Straub BK, Gyoengyoesi B, Koenig M, Hashani M, Pawella LM, Herpel E, Mueller W, Macher-Goeppinger S, Heid H, Schirmacher P. Adipophilin/perilipin-2 as a lipid droplet-specific marker for metabolically active cells and diseases associated with metabolic dysregulation. *Histopathology.* 2013 Mar;62(4):617-31. doi: 10.1111/his.12038

63. Pawella LM, Hashani M, Schirmacher P, Straub BK. [Lipid droplet-associated proteins in steatosis. Effects of induction and siRNA-mediated downregulation of PAT proteins in cell culture models of hepatocyte steatosis]. *Pathologe*. 2010 Oct;31 Suppl 2:126-31. doi: 10.1007/s00292-010-1322-1.
64. Straub BK, Herpel E, Singer S, Zimbelmann R, Breuhahn K, Macher-Goeppinger S, Warth A, Lehmann-Koch J, Longerich T, Heid H, Schirmacher P. Lipid droplet-associated PAT-proteins show frequent and differential expression in neoplastic steatogenesis. *Mod Pathol*. 2010 Mar;23(3):480-92. doi: 10.1038/modpathol.2009.19.
65. Lenz, LS. Marx J, Chamulitrat W, Kaiser I, Gröne HJ, Liebisch G, Schmitz G, Elsing C, Straub BK, Füllekrug J, Stremmel W, Herrmann T. et al. Adipocyte-specific Inactivation of Acyl-CoA Synthetase Fatty Acid Transport Protein 4 (Fatp4) in Mice Causes Adipose Hypertrophy and Alterations in Metabolism of Complex Lipids under High Fat Diet. *J. Biol. Chem. J Biol Chem*. 2011 Oct 14;286(41):35578-87. doi: 10.1074/jbc.M111.226530.
66. Yang C, Strobel P, Marx A, Hofmann I. 2013. Plakophilin-associated RNA-binding proteins in prostate cancer and their implications in tumor progression and metastasis. *Virchows Arch*. 463:379–390. doi: 10.1007/s00428-013-1452-y.
67. Yang C, Fischer-Kešo R, Schlechter T, Ströbel P, Marx A, Hofmann I: Plakophilin 1-deficient cells upregulate SPOCK1: implications for prostate cancer progression. *Tumor Biol*. (2015) DOI 10.1007/s13277-015-3628-3.
68. Fischer-Kešo R, Breuninger S, Hofmann S, Henn M, Röhrig T, Ströbel P, Stoecklin G, Hofmann I. Plakophilins 1 and 3 bind to FXR1 and thereby influence the mRNA stability of desmosomal proteins. *Mol Cell Biol*. 2014 Dec 1;34(23):4244-56. doi: 10.1128/MCB.00766-14. Epub 2014 Sep 15.
69. Rappe, U, Schlechter, T, Aschoff, M, Hotz-Wagenblatt A, Hofmann, I. Nuclear ARVCF Protein Binds Splicing Factors and Contributes to the Regulation of Alternative Splicing. *J. Biol. Chem*. 289, 12421–12434 (2014).
70. Medvetz DA, Khabibullin D, Hariharan V, Ongusaha PP, Goncharova EA, et al. (2012) Folliculin, the Product of the Birt-Hogg-Dube Tumor Suppressor Gene, Interacts with the Adherens Junction Protein p0071 to Regulate Cell-Cell Adhesion. *PLoS ONE* 7(11): e47842. doi:10.1371/journal.pone.0047842.
71. Kluge A, Rangrez AY, Kilian LS, Pott J, Bernt A, Frauen R, Rohrbeck A, Frey N, Frank D. Rho-family GTPase 1 (Rnd1) is a biomechanical stress-sensitive activator of cardiomyocyte hypertrophy. *J Mol Cell Cardiol*. 2019 Feb 21;129:130-143. doi: 10.1016/j.yjmcc.2019.01.028. [Epub ahead of print].
72. Lahav-Ariel L, Caspi M, Nadar-Ponniah PT, Zelikson N, Hofmann I, Hanson KK, Franke WW, Sklan EH, Avraham KB, Rosin-Arbesfeld R. Striatin is a novel modulator of cell adhesion. *FASEB J*. 2019 Apr;33(4):4729-4740. doi: 10.1096/fj.201801882R1
73. Domke LM, Franke WW. The cell-cell junctions of mammalian testes: II. The lamellar smooth muscle monolayer cells of the peritubular wall are laterally connected by vertical adherens junctions-a novel architectonic cell-cell junction system. *Cell Tissue Res*. 2019 Feb;375(2):451-482. doi: 10.1007/s00441-018-2968-x

ABSTRACTS

- Franke WW. Special issue Heidelberg Heart II: Abstracts of oral and poster presentations. Cell Tissue Res. 2012 May;348(2):335-70. Special Helmholtz Workshop — Heidelberg Heart II. German Cancer Research Center, Heidelberg, Germany, 9–11 September 2011
- A 4— Derk Frank, Thalia S. Seeger, Claudia Rohr, Christian Kuhn, Christine Grund, Rainer Will, Werner W. Franke, Hugo A. Katus, Norbert Frey. Transgenic overexpression of the intercalated discprotein myozap causes protein aggregate-associated cardiomyopathy.
- **A 26** — Steffen Rickelt, Stefania Rizzo, Mareike Barth, Werner W. Franke. The specific molecular ensembles of the junctions connecting mesenchymally-derived tumor cells, including cardiac myxomata: the coming and going of plakophilin-2.
- **P 9** — Sebastian Pieperhof, Steffen Rickelt, Caecilia Kuhn, Ralf Zimbelmann, Hans W Heid , Heiderose Schumacher1, Stefanie Winter-Simanowski, Norbert Frey, Werner W. Franke. The protein myozap, a major constitutive plaque component of the composite junctions (areae compositae) of the myocardial intercalated disks, is also a major and widespread protein in the cell–cell junctions of endothelial cells of blood and lymph vessels.
- **P 10** — Steffen Rickelt, Sebastian Pieperhoff, Caecilia Kuhn, Roland Moll, Werner W. Franke. Cell–cell junctions out of the textbook scheme: special structures in their own right.
- **A 4**— Derk Frank, Thalia S. Seeger, Claudia Rohr, Christian Kuhn, Christine Grund, Rainer Will, Werner W. Franke, Hugo A. Katus, Norbert Frey. Transgenic overexpression of the intercalated disc protein myozap causes protein aggregate-associated cardiomyopathy.
- **A 26** — Steffen Rickelt, Stefania Rizzo, Mareike Barth, Werner W. Franke. The specific molecular ensembles of the junctions connecting mesenchymally-derived tumor cells, including cardiac myxomata: the coming and going of plakophilin-2.

THE FOLLOWING TWO PATENTS

Method and kit for assessment of sodium channel-related anti- or pro-arrhythmic potential of compounds EP 2988129 A1.

Publication number	EP2988129 A1
Publication type	Application
Application number	EP20140181787
Publication date	Feb 24, 2016

Filing date	Aug 21, 2014
Priority date	Aug 21, 2014
Also published as	<u>WO2016026732A1</u>
Inventors	<u>Michael Koenen</u> , <u>Pessah Yampolsky</u> , <u>Patrick A. Schweizer</u> , <u>Dierk Thomas</u> , <u>Hugo A. Katus</u>
Applicant	<u>Ruprecht-Karls-Universität Heidelberg</u>
Myozap	

Method and kit for assessment of sodium channel-related anti- or pro-arrhythmic potential of compounds WO 2016026732 A1

Publication number	WO2016026732 A1
Publication type	Application
Application number	PCT/EP2015/068433
Publication date	Feb 25, 2016
Filing date	Aug 11, 2015
Priority date	Aug 21, 2014
Also published as	<u>EP2988129A1</u>
Inventors	<u>Michael Koenen</u> , <u>Pessah Yampolsky</u> , <u>Patrick A. Schweizer</u> , <u>Dierk Thomas</u> , <u>Hugo A. Katus</u>



DEPARTMENT OF VETERANS AFFAIRS
Veterans Health Administration
810 Vermont Avenue, NW
Washington, DC 20420

April 19, 2018

FOIA Request No.: 18-05919-F

Ana Maria Abreu Velez
1192 Cumberland Road NE
Atlanta, GA 30306

Dear Ms. Velez:

This letter is the initial agency decision of your March 22, 2018 request, under the Freedom of Information Act (FOIA), 5 U.S.C. § 552, to the Department of Veterans Affairs (VA), Veterans Health Administration (VHA) Central Office FOIA Office. Specifically requesting the total amount paid by VA for the following medications from Gilead Sciences Inc., for HIV, and Hepatitis in the last 20 years:

NDC	Trade Name
61958-1101	COMPLERA
61958-2002	DESCOVY
61958-0601	Emtriva
61958-0602	Emtriva
61958-2201	Epclusa
61958-1901	Genvoya
61958-0501	Hepsera
61958-2101	ODEFSEY
61958-1501	Sovaldi
61958-1201	Stribild
61958-1401	Tybost
61958-2301	VEMLIDY
61958-0401	Viread
61958-0403	Viread
61958-0404	Viread

61958-0405	Viread
61958-0406	Viread
61958-0101	Vistide
61958-1301	Vitekta
61958-1302	Vitekta
61958-2401	Vosevi

Your FOIA request was received in my office on March 22, 2018.

Initial Agency Decision

Pharmacy Benefits Management (PBM) (10P4P), which is a VHA Central Office program office's search for responsive records has concluded. The following response was provided from the program office, "From the time period of May 2004 through February 2018, VA spent a total of \$1,659,699,645.74 for the drugs provided by requestor."

If you should have any questions, please feel free to contact me at 717-675-8363.

Sincerely,

DEANA M.

MARAKOWSKI 262091

Deana Marakowski
VHA FOIA Officer

Digitally signed by DEANA M.
MARAKOWSKI 262091
Date: 2018.04.19 10:56:20
-04'00'

November 23, 2018

Ms. Elizabeth Bresnahan

2970 Peachtree Road, NW; Suite 200; Atlanta, Georgia 30305;

RE: Request to investigate a possible transaction from your bank, intended to destroy our practice.

Dear Ms. Bresnahan,

We know that very top executives at Iberia Bank have many links to Emory University, and will gladly help them with any transaction.

However maybe this loan from your bank to Mr. Mathew B. Stoddard was not completely DISCLOSED to Iberia, due to DARK REASONS, and possible violating commercial real estate laws in Georgia. Thus, in regard to a POSSIBLE FRAUDULENT TRANSACTION WE WANT YOU and IBERIA BANK TO INVESTIGATE AND REQUEST AN AFFIDAVIT FROM THE VP OF LEGAL at Emory University, Mr. Stephen D. Sencer, and from attorney Matthew B. Stoddard; and ask that they completely disclose the real, full reasons of buying the building we rented for over 16 years.

Please see the list of attacks against me and my family attached, summarizing why Emory University could want to destroy me, my family and practice.

“OUT OF THE BLUE” ON AUGUST 16, 2018 WE WERE TOLD BY THE OWNER OF THE BUILDING WE HAVE BEEN RENTING FOR OUR MEDICAL PRACTICE (GA DERMATOPATHOLOGY ASSOCIATES) FOR OVER 16 YEARS (AT 1534 NORTH DECATUR ROAD NE, ATLANTA, GA 30307) THAT HE WOULD SELL THE BUILDING HE OWNS AS “DARDEN RESEARCH CORPORATION” ON AUGUST 23, AND INDEED IT HAPPENED. IT WAS SOLD BY CLAIBOURNE DARDEN JR; THE BUILDING IS PARCEL ID: 1805302028, DECATUR, GA. TAX DISTRICT 04 UNINCORPORATED.

The building was sold to Atlanta attorney Matthew B. Stoddard, Office 404-800-1152, or Cell 919-280-4925. Business address: 5447 Roswell Road Suite 204 Atlanta, GA 30342. E-mail: matt@thestoddardfirm.com. We also know one person directly involved in the sale was David Aynes (687-665-3283; Atlanta Leasing & Investment/Commercial Real Estate). Before the sale, one of the two appraisal firms is attached in this package was involved); also before the sale, the property was visited by a geologist for a survey, i.e., Mr. John Salvino: jhonsalvino619@gmail.com. **Importantly, during the summer months this year, THREE of the top Gilead executives have left Gilead Sciences in California (Martin, Bitschofberger and Gilligan), all of whom had been at Gilead approximately 30 years.**

Given a pertinent criminal background involving Emory and Gilead via the fraudulent approval/sale of HIV and hepatitis medications over 15 years, we are concerned that the SALE

OF THE DARDEN BUILDING WAS AN ORCHESTRATED, CONSPIRACY RETALIATION TO DESTROY OUR MEDICAL PRACTICE, ORIGINATING WITH DR. MARTIN IN CALIFORNIA, AND/OR DR. RAYMOND SCHINAZI AND/OR MR. STEVEN SENCER AT EMORY, WITH MR. AYNES AND/OR OTHERS PLAYING A CRUCIAL FRONTING ROLE IN ATLANTA. Following a basic investigation of Mr. Stoddard, we believe is very strange that this young attorney (about 35 years old; who bought his current house at 1658 East Clifton Road, NE in Atlanta for about \$800,000 last year) ALSO had the resources and could obtain via financing (with Iberia Bank, 2970 Peachtree Road, NW; Suite 200; Atlanta, Georgia 30305) the sale price of 2 million dollars by the time of the sale. His wife is a veterinarian that works at CDC. He asked all the tenants of the building to vacate the property in writing, within 70 days, on the date of the sale (August 23). By his own account, he is planning to gut and refurbish the entire building under the ownership firm Lullwater Wharf, LLC as upscale commercial property (we estimate the refurbishment will cost an additional \$500,000) beginning in November, 2018.

We know Georgia law by consulting a real state commercial attorney that if a “ghost transaction happens” the real owners must be disclosed 1) to the banks that do the loan as well as 2) the underwriters that insure the property. Such information is not public, but we encourage you to report to the FBI Atlanta if this rule was violated. We already reported your bank transaction to them.

Mr. Stoddard does not have a great income neither his wife to be able to obtain such amounts. Emory may state a bogus reason for a ghost transaction, stating that the previous owner “does not like Emory”. He was not selling as late as early 2018. He was ‘out of the blue’ approached by the real estate agent.

We thus respectfully ask the bank and any other agencies that should be involved to 1) investigate all aspects of this sale; to 2) determine whether this was an honest and legal transaction with the full disclosure reasons for the likely “ghost nature” of it, and 3) whether Gilead/Emory University conducted and/or secretly financed the sale to specifically retaliate against our medical practice. Further, we 4) request suspension of the involved parties’ legal and/or real estate licenses, if indeed the sale was knowingly conducted in an illegal manner.

Emory and Gilead have very likely defrauded US tax payers out of trillions of dollars with false patents and monopolies. THE VA ALONE HAS PAID MORE THAN 1.7 TRILLION USD TO GILEAD FOR FALSE PATENT MEDICATIONS (ALL TAX MONEY INCLUDING YOURS)


PLEASE SEE ATTACHED DOCUMENT. PLEASE SEE OUR WEB SITE:

[HTTPS://CYMBALS-PURPLE-84R7.SQUARESPACE.COM/](https://CYMBALS-PURPLE-84R7.SQUARESPACE.COM/)


Please send us an internal affairs review of this transaction ensuring that these two attorneys clearly expose their dark reasons for buying the building.

IF THE BANK IDENTIFIES FRAUD BASED ON THE WEAK FINANCES OF MR Stoddard, please remove the loan and contact the FBI Atlanta with a copy to us.

Sincerely,



Ana Maria Abreu Velez, M.D., Ph.D., D.Sc.
1192 Cumberland Road NE, Atlanta, Georgia 30306
Phone W: 404-371-0077
E-mail: abreuvelez@yahoo.com



Michael S. Howard, M.D.
1192 Cumberland Road NE, Atlanta, Georgia 30306
Phone W: 404-371-0077
E-Mail: mhoward@gadermpath.com

CC FBI Atlanta, US Attorney General and SCOTUS

Exhibit 12

November 24, 2018


Dear FBI Atlanta,

Enclosed is your copy of the letter we sent today to Iberia Bank, to investigate the issues of retaliation from Emory University, Gilead Sciences, and the Board of Regents of the University System of Georgia.


We have not received any settlement from these white collar criminals, nor from the DOJ despite the DOJ making recent deals under the table with them (such as their HIV and hepatitis medications are available in generics) via FDA. The three top leaders at Gilead are "being retired". We didn't have money to file the qui tam, plus no attorney we consulted in Georgia would do the cases pro bono for us. However, we figured out the 20 years of Gilead monopolies allowed by the DOJ antitrust division, leading to the biggest pharmaceutical scam in US and world history.

No people at Emory and BOR are in jail or are being prosecuted for killing the innocent people in clinical trials either. This is unjust and inhumane. In our opinion, Dr. Dennis Liotta and Dr. Raymond Schinazi at Emory and Dr. Dennis Marcus at AU/BOR should be prosecuted for manslaughter. The VP of legal of Emory (Steven D. Sencer) is still there and he has been the main person covering all this. The person who attacked my daughter in 2006, Mr. Micah Chrenek, is still at Emory and Drs. Thomas Lawley and Dr. Robert Swerlick, who destroyed our practice and reputation, are still at Emory. Over fourteen years of retaliation and zero prosecution is absolutely unacceptable.

Sincerely,


Ana Maria Abreu Velez, M.D., Ph.D., D.Sc.
1192 Cumberland Road NE, Atlanta, Georgia 30306
Phone W: 404-371-0077

E-mail: abreuvelez@yahoo.com


Michael S Howard MD,
1192 Cumberland road NE, Atlanta, Georgia 30306
Phone W: 404-3710077
E-Mail: mhoward@gadermpath.com

Frustration grows over EU grant application procedures

Munich

Applying for research grants is always a complicated and time-consuming process. But many scientists across Europe are currently reserving their strongest complaints for applications to the European Union's (EU's) five-year Framework programme (FP5).

Not only are its application procedures especially cumbersome, claim researchers, but some say the chances of winning a grant are too low to justify the effort. Privately, some officials in the European Commission, which administers the programme, fear that the best researchers will be driven away.

Data emerging from the commission indicate that, after two rounds of proposals submitted last year, the success rate for applicants in the life sciences and information technologies — subjects earmarked by the EU as strategic priorities — remains below 20 per cent. In biotechnology, covered by a sub-programme called the 'Cell Factory', the success rate is as low as 10 per cent (see graph).

A Framework grant application involves recruiting a network of collaborating labs with an acceptable geographic balance: the chances of success are greater when researchers from smaller EU nations and from southern Europe are included. But FP5's requirement for projects to be justified in addition by their socio-economic value seems to be causing particular problems.

This requirement was agreed in 1998 by research ministers from the EU's member states and the European Parliament. Governments wanted FP5 to support research that directly addresses defined socio-economic

problems in European states, rather than simply supporting basic research, which, according to the EU's governing treaties, is the job of individual member states.

Scientists are struggling to put the idea into practice, however, and commission officials admit that the new criteria are difficult to explain, except by example. "You find yourself having to read through hundreds of pages of advice in order to construct an application," complains one frustrated, although successful, FP5 applicant.

Given the low success rates, many scientists are questioning the value of the time and effort spent on putting together an application. "For an application coordinator, an FP5 grant application is an extremely difficult and time-consuming affair that can take up to six months," says Hans-Georg Rammensee, a cell biologist at the University of Tübingen in Germany. "A rejection rate of some 90 per cent in my area makes this effort a huge waste of resources." Rammensee, although a partner in three Framework projects, says he would never volunteer to coordinate an application himself.

"You have to be desperate to apply for EU money," agrees Paula Ricciardi-Castagnoli, an immunologist at the University of Milan who has experienced the system as both a successful and an unsuccessful applicant and as a grant reviewer. "Scientists from countries with better funding opportunities like Germany and Britain will obviously turn to their national funding agencies where application procedures are less cumbersome."

A possible way around this problem would be to divert more FP5 money into life sciences and information technologies, in order to raise the success rate to the desired target of 30 to 40 per cent. But the EU's finance rules mean that, until FP5 expires at the end of 2002, money cannot be shifted from less popular research areas.

Instead, the commission is trying to tweak the system by cutting the number, and narrowing the scope, of future calls for proposals. It is also considering ways of making the application process more user-friendly.

Bruno Hansen, director of life sciences for FP5, says that simplification is a "high priority". But he defends the socio-economic criteria, arguing that this will guarantee that the European population gains maximum benefit from EU-funded research.

"I am very optimistic that it will prove fruitful, particularly in areas such as food safety or the development of new vaccines," says Hansen. "However, it is too early to say whether it is actually working."

Alison Abbott & Patrick Weydt



One in eleven: South Africa's government is reluctant to approve antiretroviral drugs.

Deaths bring South African HIV drug trials to a premature halt

Cape Town

South Africa's Medicines Control Council (MCC) has halted a clinical trial of the antiretroviral drug Coviracil (emtricitabine) following an announcement by the country's health minister that five South African women have died during the trial.

The decision has attracted particular attention because the study involved giving Coviracil to HIV-positive individuals in combination with d4T and nevirapine.


The government is already under pressure to allow HIV-positive pregnant women to be given nevirapine to prevent mother-to-child transmission of HIV, since President Thabo Mbeki has refused to sanction the use of AZT in state hospitals for this purpose (see *Nature* 402, 332; 1999).

Health minister Manto Tshabalala-Msimang has been accused of using the deaths to justify the government's refusal to provide pregnant women with antiretroviral drugs. "It is unfortunate that she has used the tragic event of deaths during the trials to make a political point that justifies her doing nothing to stop mother-to-child transmission," said opposition Member of Parliament Patricia de Lille of the Pan-African Congress.

But Tshabalala-Msimang told parliament last week that it would be "immoral and unethical" for the government to decide on the use of nevirapine until the full results of clinical trials on the drug are available.

MCC head Helen Rees denied that the government had put pressure on the council in making its decision. She described the timing of events as "serendipitous".

Michael Cherry



Slim pickings: EU grants require reams of paperwork, but the chance of success is small.

**IN THE UNITED STATES DISTRICT COURT
FOR THE NORTHERN DISTRICT OF GEORGIA
ATLANTA DIVISION**

DR. ANA MARIA ABREU-VELEZ)	
and DR. MICHAEL S. HOWARD,)	
)	
Plaintiffs,)	
)	
vs.)	Case No.: 1:19-cv-3299-AT
)	
GILEAD SCIENCES, INC., et al.,)	
)	
Defendants.)	

DEFENDANT GILEAD SCIENCES, INC.’S
NOTICE OF INTENT NOT TO FILE A REPLY IN SUPPORT OF
ITS MOTION TO DISMISS

COMES NOW Defendant Gilead Sciences, Inc. (“Defendant” or “Gilead”) by and through its undersigned counsel, and hereby gives notice of its intent not to file a reply in support of its Motion to Dismiss Plaintiffs’ Complaint filed on July 14, 2020 [Dkt. 69].

Gilead’s original brief in support of its motion to dismiss [Dkt. 69-1] comprehensively explains why the Plaintiffs’ purported whistleblower retaliation action fails to state a claim including, *inter alia*, the failure to allege an employment relationship with Gilead or any retaliatory action by Gilead, because it is time-barred, and because it is barred by the doctrine of *res judicata*.

Plaintiffs' response brief in opposition to Gilead's Motion to Dismiss was docketed on July 28, 2020 [Dkt. 75].

Because Gilead's arguments are sufficiently stated in its original brief, Gilead does not intend to file a reply brief in support of its motion to dismiss. Its motion [Dkt. 69] is therefore ready for submission to the Court.

This 29th day of July, 2020.

**BAKER, DONELSON, BEARMAN,
CALDWELL & BERKOWITZ, PC**

/s/ Joe. D. Whitley

Joe D. Whitley, GA Bar No. 756150
Brett A. Switzer, GA Bar No. 554141
Sarah M. Carrier, GA Bar No. 377848
3414 Peachtree Rd. NE, Ste 1500
Atlanta, Georgia 30326
Phone: 404-577-6000
Facsimile: 404-221-6501
Email: jwhitley@bakerdonelson.com
Email: bswitzer@bakerdonelson.com
Email: scarrier@bakerdonelson.com

Attorneys for Defendant Gilead Sciences, Inc.

CERTIFICATE OF COMPLIANCE

Undersigned counsel certifies the foregoing document has been prepared with one of the font and point selections (Times New Roman, 14 point) approved by the Court in Local Rule 5.1(C) and 7.1(D).

This 29th day of July, 2020.

/s/ Joe D. Whitley

Joe D. Whitley

GA Bar No. 756150

Attorney for Defendant Gilead Sciences, Inc.

CERTIFICATE OF SERVICE

I hereby certify that I have this day served a copy of the foregoing document upon all counsel of record via the court's electronic filing system and via First-Class U.S. Mail to the following:

Ana Maria Abreu Velez, M.D., Ph.D., D. Sc.
1192 Cumberland Road, NE
Atlanta, Georgia 30306

Michael S. Howard, M.D.
Georgia Dermatopathology Associates
1610 Lavista Road, NE
Atlanta, Georgia 30329

This 29th day of July, 2020.

/s/ Joe D. Whitley

Joe D. Whitley
GA Bar No. 756150

Attorney for Defendant Gilead Sciences, Inc.

UNITED STATES SENATE
COMMITTEE ON THE JUDICIARY

QUESTIONNAIRE FOR JUDICIAL NOMINEES

PUBLIC

1. **Name**: State full name (include any former names used).

Steven Daniel Grimberg

2. **Position**: State the position for which you have been nominated.

United States District Court for the Northern District of Georgia

3. **Address**: List current office address. If city and state of residence differs from your place of employment, please list the city and state where you currently reside.

Office: Nardello & Co.
 999 Peachtree Street, Suite 1130
 Atlanta, Georgia 30309

Residence: Marietta, Georgia

4. **Birthplace**: State year and place of birth.

1974, New York City, New York

5. **Education**: List in reverse chronological order each college, law school, or any other institution of higher education attended and indicate for each the dates of attendance, whether a degree was received, and the date each degree was received.

1995 – 1998, Emory University School of Law; J.D. (*with distinction*), 1998

1991 – 1995, University of Florida, B.A. (*with honors*), 1995

6. **Employment Record**: List in reverse chronological order all governmental agencies, business or professional corporations, companies, firms, or other enterprises, partnerships, institutions or organizations, non-profit or otherwise, with which you have been affiliated as an officer, director, partner, proprietor, or employee since graduation from college, whether or not you received payment for your services. Include the name and address of the employer and job title or description.

2018 – Present
Nardello & Co.
999 Peachtree Street, Suite 1130

Atlanta, Georgia 30309
Managing Director, General Counsel-Americas

2012 – Present
Emory University School of Law
1301 Clifton Road, N.E.
Atlanta, Georgia 30322
Adjunct Professor

2010 – 2017
United States Department of Justice
75 Ted Turner Drive S.W., Suite 600
Atlanta, Georgia 30303
Assistant United States Attorney and Deputy Chief, Economic Crime Section

2005 – 2010
United States Department of Justice
601 D Street, N.W.
Washington, D.C. 20004
Trial Attorney, Tax Division

2002 – 2005
Hunton & Williams LLP
600 Peachtree Street, N.E., Suite 4100
Atlanta, Georgia 30308
Associate

1999 – 2002
Muller Mintz, PA
200 South Biscayne Boulevard, Suite 3600
Miami, Florida 33131
Associate

Summer 1997; 1998 – 1999
Vial, Hamilton, Koch & Knox LLP
1717 Main Street, Suite 4400
Dallas, Texas 75201
Summer Associate (1997)
Associate (1998 – 1999)

1997 – 1998
Johnson, Prioleau & Kenison, LLC
41 Marietta Street, NW, Suite 600
Atlanta, Georgia 30303
Law Clerk (part-time)

1997
Georgia Supreme Court
Chief Justice Robert Benham
244 Washington Street, Room 572
Atlanta, Georgia 30334
Intern

Summer 1996; Summer 1997
Littler Mendelson, PC
1100 Peachtree Street, NE, Suite 2000
Atlanta, Georgia 30309
Summer Associate

1996 – 1997
Emory University School of Law
Professor Polly Price
1301 Clifton Road
Atlanta, Georgia 30322
Research Assistant

Other Affiliations (uncompensated):

2018 – Present
U.S. Chamber of Commerce
Technology Litigation Advisory Committee
1615 H Street, N.W.
Washington, D.C. 20062
Member

2017 – Present
Timber Ridge Foundation (Timber Ridge Elementary School)
5000 Timber Ridge Road
Marietta, Georgia 30068
Board Member

2010 – Present
Lamar Inn of Court
Emory University School of Law
1301 Clifton Road
Atlanta, Georgia 30322
President (2018 – Present)
President-Elect and Treasurer (2017 – 2018)
Secretary (2016 – 2017)
Executive Committee (2012 – Present)

7. **Military Service and Draft Status:** Identify any service in the U.S. Military, including

dates of service, branch of service, rank or rate, serial number (if different from social security number) and type of discharge received, and whether you have registered for selective service.

I did not serve in the military. I registered for the selective service upon turning 18.

8. **Honors and Awards:** List any scholarships, fellowships, honorary degrees, academic or professional honors, honorary society memberships, military awards, and any other special recognition for outstanding service or achievement.

Director's Award for Superior Performance, Executive Office of U.S. Attorneys, *SpyEye Botnet Investigation* (2017)

United States Attorney's Award, U.S. Attorney's Office for the Northern District of Georgia, *United States v. Annamalai, et al.* (2017)

Certificate of Appreciation for Outstanding Assistance and Support of Law Enforcement Responsibilities, Internal Revenue Service-Criminal Investigation (2016)

Cyber Boot Camp, Federal Bureau of Investigation National Cyber Investigative Joint Task Force (2015)

Certificate of Appreciation for Outstanding Service on Behalf of Crime Victims (2015)

Certification of Appreciation for Outstanding Service on Behalf of Crime Victims (2014)

United States Attorney's Award, U.S. Attorney's Office for the Northern District of Georgia, *United States v. Lawrence Eppelbaum* (2013)

Certificate of Appreciation for Outstanding Service on Behalf of Crime Victims, *United States v. Mitchell Gross* (2013)

Certificate of Appreciation for Outstanding Assistance and Support of Law Enforcement Responsibilities, U.S. Department of Treasury (2012)

Recognition Plaque for Outstanding Work and Contribution to "Operation Stop the Flow" and "Operation Go with the Flow", Internal Revenue Service-Criminal Investigation (2010)

Master, Lamar Inn of Court, Emory University School of Law (2010 – Present)

Director's Award for Superior Performance, Executive Office of U.S. Attorneys, *United States v. Juan Rene Caro, et al.* (2009)

Outstanding Attorney Award, U.S. Department of Justice, Tax Division (2009)

Recognition Plaque, Food and Drug Administration, Office of Criminal Investigation, *United*

States v. Michael Sherman, et al. (2008)

Outstanding Attorney Award, U.S. Department of Justice, Tax Division (2007)

Juris Doctorate, *with distinction*, Emory University School of Law (1998)

Emory International Law Review, Associate Editor (1997 – 1998)

Dean's List, Emory University School of Law (1995 – 1998)

Full Scholarship, Emory University School of Law (1995 – 1998)

Bachelor of Arts Degree, *with honors*, University of Florida (May 1995)

Full Scholarship, University of Florida (1991 – 1995)

9. **Bar Associations:** List all bar associations or legal or judicial-related committees, selection panels or conferences of which you are or have been a member, and give the titles and dates of any offices which you have held in such groups.

American Bar Association (2015 – 2016)

Atlanta Bar Association
Criminal Law Section (2011 – Present)

Cobb County Bar Association (2014 – 2016)

Federal Bar Association (2006 – 2016)
Criminal Law Section (2009 – 2016)

Georgia Bar (2003 – Present)
Corporate Counsel Section (2018 – Present)
Criminal Law Section (2010 – Present)
Appellate Practice Section (2015 – 2018)
Judicial Section (2015 – 2017)

Georgia Hispanic Bar Association (2015 – Present)

Hispanic National Bar Association (2015 – Present)

Lamar Inn of Court, Emory University School of Law (2010 – Present)
President (2018 – Present)
President-Elect and Treasurer (2017 – 2018)
Secretary (2016 – 2017)
Executive Committee (2012 – Present)

Lawyer's Club of Atlanta (2018 – Present)

Republican National Lawyers Association (2008 – Present)

10. **Bar and Court Admission:**

- a. List the date(s) you were admitted to the bar of any state and any lapses in membership. Please explain the reason for any lapse in membership.

Texas, 1998

Florida, 1999

Georgia, 2003

In 2005 I elected to be an inactive member of the Texas Bar because I was no longer practicing law in Texas. In 2010 I elected to be an inactive member of the Florida Bar because I was no longer practicing law in Florida. I am not aware of any other lapses in membership.

- b. List all courts in which you have been admitted to practice, including dates of admission and any lapses in membership. Please explain the reason for any lapse in membership. Give the same information for administrative bodies that require special admission to practice.

United States Supreme Court, 2007.

United States Court of Appeals for the Fifth Circuit, 1999.

United States Court of Appeals for the Eleventh Circuit, 2001.

U.S. District Court for the Northern District of Georgia, 2004.

U.S. District Court for the Middle District of Georgia, 2004.

U.S. District Court for the Northern District of Florida, 2000.

U.S. District Court for the Middle District of Florida, 2000.

U.S. District Court for the Southern District of Florida, 2000.

U.S. District Court for the Northern District of Texas, 1998.

Superior and State Courts of Georgia, 2003.

In 2009 my membership in the bar of the United States Court of Appeals for the Fifth Circuit lapsed because I did not renew it; I have not appeared in any matter before the court since March 2009. In 2017 my membership in the bar of the United States Court of Appeals for the Eleventh Circuit lapsed when I left government service; under the court's admission rules I was authorized to appear as an attorney for the United States Government between 2005 and 2017; I have not appeared in any matter before the court since December 2017. My membership in the United States District Court for the Middle District of Florida has likewise lapsed because I did not renew it while appearing before the court on behalf of the United States Government. The clerk's office is unable to determine exactly when it expired; I have not appeared in any matter before the court since leaving government employment. I am not aware of any other lapses in

membership.

11. Memberships:

- a. List all professional, business, fraternal, scholarly, civic, charitable, or other organizations, other than those listed in response to Questions 9 or 10 to which you belong, or to which you have belonged, since graduation from law school. Provide dates of membership or participation, and indicate any office you held. Include clubs, working groups, advisory or editorial boards, panels, committees, conferences, or publications.

The ALS Association
Georgia Chapter (2015 – 2016)

Emory University Alumni Association (1998 – Present)

The Federalist Society for Law and Public Policy Studies (1997 – 2004; 2015 – Present)
Atlanta Lawyers Chapter (2015 – Present)

Infragard Atlanta Members Alliance (2012 – Present)

Leukemia & Lymphoma Society
Team in Training (2003)

Republican Jewish Coalition
Atlanta Chapter (2015 – 2016)

Timber Ridge Foundation (Timber Ridge Elementary School)
Board Member (2017 – Present)

University of Florida Alumni Association (1995 – 2012)

U.S. Hereditary Angiodema Association (2015 – 2016)

- b. The American Bar Association's Commentary to its Code of Judicial Conduct states that it is inappropriate for a judge to hold membership in any organization that invidiously discriminates on the basis of race, sex, or religion, or national origin. Indicate whether any of these organizations listed in response to 11a above currently discriminate or formerly discriminated on the basis of race, sex, religion or national origin either through formal membership requirements or the practical implementation of membership policies. If so, describe any action you have taken to change these policies and practices.

To the best of my knowledge, none of the organizations listed above currently discriminates or formerly discriminated on the basis of race, sex, religion, or

national origin, either through formal membership requirements or the practical implementation of membership policies.

12. Published Writings and Public Statements:

- a. List the titles, publishers, and dates of books, articles, reports, letters to the editor, editorial pieces, or other published material you have written or edited, including material published only on the Internet. Supply four (4) copies of all published material to the Committee.

Hot Topics and Current Trends in Public Corruption Investigations, Nardello & Co., Insights (August 2018). Copy supplied.

A Call to Action: Cybersecurity Due Diligence in Today's Business Climate, 5 Emory Corp. Governance & Accountability Rev. 73 (2018). Copy supplied.

Cybersecurity Challenges for the Boardroom: What Publicly Traded Companies Should Consider, Forbes.com, byline Christopher P. Skroupa (March 12, 2018). Copy supplied.

Major Changes to OSHA's Recordkeeping Rule, Mondaq Business Briefing (January 14, 2002). Copy supplied.

- b. Supply four (4) copies of any reports, memoranda or policy statements you prepared or contributed in the preparation of on behalf of any bar association, committee, conference, or organization of which you were or are a member. If you do not have a copy of a report, memorandum or policy statement, give the name and address of the organization that issued it, the date of the document, and a summary of its subject matter.

None.

- c. Supply four (4) copies of any testimony, official statements or other communications relating, in whole or in part, to matters of public policy or legal interpretation, that you have issued or provided or that others presented on your behalf to public bodies or public officials.

None.

- d. Supply four (4) copies, transcripts or recordings of all speeches or talks delivered by you, including commencement speeches, remarks, lectures, panel discussions, conferences, political speeches, and question-and-answer sessions. Include the date and place where they were delivered, and readily available press reports about the speech or talk. If you do not have a copy of the speech or a transcript or recording of your remarks, give the name and address of the group before whom the speech was given, the date of the speech, and a summary of its subject matter.

If you did not speak from a prepared text, furnish a copy of any outline or notes from which you spoke.

October 12, 2018: Panelist, *Anatomy of a Health Care Data Breach*, Georgia Bar, Institute of Continuing Legal Education, Advanced Health Law CLE, Atlanta, Georgia. PowerPoint supplied.

May 17, 2018: Co-presenter, *Cybercrime: Privacy, Speech and Safety*, 2nd Annual Lightfoot White Collar Institute, Lightfoot Franklin & White, LLC, Birmingham, Alabama. The presentation addressed best practices for interacting with law enforcement on cyber-related incidents. I have no notes, transcript, or recording. The address for Lightfoot Franklin & White, LLC, is The Clark Building, 400 20th Street North, Birmingham, Alabama 35203.

April 16, 2018: Panelist, *Law Enforcement Hot Topics Debate*, e-Fraud Global Conference, San Francisco, California. Description of the panel, outlines, and questions supplied.

April 12, 2018: Lecture, *SpyEye Case Study*, Georgetown Law School, Washington, D.C. I guest-lectured a class along with my colleague, Mark Ray, entitled "Cyber Threats and Technological Insecurity: Emerging Legal, Policy, and Operational Challenges," on a cyber case we investigated and prosecuted relating to a prolific computer botnet. I have no notes, transcript, or recording. The address for Georgetown Law School is 600 New Jersey Avenue, N.W., Washington, D.C. 20001.

March 29, 2018: Panelist, *Pigs Get Fat, Hogs Get Slaughtered: A Look at Fraud Through the Corporate Umbrella*, 2018 Emory Corporate Governance and Accountability Review Symposium, Atlanta, Georgia. Video available at <https://www.youtube.com/watch?reload=9&v=zUzsDAi0MJc>.

March 16, 2018: Panelist, *Cybersecurity Spy Craft: The Next Wave of Cybersecurity Threats and Cyber Risk Management from a Global Perspective*, Hispanic National Bar Association Corporate Counsel Conference, San Francisco, California. The panel discussed cyber-related risks and best practices. I have no notes, transcript, or recording. The address for the Hispanic National Bar Association is 1020 19th Street, N.W., Suite 505, Washington, D.C. 20036.

February 27, 2018: Co-convenor, *Human Trafficking*, Lamar Inn of Court, Atlanta, Georgia. I introduced a speaker, Susan Coppedge, former Ambassador-at-Large for the Office to Monitor and Combat Trafficking in Persons at the United States Department of State. A copy of the biography I used as a resource is supplied.

February 26, 2018: Co-presenter, *Cyber Risk Assessments*, EO Atlanta, Atlanta, Georgia. The presentation was on cybersecurity best practices. I have no notes, transcript, or recording. The address for EO Atlanta is P.O. Box 924202, Norcross, Georgia 30010.

October 20, 2017: Panelist, *Enforcement/White Collar Developments*, Georgia Bar, Institute of Continuing Legal Education, Securities Litigation and Regulatory Practice CLE, Atlanta, Georgia. Outline supplied.

October 6, 2017: Speaker, *Hot Topics and Current Trends in Federal White-Collar Prosecutions*, Georgia Association of Certified Fraud Examiners, Atlanta, Georgia. The speech was on criminal enforcement priorities of the U.S. Attorney's Office for the Northern District of Georgia in the white-collar prosecution arena. I have no notes, transcript, or recording. The address for the Georgia Association of Certified Fraud Examiners is P.O. Box 79498, Atlanta, Georgia 30357.

October 3, 2017: Panelist, *Cybersecurity Roundtable Discussion*, Baker Donelson PC, Atlanta, Georgia. The panel was on cyber threats and data breach response. I have no notes, transcript, or recording. The address for Baker Donelson is 3414 Peachtree Road, N.E., Monarch Plaza, Suite 1600, Atlanta, Georgia 30326.

April 26, 2017: Panelist, *Cybersecurity Roundtable Discussion*, Baker Donelson, PC, Atlanta, Georgia. The panel was on cyber threats and data breach response. I have no notes, transcript, or recording. The address for Baker Donelson is 3414 Peachtree Road, N.E., Monarch Plaza, Suite 1600, Atlanta, Georgia 30326.

March 21, 2017: Panelist, *Elements of an Effective Compliance Plan*, Atlanta Bar Association, Business and Finance Section, Atlanta, Georgia. A copy of the PowerPoint slides utilized during the presentation is supplied.

February 16, 2017: Speaker, *SpyEye: A Lesson for Italy?*, Center for American Studies, Rome, Italy. The speech was a case study on a cyber case that I investigated and prosecuted relating to a prolific computer botnet. I have no notes, transcript, or recording. The address for the Center for American Studies is via Michelangelo Caetani 32, 00186 Roma RM, Italy.

February 16, 2017: Speaker, *Cybersecurity: The New Dimension of Conflict*, LUISS University, Rome, Italy. The speech was delivered to a class at the university on a cyber case that I investigated and prosecuted relating to a prolific computer botnet. I have no notes, transcript, or recording. The address for LUISS University is Viale Pola 12, 00198 Roma RM, Italy.

January 25, 2017: Speaker, *A Case Study on a Cyber-Crime Prosecution: SpyEye*, International Security Management Association, Atlanta, Georgia. The speech was a case study on a cyber case that I investigated and prosecuted relating to a prolific computer botnet. I have no notes, transcript, or recording. The address for the International Security Management Association is 3294 210th Street, Thayer, Iowa 50254.

September 29, 2016: Speaker, *The Cybercrime Landscape*, Fraud and Forensic Accounting Conference, The Georgia Society of CPAs, Atlanta, Georgia. The speech was on cyber-crime threats and private sector-law enforcement collaboration. I have no notes, transcript, or recording. The address for the Georgia Society of CPAs is Six Concourse Parkway, Suite 800, Atlanta, Georgia 30328.

September 9, 2016: Panelist, *Economic Espionage Prosecutions and International Criminal Enforcement*, American Bar Association, Criminal Justice Section, Southeastern White Collar Crime Institute, Braselton, Georgia. Outline supplied.

August 12, 2016: Speaker, *Cybersecurity*, Engage16 Conference, Greenway Health, Atlanta, Georgia. The speech was on cyber-related threats and best practices for cybersecurity. I have no notes, transcript, or recording. The address for Greenway Health is 4301 West Boy Scout Boulevard, Suite 800, Tampa, Florida 33607.

May 12, 2016: Speaker, *Threat Brief: The Cyber Crime Landscape*, CISO Coalition, Webinar. The presentation was on cyber related threats to the private sector. I have no notes, transcript, or recording. The address for the CISO Coalition is 222 S.W. Columbia Street, 10th Floor, Portland, Oregon 97201.

May 10, 2016: Panelist, *Criminal Enforcement and other Emerging Issues*, Cyber Liability Summit, Freeman Mathis & Gary LLP, Atlanta, Georgia. The panel was on cyber-related threats and best practices. I have no notes, transcript, or recording. The address for Freeman Mathis & Gary LLP is 100 Galleria Parkway, Suite 1600, Atlanta, Georgia 30339.

February 11, 2016: Moderator, *Cybersecurity Beyond the Media Coverage: Applicable Law Doctrines, Corporate Responsibility, and Practical Implications*, Thrower Symposium, Emory University School of Law, Atlanta, Georgia. Video available at <https://www.youtube.com/watch?v=hv8gVaDcNVI>.

November 18, 2015: Panelist, *Criminal Tax Prosecutions: Policies and Priorities*, Atlanta Bar Association, Criminal Law Section Luncheon, Atlanta, Georgia. The panel was on recent trends in criminal tax enforcement. I have

no notes, transcript, or recording. The address for the Atlanta Bar Association is 229 Peachtree Street, Suite 400, Atlanta, Georgia 30303.

October 1, 2015: Panelist, *Cyber Liability Trends and Developments – Where We Are and Where We Are Going*, Professional Liability Attorney Network, Alpharetta, Georgia. The panel was on cyber-related threats and best practices. I have no notes, transcript, or recording. The address for the Professional Liability Attorney Network is 275 North York Street, Suite 401, Elmhurst, Illinois 60126.

August 20, 2015: Panelist, *Cybersecurity Forum*, Baker Donelson, PC, Atlanta, Georgia. The panel was on cyber threats and data breach response. I have no notes, transcript, or recording. The address for Baker Donelson is 3414 Peachtree Road, N.E., Monarch Plaza, Suite 1600, Atlanta, Georgia 30326.

April 7, 2015: Panelist, *Law Panel on Legal Careers and the Legal Job Market*, Georgia State University Law School, Atlanta, Georgia. The panel was on career options and networking. I have no notes, transcript, or recording. The address for Georgia State University College of Law is 85 Park Place, N.E., Atlanta, Georgia 30303.

February 26, 2015: Lecture, *Practical Application of the Electronic Communications Privacy Act*, Emory University School of Law, Atlanta, Georgia. I guest-lectured a class on the various evidence-gathering and surveillance tools utilized by federal law enforcement under the Electronic Communications Privacy Act of 1986. I have no notes, transcript, or recording. The address for Emory University School of Law is 1301 Clifton Road, Atlanta, Georgia 30322.

February 21, 2015: Moderator, *Cyber Crime Investigations and Prosecutions*, Emory University School of Law, Cyber Crime Colloquium, Atlanta, Georgia. The panel was on the challenges of investigating and prosecuting cyber-related crimes. I have no notes, transcript, or recording. The address for Emory University School of Law is 1301 Clifton Road, Atlanta, Georgia 30322.

January 29, 2015: Speaker, *Annamalai Annamalai Case Study*, Atlanta Bar Association, Bankruptcy Section Breakfast Meeting, Atlanta, Georgia. The speech was a case study on a bankruptcy fraud case I prosecuted. I have no notes, transcript, or recording. The address for the Atlanta Bar Association is 229 Peachtree Street, Suite 400, Atlanta, Georgia 30303.

November 6, 2014: Panelist, *Cyber Panel*, Georgia Chapter of the Association of Certified Fraud Examiners, Atlanta, Georgia. The panel was on the latest trends in cyber threats and mitigation strategies. I have no notes,

transcript, or recording. The address for the Georgia Chapter of the Association of Certified Fraud Examiners is P.O. Box 79498, Atlanta, Georgia 30357.

September 29, 2014: Panelist, *Cybersecurity*, U.S. Chamber of Commerce, National Security Task Force and Chief Security Officer Roundtable Meeting, Atlanta, Georgia. The panel was on emerging threats in the cyber landscape. I have no notes, transcript, or recording. The address for the U.S. Chamber of Commerce is 1615 H Street, N.W., Washington, D.C. 20062.

May 16, 2014: Speaker, *Cybersecurity in Healthcare*, Georgia Academy of Healthcare Attorneys, Annual Meeting, Atlanta, Georgia. PowerPoint and video available at <https://slideplayer.com/slide/4706905/>.

May 14, 2014: Panelist, *Cyber Law Enforcement Priorities*, Georgia Tech, Institute for Information and Security, Third Annual Emerging Threats and Cyber Defense Symposium, Atlanta, Georgia. The panel was on cyber-related investigations and prosecutions. I have no notes, transcript, or recording. The address for Georgia Tech, Institute for Information and Security, is 266 Ferst Drive, Atlanta, Georgia 30332.

March 25, 2014: Speaker, *Cyber Liability*, Federal Bar Association, Atlanta, Georgia. The speech was on cyber-related threats and emerging issues. I have no notes, transcript, or recording. The address for the Federal Bar Association is 1220 North Fillmore Street, Suite 444, Arlington, Virginia 22201.

March 25, 2014: Panelist, *Cyber Crime*, Sandpiper Partners, LLC, Atlanta, Georgia. The panel was on cyber-related threats and emerging issues. I have no notes, transcript, or recording. The address for Sandpiper Partners, LLC, is 855 Valley Road, Suite 209, Clifton, New Jersey 07013.

November 13, 2013, Speaker, *Cyber Law Enforcement Priorities*, Infragard Atlanta Chapter meeting, Atlanta, Georgia. The speech was on criminal law enforcement priorities in the cyber arena for the U.S. Attorney's Office in the Northern District of Georgia. I have no notes, transcript, or recording. The address for Infragard is c/o Federal Bureau of Investigation, 3000 Flowers Road South, Atlanta, Georgia 30341.

April 4, 2013: Speaker, *Counterattack*, Alpharetta Public Safety Foundation, Norcross, Georgia. The speech was on emerging cybersecurity threats. Press report supplied.

September 27, 2012: Speaker, *Cyber Crime*, Fourth Annual Law Enforcement and Business Continuity Summit, U.S. Attorney's Office, Atlanta, Georgia. I have no notes, transcript, or recording. The address for the U.S. Attorney's

Office is c/o Didi Nelson, 75 Ted Turner Drive S.W., Suite 600, Atlanta, Georgia 30303.

June 24, 2011: Moderator, *Reforms in the Macedonian Judiciary System*, 3rd Annual United Macedonian Diaspora, Washington, D.C. Video available at <https://m.youtube.com/watch?v=LENZilygAb8>.

- e. List all interviews you have given to newspapers, magazines or other publications, or radio or television stations, providing the dates of these interviews and four (4) copies of the clips or transcripts of these interviews where they are available to you.

Ryan Kruger, *Private investigator peels back process of vetting high-profile candidates*, 11 Alive News, September 27, 2018. Video available at <https://www.11alive.com/article/news/politics/national-politics/private-investigator-peels-back-process-of-vetting-high-profile-candidates/85-598935614>. Copy supplied.

Aaron Diamant, *LabCorp detects suspicious activity on its network*, July 19, 2018. Copy supplied.

Clara Hudson, *Nardello recruits former US prosecutor in Atlanta*, Global Investigations Review, January 12, 2018. Copy supplied.

Stephanie Forshee, *Investigations Firm Nardello Tracks Down a New GC in Steven Grimberg*, Corporate Counsel, January 8, 2018. Copy supplied.

Nardello & Co. press release, *Steven Grimberg Joins Nardello & Co. As A Managing Director and General Counsel for The Americas*, January 8, 2018. Copy supplied.

Kate Brumback, *Cybercrimes present unique challenges for investigators*, Associated Press, November 12, 2017. Copy supplied.

R. Robin McDonald, *Sentenced Russian Hacker a 'Key Resource' For Cyber Underworld*, The Daily Report (Fulton County, Georgia), July 19, 2017. Copy supplied.

Justin S. Daniels and Joe D. Whitley, *Cybersecurity Public Private Partnerships: Challenges and Opportunities*, Law Journal Newsletters' Cybersecurity Law & Strategy, February 2017. Copy supplied.

Carol Sbarge, *Peachtree Orthopedics' data breach put half a million Georgians at risk*, WSB-TV Channel 2 Action News, December 13, 2016. Video available at <https://www.wsbtv.com/news/local/atlanta/peachtree-orthopedics-data-breach-put-thousands-at-risk/475682805>. Copy supplied.

Aaron Diamant, *Medical records are being sold on the black market*, WSB-TV Channel 2 Action News, November 9, 2016. Video available at <https://www.wsbtv.com/news/2-investigates/your-medical-records-are-being-sold-on-the-black-market/465680836>. Copy supplied.

Insider Law, *Dietary Supplement Marketer Convicted of Selling Ephedra Years After FDA Ban*, Natural Products Insider, June 3, 2016. Copy supplied.

P. Rajendran, *'Heartless' and 'Ruthless' Annamalai sentenced to 27 years in prison*, India Abroad (New York edition), April 24, 2015. Copy supplied.

Randy Travis, *"Dr. Commander" Trial*, Fox 5 News, August 29, 2014. Video available at <https://m.youtube.com/watch?v=zq7rjeY7a7s>.

R. Robin McDonald, *Would-Be Judge Pleads Guilty to Wire Fraud*, The Daily Report (Fulton County, Georgia), September 12, 2013. Copy supplied.

Karen Scannell, *The Fraudbusters*, Financial Times, August 16, 2013. Copy supplied.

Thomas Mullen, *Spellbinder*, Atlanta Magazine, October 1, 2012. Copy supplied.

Bill Rankin, *Marietta author admits to scams*, Atlanta Journal-Constitution, February 22, 2012. Copy supplied.

13. **Judicial Office:** State (chronologically) any judicial offices you have held, including positions as an administrative law judge, whether such position was elected or appointed, and a description of the jurisdiction of each such court.

I have not held judicial office.

- a. Approximately how many cases have you presided over that have gone to verdict or judgment? _____
- i. Of these, approximately what percent were:
- | | |
|-----------------------|---------------------|
| jury trials: | _____% |
| bench trials: | _____% [total 100%] |
| civil proceedings: | _____% |
| criminal proceedings: | _____% [total 100%] |
- b. Provide citations for all opinions you have written, including concurrences and dissents.

- c. For each of the 10 most significant cases over which you presided, provide: (1) a capsule summary of the nature the case; (2) the outcome of the case; (3) the name and contact information for counsel who had a significant role in the trial of the case; and (3) the citation of the case (if reported) or the docket number and a copy of the opinion or judgment (if not reported).
- d. For each of the 10 most significant opinions you have written, provide: (1) citations for those decisions that were published; (2) a copy of those decisions that were not published; and (3) the names and contact information for the attorneys who played a significant role in the case.
- e. Provide a list of all cases in which certiorari was requested or granted.
- f. Provide a brief summary of and citations for all of your opinions where your decisions were reversed by a reviewing court or where your judgment was affirmed with significant criticism of your substantive or procedural rulings. If any of the opinions listed were not officially reported, provide copies of the opinions.
- g. Provide a description of the number and percentage of your decisions in which you issued an unpublished opinion and the manner in which those unpublished opinions are filed and/or stored.
- h. Provide citations for significant opinions on federal or state constitutional issues, together with the citation to appellate court rulings on such opinions. If any of the opinions listed were not officially reported, provide copies of the opinions.
- i. Provide citations to all cases in which you sat by designation on a federal court of appeals, including a brief summary of any opinions you authored, whether majority, dissenting, or concurring, and any dissenting opinions you joined.

14. **Recusal:** If you are or have been a judge, identify the basis by which you have assessed the necessity or propriety of recusal (If your court employs an "automatic" recusal system by which you may be recused without your knowledge, please include a general description of that system.) Provide a list of any cases, motions or matters that have come before you in which a litigant or party has requested that you recuse yourself due to an asserted conflict of interest or in which you have recused yourself sua sponte. Identify each such case, and for each provide the following information:

I have not held judicial office.

- a. whether your recusal was requested by a motion or other suggestion by a litigant or a party to the proceeding or by any other person or interested party; or if you recused yourself sua sponte;
- b. a brief description of the asserted conflict of interest or other ground for recusal;

- c. the procedure you followed in determining whether or not to recuse yourself;
- d. your reason for recusing or declining to recuse yourself, including any action taken to remove the real, apparent or asserted conflict of interest or to cure any other ground for recusal.

15. Public Office, Political Activities and Affiliations:

- a. List chronologically any public offices you have held, other than judicial offices, including the terms of service and whether such positions were elected or appointed. If appointed, please include the name of the individual who appointed you. Also, state chronologically any unsuccessful candidacies you have had for elective office or unsuccessful nominations for appointed office.

I have not held any public office. I have not had any unsuccessful candidacies for elective office, nor have I had any unsuccessful nominations for appointed office.

- b. List all memberships and offices held in and services rendered, whether compensated or not, to any political party or election committee. If you have ever held a position or played a role in a political campaign, identify the particulars of the campaign, including the candidate, dates of the campaign, your title and responsibilities.

I have not held any membership or office in a political party or election committee. I have not held a position or played a role in a political campaign.

16. Legal Career: Answer each part separately.

- a. Describe chronologically your law practice and legal experience after graduation from law school including:

- i. whether you served as clerk to a judge, and if so, the name of the judge, the court and the dates of the period you were a clerk;

I have not served as clerk to a judge.

- ii. whether you practiced alone, and if so, the addresses and dates;

I have not practiced alone.

- iii. the dates, names and addresses of law firms or offices, companies or governmental agencies with which you have been affiliated, and the nature of your affiliation with each.

1998 – 1999
Vial, Hamilton, Koch & Knox LLP
1717 Main Street, Suite 4400
Dallas, TX 75201
Associate

1999 – 2002
Muller Mintz, PA
200 South Biscayne Boulevard, Suite 3600
Miami, Florida 33131
Associate

2002 – 2005
Hunton & Williams LLP
600 Peachtree Street, N.E., Suite 4100
Atlanta, Georgia 30308
Associate

2005 – 2010
United States Department of Justice
601 D Street, N.W.
Washington, D.C. 20004
Trial Attorney, Tax Division

2010 – 2017
United States Department of Justice
75 Ted Turner Drive S.W., Suite 600
Atlanta, Georgia 30303
Assistant U.S. Attorney and Deputy Chief, Economic Crimes Section

2017 – Present
Nardello & Co.
999 Peachtree Street, Suite 1130
Atlanta, Georgia 30309
Managing Director
General Counsel – Americas

- iv. whether you served as a mediator or arbitrator in alternative dispute resolution proceedings and, if so, a description of the 10 most significant matters with which you were involved in that capacity.

I have not served as a mediator or arbitrator.

b. Describe:

- i. the general character of your law practice and indicate by date when its

character has changed over the years.

From 1998 to 1999, I was a litigation associate at Vial, Hamilton, Koch & Knox LLP in Dallas, Texas. I represented both plaintiffs and defendants in a diverse commercial litigation practice, including construction disputes, shareholder derivative litigation, and insurance coverage matters.

From 1999 to 2002, I was a litigation associate with Muller Mintz, PA in Miami, Florida. I represented employers and management executives in labor and employment law litigation. I also counseled clients on employment law best practices, monitored the integrity of labor union campaigns and elections, and defended clients before state and federal regulatory and administrative enforcement agencies.

From 2002 to 2005, I was a litigation associate with Hunton & Williams LLP in Atlanta, Georgia. I represented individuals, businesses and employers in complex civil litigation, including collective and class actions in both state and federal courts, as well as before administrative bodies and arbitration panels.

From 2005 to 2010, I served as a Trial Attorney with the United States Department of Justice, Tax Division, in Washington, D.C. While there I prosecuted and litigated both criminal and civil financial fraud, tax, bankruptcy, securities, and banking cases across the country, including in Georgia.

From 2010 to 2017, I served as an Assistant United States Attorney for the Northern District of Georgia. As a federal prosecutor, I investigated and prosecuted a broad array of criminal matters, including prosecutions for bank fraud, healthcare fraud, identity theft, securities fraud, tax fraud, Ponzi and investment schemes, cyber-crime, and public corruption. I worked closely with civil division counterparts on parallel proceedings and *Qui Tam* investigations. I also charged violations of the immigration laws and prosecuted drug dealers, child exploiters, elder abusers, gang members, bank robbers and other violent criminals.

In addition to my duties as an Assistant United States Attorney, in 2012 I was promoted to Deputy Chief of the Economic Crime Section, where I helped supervise and manage approximately twenty-five white-collar prosecutors. I analyzed and approved proposed matters for prosecution, reviewed and approved charging documents and plea agreements, assisted with developing strategies for pretrial hearings and trials, approved sentencing recommendations, reviewed and revised trial and appellate briefs, and helped prepared prosecutors for oral argument before both the District Court and Eleventh Circuit Court of Appeals. I often attended grand jury sessions and court hearings, including trials, with less

experienced prosecutors to provide them with support and feedback. I also participated in developing, reviewing and revising office-wide policies and practices.

As Deputy Chief, I also led a stand-alone Cyber-Crime Unit within the United States Attorney's Office comprised of approximately six prosecutors. In this role, I was solely responsible for overseeing all cyber-related investigations and prosecutions. This encompassed not only computer hacking cases, but also national security and terrorism investigations, as well as data breaches resulting in the theft or loss of trade secrets, intellectual property, and proprietary information.

Since January 2018, I am the General Counsel of the Americas for Nardello & Co., a global investigations firm, serving as the chief legal officer for the domestic offices including New York, Washington, D.C., and Atlanta. I am responsible for counseling and advising the executive management and leadership teams of the firm on a myriad of legal, compliance, regulatory and corporate governance matters. Central issues that touch upon my day-to-day work pertain to conflicts-of-interest, ethical and professionalism dilemmas, and data privacy safeguards.

I also serve as a Managing Director and head of the Atlanta office, supervising a staff of investigators, analysts and trained professionals on complex investigation matters for clients. The subject matters of the investigation work encompass a broad range of issues, including the Foreign Corrupt Practices Act and other corruption-related investigations, civil litigation and arbitration support, white-collar criminal defense, asset tracing, cybersecurity and computer forensics, and reputational due diligence.

- ii. your typical clients and the areas at each period of your legal career, if any, in which you have specialized.

During my time in private practice between 1998 and 2005, I represented a wide variety of clients on commercial and employment-related matters, including individuals, business owners, investors, shareholders, non-profit organizations, family-owned businesses, financial institutions, insurance companies, nuclear power plants, energy companies, hospitals, academic institutions, and companies of all sizes, including Fortune 500 companies and their executives. The law firm Muller Mintz, PA, where I worked as an associate between 1999 and 2002, was a management-side labor and employment law boutique, so while there I represented private- and public-sector employers and management executives on labor and employment law matters. My practice at Hunton & Williams LLP between 2002 and 2005 likewise involved the representation of employers and management executives on labor and employment law matters, as well

as insurance companies and financial institutions in collective and class action matters.

As a trial attorney and federal prosecutor for the United States Department of Justice between 2005 and 2017, my client was exclusively the United States of America.

As General Counsel for the Americas at Nardello & Co. since January 2018, my legal practice is internal-facing only so my client is my own employer, Nardello & Co. Outward facing, we serve as a private investigations firm, not a law firm. Clients include law firms and financial institutions, individuals (primarily in white-collar defense matters), private and publicly-traded companies, professional sports organizations and academic institutions.

- c. Describe the percentage of your practice that has been in litigation and whether you appeared in court frequently, occasionally, or not at all. If the frequency of your appearances in court varied, describe such variance, providing dates.

My practice has been exclusively in litigation, except for my current role since January 2018 as General Counsel for Nardello & Co. As a Trial Attorney and Assistant United States Attorney for the U.S. Department of Justice between 2005 and 2017, I appeared in court frequently. I appeared in court occasionally while in private practice between 1998 and 2005, and not at all since joining Nardello & Co. in January 2018.

- i. Indicate the percentage of your practice in:

- | | |
|-----------------------------|-----|
| 1. federal courts: | 90% |
| 2. state courts of record: | 5% |
| 3. other courts: | 0% |
| 4. administrative agencies: | 5% |

- ii. Indicate the percentage of your practice in:

- | | |
|--------------------------|-----|
| 1. civil proceedings: | 40% |
| 2. criminal proceedings: | 60% |

- d. State the number of cases in courts of record, including cases before administrative law judges, you tried to verdict, judgment or final decision (rather than settled), indicating whether you were sole counsel, chief counsel, or associate counsel.

I have tried approximately fifteen cases to verdict, judgment or final decision. I was the chief counsel or sole counsel for the vast majority of these cases. In addition, as Deputy Chief of the Economic Crime Section for the U.S. Attorney's Office in the Northern District of Georgia, I assisted in varying degrees with dozens of trials for the approximately 25 prosecutors over whom I had

supervisory responsibilities.

i. What percentage of these trials were:

- | | |
|--------------|-----|
| 1. jury: | 95% |
| 2. non-jury: | 5% |

e. Describe your practice, if any, before the Supreme Court of the United States. Supply four (4) copies of any briefs, amicus or otherwise, and, if applicable, any oral argument transcripts before the Supreme Court in connection with your practice.

I have not practiced before the Supreme Court of the United States.

17. **Litigation**: Describe the ten (10) most significant litigated matters which you personally handled, whether or not you were the attorney of record. Give the citations, if the cases were reported, and the docket number and date if unreported. Give a capsule summary of the substance of each case. Identify the party or parties whom you represented; describe in detail the nature of your participation in the litigation and the final disposition of the case. Also state as to each case:

- a. the date of representation;
- b. the name of the court and the name of the judge or judges before whom the case was litigated; and
- c. the individual name, addresses, and telephone numbers of co-counsel and of principal counsel for each of the other parties.

1. *United States v. Annamalai Annamalai, et al.*, No. 1:13-CR-00437-TCB-CMS (N.D. Ga.)

Dates of Representation: 2013 – 2015

I represented the United States in its investigation and prosecution of Annamalai Annamalai, also known as Dr. Commander Selvam, a self-proclaimed priest. Among other misconduct, Annamalai charged his followers' credit card accounts for spiritual services without authorization and threatened followers that they and their families would suffer consequences from the Hindu gods if they disputed the charges. Annamalai manipulated audio recordings of the followers to make it sound as if they had agreed to pay the disputed charges, and he submitted those recordings to police departments across the country that were investigating criminal complaints lodged against Annamalai. Following a two-week jury trial, Annamalai was found guilty on all 34 counts of the indictment, including bank fraud, tax fraud, bankruptcy fraud, and obstruction charges. Annamalai was sentenced to serve over 27 years in prison. Annamalai's appeal with the Eleventh Circuit Court of Appeals is pending.

United States District Court for the Northern District of Georgia, Hon. Timothy C. Batten, Sr. (U.S. District Court Judge)

Co-Counsel for the United States:

Samir Kaushal
Assistant U.S. Attorney
Office of the United States Attorney
600 United States Courthouse
75 Ted Turner Drive, S.W.
Atlanta, Georgia 30303
Tel: 404-581-6000

Counsel for Defendant Annamalai Annamalai:

Donald F. Samuel
Garland, Samuel & Loeb, P.C.
3151 Maple Drive, N.E.
Atlanta, Georgia 30305
Tel: 404-262-2225

Bruce S. Harvey
Law Office of Bruce Harvey
146 Nassau Street, N.W.
Atlanta, Georgia 30303
Tel: 404-659-4628

Counsel for Co-Defendant Kumar Chinnathambi:

Thomas Colin Wooldridge
Wooldridge & Jezek, LLP
Suite 1900
1230 Peachtree Street, N.E.
Atlanta, Georgia 30309
Tel: 404-942-3300

Counsel for Co-Defendant Parvathi Sivanadiyan:

Brian Steel
The Steel Law Firm
1800 Peachtree Street, N.W.
Suite 300
Atlanta, Georgia 30309
Tel: 404-605-0023

2. *United States v. Juan Rene Caro, Maytemar Corp. d/b/a La Bamba Check Cashing, Jose Chaoui and Alfredo Gonzalez*, No. 1:08-cr-20044-JAL (S.D. Fla.)

Dates of Representation: 2008 – 2009

I represented the United States as co-counsel in a three-month criminal trial against Maytemar Corporation and its principals. The defendants engaged in a scheme by which their customers wrote checks payable to shell companies, and then for a fee cashed those checks at the defendants' business. The defendants accepted the cashed checks made payable to the shell companies and filed Currency Transaction Reports (CTRs) totaling over \$132 million with the Treasury Department, falsely representing the true source of the money and disguising the identity of the parties involved in the check cashing transactions. The jury found defendants Juan Rene Caro and Maytemar Corporation guilty on thirteen and fifteen felony counts, respectively. The jury was unable to reach a unanimous verdict on defendants Jose Chaoui and Alfredo Gonzalez, but they each subsequently pled guilty and were sentenced to a superseding tax charge.

United States District Court for the Southern District of Florida, Hon. Joan A. Lenard (U.S. District Court Judge)

Co-Counsel for the United States:

Wilfredo Fernandez (then at the Office of the United States Attorney)
U.S. Securities & Exchange Commission
801 Brickell Avenue Suite 1800
Miami, Florida 33131
Tel: 305-982-6376

Counsel for Defendants Juan Rene Caro and Maytemar Corporation:

Arturo V. Hernandez
40 N.W. 3rd Street
Suite 200
Miami, Florida 33128
Tel: 305-579-4850

Melvin Black
2829 Bird Avenue, Suite 5-307
Miami, Florida 33133
Tel: 305-443-1600

Counsel for Defendant Jose Chaoui:

David Garvin
David M Garvin, PA
200 South Biscayne Boulevard
Suite 3150
Miami, Florida 33131
Tel: 305-371-8101

Counsel for Defendant Alfredo Gonzalez:

Bruce Alter
9700 SW 84th Avenue
Miami, Florida 33156
Tel: 305-975-6061

3. *United States v. Chenhsin Chan, a/k/a Paul Chan*, No. 1:14-cr-203-ODE-AJB (N.D. Ga.)

Dates of Representation: 2014 – 2016

I represented the United States in its investigation and prosecution of Paul Chan, who owned and operated a company that marketed and sold dietary supplements, including supplements that contained ephedrine alkaloids in violation of law. Chan was found guilty by jury trial on 30 felony counts. The jury also made findings that criminally forfeited assets Chan purchased with proceeds from his crimes.

United States District Court for the Northern District of Georgia, Hon. Orinda D. Evans (U.S. District Court Judge) and Hon. Alan J. Baverman (U.S. Magistrate Judge)

Co-Counsel for the United States:

Kelly Connors
Assistant U.S. Attorney
Office of the United States Attorney
600 United States Courthouse
75 Ted Turner Drive, S.W.
Atlanta, Georgia 30303
Tel: 404-581-6000

Counsel for Defendant Paul Chan:

Romeo Salta
Law Office of Romeo Salta
630 Ninth Avenue
New York, New York 10036
Tel: 917-562-3347

Carl Lietz, III
Finch McCranie
225 Peachtree Street, N.E.
1700 South Tower
Atlanta, Georgia 30303
Tel: 404-658-9070

4. *United States v. Dr. Lawrence Eppelbaum*, No. 1:11-CR-00127-AT-AJB (N.D. Ga.)

Dates of Representation: 2011 – 2014

I represented the United States in its healthcare fraud prosecution of Lawrence Eppelbaum, a medical doctor specializing in back pain treatment. Eppelbaum utilized a purported charitable organization that he controlled to provide financial inducements to his Medicare patients. Over the course of his scheme, Eppelbaum received approximately \$16 million in kickback-induced revenue from Medicare. Eppelbaum was initially tried in June 2012, but following a three-week jury trial the case ended in a mistrial due to juror misconduct during deliberations. Eppelbaum was retried and convicted on 27 counts following a two-week trial in June 2013.

United States District Court for the Northern District of Georgia, Hon. Amy Totenberg

Co-Counsel for the United States:

Stephen H. McClain
Assistant U.S. Attorney
Office of the United States Attorney
600 United States Courthouse
75 Ted Turner Drive, S.W.
Atlanta, Georgia 30303
Tel: 404-581-6000

Counsel for Defendant Lawrence Eppelbaum:

Byung J. Pak
(currently U.S. Attorney, Northern District of Georgia)
Office of the United States Attorney
600 United States Courthouse
75 Ted Turner Drive, S.W.
Atlanta, Georgia 30303
Tel: 404-581-6000

Donald F. Samuel
Garland, Samuel & Loeb, P.C.
3151 Maple Drive, N.E.
Atlanta, Georgia 30305
Tel: 404-262-2225

5. *United States v. Cora Ford*, 784 F.3d 1386 (11th Cir. 2015); Case No. 1:12-CR-00297-TWT-ECS (N.D. Ga.)

Dates of Representation: 2012 – 2014

I represented the United States as co-counsel in a criminal trial against Cora Ford, who used stolen identities from the poor, homeless, and physically or mentally disabled people to file false and fraudulent tax returns with the IRS. Ford obtained her victims' names and social security numbers in a variety of ways, including by convincing her victims to provide her with their identifying information so that she could apply on their behalf for a grant from the government. In fact, no such government grant existed. Ford was found guilty by a jury on 30 counts of mail fraud, aggravated identity theft, and filing false claims with the government.

United States District Court for the Northern District of Georgia, Hon. Thomas W. Thrash, Jr. (U.S. District Court Judge)

Co-Counsel for the United States:

Thomas J. Krepp
Assistant U.S. Attorney
Office of the United States Attorney
600 United States Courthouse
75 Ted Turner Drive, S.W.
Atlanta, Georgia 30303
Tel: 404-581-6000

Counsel for Defendant Cora Ford:

Allison Dawson
Federal Defender Program, Inc.
Suite 1500, Centennial Tower
101 Marietta Street, N.W.
Atlanta, Georgia 30303
Tel: 404-688-7530

Victoria Calvert
Federal Defender Program, Inc.
Suite 1500, Centennial Tower
101 Marietta Street, N.W.
Atlanta, Georgia 30303
Tel: 404-688-7530

6. *United States v. Randy Haile, Jr. and Mark Beckford*, 685 F.3d 1211 (11th Cir. 2012)

Dates of Representation: 2011 – 2013

I represented the United States in this case during oral argument on an issue of first impression before the Eleventh Circuit Court of Appeals. Defendants Haile and Beckford were convicted following a jury trial on drug-trafficking and firearm offenses, and were sentenced to serve terms of imprisonment of 468 months and 438 months, respectively. (I

was not involved with this case during the district court proceedings.) The Eleventh Circuit affirmed the defendants' convictions and sentences on all issues raised, except that it reversed defendant Beckford's conviction for knowingly possessing a firearm with an obliterated serial number, in violation of 18 U.S.C. § 922(k). The Eleventh Circuit joined sister circuit courts in holding that a defendant's actual knowledge of the obliterated serial number is an element of the charge. The Court ruled that there was insufficient evidence that Beckford knew of the obliterated serial number on the firearm in question, requiring the conviction to be overturned. The reversal, however, had no impact on defendant Beckford's overall sentence.

United States Court of Appeals for the Eleventh Circuit, Hon. J.L. Edmondson, Hon. Charles R. Wilson, Hon. Phyllis A. Kravitch (deceased) (U.S. Circuit Court Judges)

Appellant Counsel for Defendant Randy Haile, Jr.:

Kristen Novay
Garland, Samuel & Loeb, P.C.
3151 Maple Drive, N.E.
Atlanta, Georgia 30305
Tel: 404-262-2225

Appellant Counsel for Defendant Mark Beckford:

Kendal Silas
Federal Defender Program, Inc.
Suite 1500, Centennial Tower
101 Marietta Street, N.W.
Atlanta, Georgia 30303
Tel: 404-688-7530

7. *United States v. Aleksandr Andreevich Panin, a/k/a Gribodemon, and Hamza Bendelladj, a/k/a Bx1* (SpyEye Botnet Investigation), No. 1:11-CR-00557-AT-AJB (N.D. Ga.)

Dates of Representation: 2014 – 2016

The defendants in this case were responsible for "SpyEye", a prolific botnet that infected over 50 million computers and caused close to \$1 billion in losses to individuals and financial institutions around the world. I represented the United States during the contested sentencing hearing of Hamza Bendelladj (aka "Bx1"), an Algerian national who facilitated the development and distribution of the *SpyEye* botnet. Bendelladj was sentenced to 15 years in prison.

United States District Court for the Northern District of Georgia, Hon. Amy Totenberg (U.S. District Court Judge)

Co-Counsel for the United States:

Kamal Ghali (then at the Office of the United States Attorney)
Bondurant, Mixson & Elmore LLP
1201 West Peachtree Street NW
Suite 3900
Atlanta, Georgia 30309
Tel: 404-881-4173

Counsel for Defendant Aleksandr Panin:

Arkady Bukh
Law Offices of Arkady Bukh, Esq.
1123 Avenue Z
Brooklyn, New York 11235
Tel: 718-376-4766

Leonard Franco
The Franco Law Firm, PC
1800 Peachtree Street, N.W.
Suite 300
Atlanta, Georgia 30309
Tel: 404-875-1300

Counsel for Defendant Hamza Bendelladj:

Jay Strongwater
Strongwater & Associates, LLC
One Midtown Plaza, Suite 910
1360 Peachtree Street, N.E.
Atlanta, Georgia 30309
Tel: 404-872-1700

Emily Strongwater
Strongwater & Associates, LLC
One Midtown Plaza, Suite 910
1360 Peachtree Street, N.E.
Atlanta, Georgia 30309
Tel: 404-606-1963

8. *United States v. Donald Platten*, No. 9:08-cr-80148-DMM (S.D. Fla.)

Dates of Representation: December 2008 – February 2010

I represented the United States in the criminal jury trial of Donald Platten, who was charged with securities fraud and tax offenses. Platten was found guilty and sentenced to 21 years, 10 months' imprisonment.

United States District Court for the Southern District of Florida, Hon. Donald M. Middlebrooks (U.S. District Court Judge)

Co-Counsel for the United States:

Gregory Bockin (Then at the U.S. Department of Justice, Tax Division)
U.S. Securities & Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Tel: 202-551-5684

Counsel for Defendant Donald Platten:

Michael Pasano
Carlton Fields Jorden Burt, P.A.
100 S.E. 2nd Street
Suite 4200
Miami, Florida 33131
Tel: 305-530-0050

9. *United States v. The Public Warehousing Company K.S.C., a/k/a Agility, et al.*, No. 1:09-cr-490-TWT-AJB (N.D. Ga.) and No. 1:17-cr-177-TWT (N.D. Ga.)

Dates of Representation: 2010 – 2017

The defendant in this case was a Kuwaiti corporation charged with major fraud and other offenses in connection with contracts it entered with the U.S. Department of Defense (DOD) to supply food and other items for U.S. troops in the Middle East during the Iraq War between 2003 and 2010. I represented the United States during extensive pretrial litigation. The criminal case ultimately settled as part of a global resolution with parallel civil and administrative claims.

United States District Court for the Northern District of Georgia, Hon. Thomas W. Thrash, Jr. (U.S. District Court Judge) and Hon. Alan J. Baverman (U.S. Magistrate Judge)

Co-Counsel for the United States:

Glenn D. Baker
Assistant U.S. Attorney
Office of the United States Attorney
600 United States Courthouse
75 Ted Turner Drive, S.W.
Atlanta, Georgia 30303
Tel: 404-581-6000

Nathan P. Kitchens
Assistant U.S. Attorney
Office of the United States Attorney
600 United States Courthouse
75 Ted Turner Drive, S.W.
Atlanta, Georgia 30303
Tel: 404-581-6000

Kamal Ghali (then at the Office of the United States Attorney)
Bondurant, Mixson & Elmore LLP
1201 West Peachtree Street NW
Suite 3900
Atlanta, Georgia 30309
Tel: 404-881-4173

Counsel for Defendant The Public Warehousing Company, a/k/a Agility:

Richard Marmaro
Skadden Arps Slate Meagher & Flom LLP
Suite 3400
300 South Grand Avenue
Los Angeles, California 90071
Tel: 213-687-5480

Kristin N. Tahler
Quinn Emanuel Urquhart & Sullivan, LLP
10th Floor
865 South Figueroa Street
Los Angeles, California 90017
Tel: 213-443-3000

Richard H. Deane, Jr.
Jones Day
Suite 800
1420 Peachtree Street, N.E.
Atlanta, Georgia 30309
Tel: 404-521-3939

Counsel for Co-Defendant Agility DGS Holdings, Inc.:

Brian McEvoy
Polsinelli, P.C.
Suite 1100
1201 West Peachtree Street, N.W.
Atlanta, Georgia 30309
Tel: 404-253-6000

Thomas D. Bever
Chilivis Cochran Larkins & Bever
3127 Maple Drive, N.E.
Atlanta, Georgia 30305
Tel: 404-233-4171

Counsel for Co-Defendant Agility DGS Logistics Services Company, KSC(c):

Richard Hendrix
Finch McCranie
225 Peachtree Street, N.E.
1700 South Tower
Atlanta, Georgia 30303
Tel: 404-658-9070

10. *United States v. Cesar Arbelaez Tabares and Juan Carlos Bazantes*, No. 1:15-cr-277-SCJ-JFK (N.D. Ga.)

Dates of Representation: 2015 – 2017

I represented the United States in the criminal prosecution and trial of Cesar Arbelaez Tabares, the Chief Executive Officer, and Juan Carlos Bazantes, the Chief Financial Officer, of a company that supplied laborers for construction projects. Tabares and Bazantes caused their company to submit fraudulent certified payroll forms to the Centers for Disease Control and Prevention (CDC), signed under penalty of perjury, which falsely represented that employment taxes had been withheld for all of their workers. Tabares and Bazantes were found guilty by a jury on one count of conspiracy and six counts of submitting false certified payroll forms to the CDC. They were acquitted of related tax charges. Their appeal to the Eleventh Circuit Court of Appeals is pending.

United States District Court for the Northern District of Georgia, Hon. Steve C. Jones (U.S. District Court Judge) and Hon. Janet F. King (U.S. Magistrate Judge)

Co-Counsel for the United States:

Ryan Huschka
Assistant U.S. Attorney
Office of the United States Attorney
600 United States Courthouse
75 Ted Turner Drive, S.W.
Atlanta, Georgia 30303
Tel: 404-581-6000

Counsel for Defendant Cesar Arbelaez Tabares:

James M. Deichert
Fellows LaBriola, LLP
225 Peachtree Street, N.E.
South Tower, Suite 2300
Atlanta, Georgia 30303
Tel: 404-586-2029

Counsel for Juan Carlos Bazantes:

Vivian D. Hoard
Taylor English Duma LLP
Suite 400
1600 Parkwood Circle
Atlanta, Georgia 30339
Tel: 770-434-6868

18. **Legal Activities:** Describe the most significant legal activities you have pursued, including significant litigation which did not progress to trial or legal matters that did not involve litigation. Describe fully the nature of your participation in these activities. List any client(s) or organization(s) for whom you performed lobbying activities and describe the lobbying activities you performed on behalf of such client(s) or organizations(s). (Note: As to any facts requested in this question, please omit any information protected by the attorney-client privilege.)

During my tenure at the Office of the United States Attorney, some of my most significant legal activities related to my position as the U.S. Department of Justice National Security Cyber Specialist for the Northern District of Georgia, between 2012 and 2017. In this role, I served as the point of contact for all cyber-related threats and attacks that had terrorism or national security implications for the district. I maintained a top-secret clearance, which enabled me to receive regular briefings from the Federal Bureau of Investigation and other agencies in the intelligence community concerning emerging threats. A central component of this position also involved outreach to the private sector to educate and inform corporate constituents in the district on cyber-related threats and best practices for responding to such threats. Towards that end I regularly participated in public speaking engagements, and I met with officers, directors, and employees of companies that had been or could be the target of a state-sponsored cyber-attack.

In my current position as Managing Director and General Counsel for Nardello & Co., we are regularly engaged by clients to support the legal work of outside counsel or in-house counsel in connection with internal investigations. These investigations may relate to criminal investigations, including potential violations of the False Claims Act and the Foreign Corrupt Practices Act, or regulatory investigations by federal, state or local agencies. In other instances, our internal investigation work may relate to potential employee malfeasance, such as suspected corporate embezzlement, accounting irregularities, or allegations of sexual harassment or assault. Our work on these matters is generally considered attorney-client privileged and confidential.

As part of the legal community generally, since 2012 I have served on the Executive Board for the Lamar Inn of Court, a chapter of the American Inns of Court, which promotes professionalism, ethics, and civility in the legal profession. I am currently serving as President of the chapter, with my term set to expire in April 2019.

I have not performed any lobbying activities for clients or organizations.

19. **Teaching:** What courses have you taught? For each course, state the title, the institution at which you taught the course, the years in which you taught the course, and describe briefly the subject matter of the course and the major topics taught. If you have a syllabus of each course, provide four (4) copies to the committee.

As an Adjunct Professor at Emory University School of Law since 2012, I have taught the following courses:

Criminal Procedure Investigations Skills Workshop: Fall 2012, Spring 2014, Fall 2014, Fall 2015. This course taught practical skills in the area of pre-trial criminal litigation. The students practiced both oral and written advocacy skills, and learned how to develop persuasive case theories and pretrial strategies. Copies of the syllabus are supplied.

Federal Prosecutions Practice: Spring 2013, Spring 2015, Fall 2016, Fall 2017. This course addressed the role and responsibilities of federal prosecutors at each stage of the criminal justice system. The class involved a mix of lecture and “learn by doing” exercises that were geared towards developing the students’ analytical, oral and written advocacy skills. Copies of the syllabus are supplied.

Prosecuting Criminal Tax Cases: Fall 2013, Spring 2016. This course taught the various aspects of investigating and prosecuting criminal tax and tax-related cases. The class involved a mix of lecture and “learn by doing” exercises that were geared towards developing the students’ analytical, oral and written advocacy skills. A copy of the syllabus for the Spring 2016 course is supplied. I cannot locate a copy of the syllabus from the Fall 2013 course, but it was almost identical to the Spring 2016 course in all material respects.

In addition, since approximately 2009 I have been a regular faculty participant in Emory Law School’s annual *Kessler-Eidson Program for Trial Techniques*, which is a required one-week course for all second-year law students. The course teaches trial advocacy skills and culminates in a mock jury trial at the conclusion of the week. A copy of the syllabus from the May 2018 program is supplied. Prior programs were substantially similar in content.

20. **Deferred Income/ Future Benefits:** List the sources, amounts and dates of all anticipated receipts from deferred income arrangements, stock, options, uncompleted contracts and other future benefits which you expect to derive from previous business relationships, professional services, firm memberships, former employers, clients or customers. Describe the arrangements you have made to be compensated in the future for any financial or business interest.

None.

21. **Outside Commitments During Court Service:** Do you have any plans, commitments, or agreements to pursue outside employment, with or without compensation, during your service with the court? If so, explain.

No.

22. **Sources of Income:** List sources and amounts of all income received during the calendar year preceding your nomination and for the current calendar year, including all salaries, fees, dividends, interest, gifts, rents, royalties, licensing fees, honoraria, and other items exceeding \$500 or more (if you prefer to do so, copies of the financial disclosure report, required by the Ethics in Government Act of 1978, may be substituted here).

When my nomination is formally submitted to the Senate and I file my Financial Disclosure Report, I will supplement this Questionnaire with a copy of that Report.

23. **Statement of Net Worth:** Please complete the attached financial net worth statement in detail (add schedules as called for).

See the attached Net Worth Statement.

24. **Potential Conflicts of Interest:**

- a. Identify the family members or other persons, parties, categories of litigation, and financial arrangements that are likely to present potential conflicts-of-interest when you first assume the position to which you have been nominated. Explain how you would address any such conflict if it were to arise.

I am not aware of any conflict-of-interest that is likely to arise. I will recuse myself from any litigation in which I played a role. I will recuse myself from matters involving my family and my own financial interests. For a period of time, I would recuse from all cases in which I know or am made aware that my current firm was retained by a party on the matter. I will evaluate any other real or potential conflict, or relationship that could give rise to the appearance of a conflict, on a case-by-case basis and determine appropriate action, including recusal, when necessary.

- b. Explain how you will resolve any potential conflict of interest, including the procedure you will follow in determining these areas of concern.

I will follow the established practices, policies, and procedures established by the district court. I will carefully review and address any real or potential conflicts by reference to 28 U.S.C. § 455, Canon 3 of the Code of Conduct for United States Judges, and all other laws, rules, and practices governing such circumstances.

25. **Pro Bono Work:** An ethical consideration under Canon 2 of the American Bar Association's Code of Professional Responsibility calls for "every lawyer, regardless of professional prominence or professional workload, to find some time to participate in serving the disadvantaged." Describe what you have done to fulfill these responsibilities, listing specific instances and the amount of time devoted to each.

I am dedicated to the *pro bono* representation of disadvantaged individuals. When I was in private practice, I routinely handled *pro bono* litigation matters and staffed *pro bono* legal clinics. In fact, my first trial was a *pro bono* matter, in which I represented six disadvantaged individuals in a breach of contract case against a local car dealership (the case settled during jury deliberations). The preparation and trial of this case took a substantial amount of time.

During my tenure with the United States Department of Justice, I was limited by department policy and agency rules governing conflicts-of-interest and outside activities on engaging in *pro bono* legal services. Since leaving the government in January 2018, I have re-engaged on *pro bono* matters through my firm, assisting disadvantaged clients with investigation work in support of legal representation. I have also sponsored (through my firm) and attended fundraising events for the Georgia Asylum and Immigration Network (GAIN) and Urban League of Greater Atlanta.

With regard to community service generally, I actively participate in the mentor program sponsored by the Georgia Latino Law Foundation (GLLF), which seeks to increase diversity in the legal profession, and I have attended Latino leadership and networking events sponsored by GLLF. I also routinely mentor law students through the Lamar Inn of Court, as well as on an informal basis. I participate in community service projects through the Lamar Inn of Court, such as helping to plant trees in a developing neighborhood in metro Atlanta through Trees Atlanta, a non-profit organization.

Finally, I serve on the Board of Directors for the Timber Ridge Elementary School Foundation, a non-profit organization dedicated to raising money to support the mission and educational goals of the school.

26. **Selection Process:**

- a. Please describe your experience in the entire judicial selection process, from beginning to end (including the circumstances which led to your nomination and the interviews in which you participated). Is there a selection commission in your jurisdiction to recommend candidates for nomination to the federal courts? If so, please include that process in your description, as well as whether the commission recommended your nomination. List the dates of all interviews or communications you had with the White House staff or the Justice Department regarding this nomination. Do not include any contacts with Federal Bureau of Investigation personnel concerning your nomination.

The United States Senators from Georgia utilize a selection committee to screen

candidates for potential nomination to federal government appointments. I applied for a previous vacancy on January 28, 2018, and interviewed with the committee for that vacancy on March 28, 2018. I reapplied for the current vacancy on September 27, 2018, but did not need to interview with the committee again because I had interviewed for the previous vacancy. On October 29, 2018, I interviewed with the White House Counsel's Office and the Department of Justice Office of Legal Policy in Washington, D.C. Since then, I have been in contact with officials from the White House Counsel's Office and the Office of Legal Policy. On April 2, 2019, the President announced his intent to nominate me.

- b. Has anyone involved in the process of selecting you as a judicial nominee discussed with you any currently pending or specific case, legal issue or question in a manner that could reasonably be interpreted as seeking any express or implied assurances concerning your position on such case, issue, or question? If so, explain fully.

No.